

FO&M-PTO-1390 (Rev. 10-96)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 001560-376	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 09/424039	
INTERNATIONAL APPLICATION NO. PCT/JP99/01422		INTERNATIONAL FILING DATE March 19, 1999		PRIORITY DATE CLAIMED March 20, 1998	
TITLE OF INVENTION NF-KB INHIBITOR COMPRISING PHENYLMETHYL BENZOQUINONE AS AN ACTIVE INGREDIENT.					
APPLICANT(S) FOR DO/EO/US Yoichi NUNOKAWA, Kenji SUZUKI and Masayuki SAITOH					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.					
2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.					
3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1).					
4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.					
5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))					
a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).					
b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.					
c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)					
6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).					
7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))					
a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).					
b. <input type="checkbox"/> have been transmitted by the International Bureau.					
c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.					
d. <input type="checkbox"/> have not been made and will not be made.					
8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).					
9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).					
10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
Items 11. to 16. below concern other document(s) or information included:					
11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.					
12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.					
13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.					
<input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.					
14. <input type="checkbox"/> A substitute specification.					
15. <input type="checkbox"/> A change of power of attorney and/or address letter.					
16. <input type="checkbox"/> Other items or information:					

U.S. APPLICATION NO. (If known, see 37 CFR 1.55) 09/424059		INTERNATIONAL APPLICATION NO. PCT/JP99/01422		ATTORNEY'S DOCKET NUMBER 001560-376	
---	--	---	--	--	--

17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS	PTO USE ONLY
Basic National Fee (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO \$840.00 (970) International preliminary examination fee paid to USPTO (37 CFR 1.482) \$670.00 (956) No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$760.00 (958) Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970.00 (960) International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$96.00 (962)					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 840.00	
Surcharge of \$130.00 (154) for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). 20 <input type="checkbox"/> 30 <input type="checkbox"/>				\$	
Claims	Number Filed	Number Extra	Rate		
Total Claims	37 - 20 =	17	X \$18.00 (966)	\$ 306.00	
Independent Claims	6 - 3 =	3	X \$78.00 (964)	\$ 234.00	
Multiple dependent claim(s) (if applicable)			+ \$260.00 (968)	\$	
TOTAL OF ABOVE CALCULATIONS =				\$ 1,380.00	
Reduction for 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$ 1,380.00	
Processing fee of \$130.00 (156) for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)). 20 <input type="checkbox"/> 30 <input type="checkbox"/>				\$	
TOTAL NATIONAL FEE =				\$ 1,380.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). per property +				\$ 40.00	
TOTAL FEES ENCLOSED =				\$ 1,420.00	
				Amount to be:	
				refunded	\$
				charged	\$

a. ☒ A check in the amount of \$ 1,420.00 to cover the above fees is enclosed.


b. ☐ Please charge my Deposit Account No. 02-4800 in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4800. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Ronald L. Grudziecki
 BURNS, DOANE, SWECKER & MATHIS, L.L.P.
 P.O. Box 1404
 Alexandria, Virginia 22313-1404


 SIGNATURE
 Ronald L. Grudziecki
 NAME
 24,970
 REGISTRATION NUMBER

Reg. No. 44,118

Patent
Attorney's Docket No. 001560-376

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
)
Yoichi NUNOKAWA et al.) Group Art Unit: Not Yet Assigned
)
Application No.: Not Yet Assigned) Examiner: Not Yet Assigned
(Corresponds to PCT/JP99/01422))
)
Filed: November 18, 1999)
)
For: NF- κ B INHIBITOR COMPRISING)
PHENYLMETHYL)
BENZOQUINONE AS AN ACTIVE)
INGREDIENT)

PRELIMINARY AMENDMENT

BOX PCT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination on the merits, please amend the above-captioned application as follows:

IN THE CLAIMS:

Kindly amend the claims as follows:

Claim 2, lines 1 and 2, delete "in which" and insert --wherein--;

Claim 3, lines 1 and 2, delete "or 2 in which" and insert --wherein--;

Claim 4, lines 1 and 2, delete ", 2, or 3 in which" and insert --wherein--;

Claim 5, lines 1 and 2, delete ", 2, or 3 in which" and insert --wherein--;

Claim 6, lines 1 and 2, delete "any one of claims 1 to 5 in which" and insert --claim 1
wherein--;

Claim 7, lines 1 and 2, delete "any one of claims 1 to 5 in which" and insert --claim 1
wherein--;

Claim 8, lines 1 and 2, delete "any one of claims 1 to 5 in which" and insert --claim 1
wherein--;

Claim 9, lines 1 and 2, delete ", 6, 7, or 8 in which" and insert --wherein--;

Claim 10, lines 1 and 2, delete "any one of claims 1 to 9 which is a" and insert
--wherein the-- and line 3, after "substances", insert --is--;

Claim 11, lines 1 and 2, delete "any one of claims 1 to 9" and insert --claim 1--;

Claim 12, lines 1 and 2, delete "any one of claims 1 to 9" and insert --claim 1--;

Claim 13, lines 1 and 2, delete "any one of claims 1 to 9" and insert --claim 1--;

Claim 17, line 2, delete "in which" and insert --wherein--;

Claim 18, line 2, delete "or 17 in which" and insert --wherein--;

Claim 19, line 2, delete ", 17, or 18 in which" and insert --wherein--;

Claim 20, line 2, delete ", 17, or 18 in which" and insert --wherein--;

Claim 21, line 2, delete "any one of claims 16 to 20 in which" and insert --claim 16
wherein--;

Claim 22, line 2, delete "any one of claims 16 to 20 in which" and insert --claim 16
wherein--;

Claim 23, line 2, delete "any one of claims 16 to 20 in which" and insert --claim 16 wherein--.

Claim 24, line 2, delete ", 21, 22, or 23 in which" and insert --wherein--;

Claim 25, line 2, delete "any one of claims 16 to 24 which is a" and insert --claim 16 wherein the" and line 3, after "substances", insert --is--;

Claim 26, line 2, delete "any one of claims 16 to 24" and insert --claim 16--;

Claim 27, line 2, delete "any one of claims 16 to 24" and insert --claim 16--;

Claim 28, line 2, delete "any one of claims 16 to 24" and insert --claim 16--;

Claim 31, line 2, delete "in which" and insert --wherein--;

Claim 32, line 2, delete "or 31 in which" and insert --wherein--;

Claim 33, line 2, delete ", 31, or 32 in which" and insert --wherein--;

Claim 34, lines 1 and 2, delete "any one of claims 30 to 33 in which" and insert --claim 30 wherein--;

Claim 35, lines 1 and 2, delete "any one of claims 30 to 33 in which" and insert --claim 30 wherein--.

Claim 36, lines 1 and 2, delete "any one of claims 30 to 33 in which" and insert --claim 30 wherein--;

Claim 37, line 2, delete ", 34, 35, or 36 in which" and insert --wherein--.

REMARKS

Entry of the foregoing amendment is respectfully requested.


The claims have been amended to eliminate multiple dependency and to place them in better condition for U.S. patent practice.

Should the Examiner have any questions concerning the subject application, a telephone call to the undersigned would be appreciated.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:



Dawn M. Gardner
Registration No. 44,118

Post Office Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: November 18, 1999

6/PRTS

514 Rec'd PCT/PTO

09/424059

18 NOV 1999
STY-G830/PCT

- 1 -

DESCRIPTION

NF- κ B INHIBITOR COMPRISING PHENYLMETHYL BENZOQUINONE AS
AN ACTIVE INGREDIENT

5 Technical Field

The present invention relates to NF- κ B inhibitors,
and more specifically to preventive or therapeutic agents
for diseases caused by the activation of NF- κ B comprising
as an active ingredient a benzoquinone derivative or its
10 hydroquinone form or a pharmaceutical acceptable salt
thereof.

Background Art

Nitric oxide (NO) is biosynthesized from L-arginine
as the substrate by NO synthase (NOS). Currently three
15 isozymes of NOS have been found: the brain isozyme
(bNOS), the endothelial isozyme (eNOS), and the inducible
isozyme (iNOS) (Moncada, S. and Higgs, A. (1993) N. Eng.
J. Med. 329: 2002-2012). The transcription of iNOS can
be activated by an action of endotoxins and cytokines on
20 macrophage, vascular smooth muscle cells, hepatic cells,
chondrocytes, gliocytes, etc., resulting in expression
thereof (Forstermann, U., Gath, I., Schwarz, P., Closs,
E. I. and Kleinert, H. (1995) Biochem. Pharmacol. 50:
1321-1332).

25 The iNOS has been reported to be induced by
inflammatory conditions regardless of the species, and
the suppression of the enzymatic activity and of the
expression has been shown to be useful for amelioration
of the disease states (Cattell, V. and Jansen, A. (1995)
30 Histochem. J. 27: 777-784; Nussler, A. K. and Billiar, T.
R. (1993) J. Leukoc. Biol. 54: 171-178).

It has been reported that arginine derivatives or
aminoguanidine exhibit pharmacological effects in model
animals of myocarditis, cerebral infarction, arthritis,
35 sepsis, multiple sclerosis, systemic lupus erythematosus,
and insulin-dependent diabetes mellitus (Moncada, S. and

Higgs, E. A. (1995) *Faseb. J.* 9: 1319-1330). Though L-N-monomethyl arginine, a NOS inhibitor, is highly toxic at high doses, it not only improves low blood pressure in sepsis but has a marked preventive effect, on which a
5 clinical trial is under way (Moncada, S. and Higgs, E. A. (1995) *Faseb. J.* 9: 1319-1330).

Furthermore, resistance against sepsis or inflammation induced by carageenin has been shown in experiments using iNOS knockout mice, revealing that the
10 expression of iNOS causes these pathological states (Wei, X.Q., Charles, I. G., Smith, A., Ure, J., Feng, G. J., Huang, F. P., Xu, D., Muller, W., Moncada, S. and Liew, F. Y. (1995) *Nature* 375: 408-411).

An excess of NO produced by the induction of iNOS
15 expression is believed to damage normal cells and cause various disease states. On the other hand, the constitutively occurring NOS (cNOS) termed eNOS or bNOS is required to suppress an increase in blood pressure and to maintain it. Thus, inhibitors which do not inhibit
20 the activity of cNOS and that are specific for iNOS are required. However, since the regions of the proteins that regulates the enzymatic activity of isozymes are very similar to one another in the primary structure, no NOS inhibitors have yet been found which are sufficiently
25 specific (Ogden, J. E. and Moore, P. K. (1995) *Trends Biotechnol.* 13: 70-78, Manning, R., Jr., Hu. L., Mizelle, H. L., Montani, J. P. and Norton, M. W. (1993) *Hypertension* 22: 40-48).

As enzyme inhibitors, L-arginine (and amino acid)
30 derivatives have mainly been developed but many of them are low in isozyme specificity. Although aminoguanidine and amidine derivatives, though weakly effective, have been reported to have relatively iNOS-specific inhibitory effects (Southan, G. J. and Szabo, C. (1996) *Biochem.*
35 *Pharmacol.* 51: 383-394), pharmaceutical agents having adequate specificity have yet not to be found.

On the other hand, TNF- α , a cytokine produced by

various cells including macrophage, is believed to be an important mediator of inflammation (Vassalli, P. (1992) *Annu. Rev. Immunol.* 10: 411-452). There is growing evidence that the excessive production of TNF- α damages normal cells and causes various pathological conditions (Muto, Y., Nouri-Aria, K. T., Meager, A., Alexander, G. J., Eddleston, A. L. and Williams, R. (1988) *Lancet* 2: 72-74, Sharief, M. K. and Hentges, R. (1991) *N. Engl. J. Med.* 325: 467-472).

Increases in TNF- α have been observed in the synovial fluid and the blood of patients with, for example, rheumatoid arthritis (Tetta, C., Camussi, G., Modena, V., Di Vittorio, C. and Baglioni, C. (1990) *Ann. Rheum. Dis.* 49: 665-667; Venn, G., Nietfeld, J. J., Duits, A. J., Brennan, F. M., Arner, E., Covington, M., Billingham, M. E. and Hardingham, T. E. (1993) *Arthritis Rheum.* 36: 819-826). Antibody against TNF- α has also been demonstrated to be effective in clinical trials (Elliott, M. J., Maini, R. N., Feldmann, M., Long-Fox, A., Charles, P., Bijl, H. and Woody, J. N. (1994) *Lancet* 344: 1125-1127; Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, H. and et al. (1994) *Lancet* 344: 1105-1110; Rankin, E. C., Choy, E. H., Kassimos, D., Kingsley, G. H., Sopwith, A. M., Isenberg, D. A. and Panayi, G. S. (1995) *Br. J. Rheumatol.* 34: 334-342).

Furthermore, the involvement of TNF- α in sepsis or inflammatory bowel diseases has been pointed out and the ameliorating effects of anti-TNF- α antibody on these diseases have been observed (Vincent, J. L., Bakker, J., Marecaux, G., Schandene, L., Kahn, R. J. and Dupont, E. (1992) *Chest* 101: 810-815; Hinshaw, L. B., Tekamp-Olson, P., Chang, A. C., Lee, P. A., Taylor, F., Jr., Murray, C. K., Peer, G. T., Emerson, T., Jr., Passey, R. B. and Kuo,

G. C. (1990) Circ. Shock 30: 279-292).

These findings expressly indicate that the excessive production of TNF- α causes and aggravates various inflammations, and thereby there the development of pharmaceutical agents which can inhibit the production of TNF- α is required (Nyman, U., Mussener, A., Larsson, E., Lorentzen, J. and Klareskog, L. (1997) Clin. Exp. Immunol. 108: 415-419).

Thus, iNOS or TNF- α have been recognized to be one of the causes of various inflammations. However, the fact that many other mediators have been demonstrated to cause inflammation and thereby the cause of the diseases cannot be attributed to any one particular mediator makes the development of therapeutic agents difficult. Under these circumstances, there is a great need for low molecular weight compounds that not only suppress the expression of particular proteins but inhibit widely the production and expression of proteins involved as causative factor in the inflammation.

NF- κ B is a protein that regulates gene expression and is one of the so-called transcription factors. When normal cells are stimulated with an inflammatory cytokine such as interleukin-1 (IL-1) and TNF- α , a lipopolysaccharide, or ultraviolet rays, NF- κ B are activated and then they translocate from the cytoplasm into the nucleus where they bind to specific nucleotide sequences on the genomic DNA and thereby become involved in the expression of various genes (Blackwell, T. S. and Christman, J. W. (1997) Am. J. Respir. Cell Mol. Biol. 17: 3-9).

Genes encoding iNOS and TNF- α , though entirely different from one another, have regions to which NF- κ B binds on the expression control region of the genomic gene thereof, and there is growing evidence that the activation of NF- κ B is important for the expression of

these proteins in common (Jongeneel, C. V. (1994) Prog. Clin. Biol. Res. 388: 367-381; Xie, Q. W., Kashiwabara, Y. and Nathan, C. (1994) J. Biol. Chem. 269: 4705-4708; Nunokawa, Y., Oikawa, S. and Tanaka, S. (1996) Biochem. Biophys. Res. Commun. 223: 347-352).

Many genes that are involved in immunological inflammatory reactions under expression control by NF- κ B are recognized, in addition to iNOS and TNF- α , ones for inflammatory cytokines such as IL-1, IL-6 and IL-8, as well as cell adhesion factors such as ICAM-1, VCAM-1 and ELAM-1 or the like (Collins, T., Read, M. A., Neish, A. S., Whitley, M. Z., Thanos, D. and Maniatis, T. (1995) Faseb. J. 9: 899-909). Furthermore, it is known that inflammatory cytokines, when bound to receptors, transduce NF- κ B-activating signals via various routes, and this fact is believed to be cause that further aggravates inflammation. Thus, the activation of NF- κ B in inflammation is understood as an etiological and aggravating matter of diseases (Baeuerle, P. A. and Baichwal., V. R. (1997) Adv. Immunol. 65: 111-137).

In recent years, it has also been reported that HIV, HTLV-1, CMV, adenovirus and the like activate NF- κ B in host cells (Dezube, B. J., Pardee, A. B., Beckett, L. A., Ahlers, C. M., Ecto, L., Allen-Ryan, J., Anisowicz, A., Sager, R. and Crumpacker, C. S. (1992) J. Acquir. Immune Defic. Syndr. 5: 1099-1104; Nabel, G. and Baltimore, D. (1987) Nature 326: 711-713; Fazely, F., Dezube, B. J., Allen-Ryan, J., Pardee, A. B. and Ruprecht, R. M. (1991) Blood 77: 1653-1656; Munoz, E. and Israel, A. (1995) Immunobiology 193: 128-136). The activation of NF- κ B in turn activates its transcription leading to the progression of viral propagation and infection.

Accordingly, it is possible to suppress altogether the induction of expression of these inflammatory cytokines, genes of adhesion molecules, and viruses by

inhibiting the activation of NF- κ B, and NF- κ B inhibitors are promising as therapeutic agents of such diseases as are caused either directly or indirectly by the activation of NF- κ B, specifically various inflammatory diseases, autoimmune diseases and viral diseases, and immunosuppressive agents.

Therapeutic agents currently used for chronic diseases include steroid hormones such as glucocorticoids, non-steroidal aspirin formulations, and the like. However, glucocorticoids are known to be associated with the appearance of severe side effects such as the aggravation of infectious diseases, onset of peptic ulcer, and central effects, and therefore are not amenable to a long-term administration. Furthermore, although the non-steroidal agents, suppress the production of prostaglandins etc., they do not provide curative treatments and they are known to exhibit such side effects as the onset of peptic ulcer and central effects.

It has also been reported in recent years that anti-inflammatory drugs at high doses inhibit the activation of NF- κ B (Auphan, N., DiDonato, J. A., Rosette, C., Helmborg, A. and Karin, M. (1995) Science 270: 286-290; Shackelford, R. E., Alford, P. B., Xue, Y., Thai, S. F., Adams, D. O. and Pizzo, S. (1997) Mol Pharmacol. 52: 421-429; Bitko, V., Velazquez, A., Yang, L., Yang, Y. C. and Barik, S. (1997) Virology 232: 369-378). However, due to their diverse pharmacological actions, these compounds have side effects, and therefore the development of safer drugs based on a novel mechanism is required.

As a method of inhibiting the actions of TNF- α , it is thought that the use of antibodies that specifically bind to TNF- α and TNF receptor proteins. However, those are both macromolecule proteins and are not suitable for oral administration.

Phenylmethyl benzoquinone derivatives exhibit the effect of improving cerebral functions in experimental animals of anoxia at low doses, and are shown to be effective for improving and treating intracerebral organic disorders and mental function disorders (Suzuki, K., Tatsuoka, T., Murakami, T., Ishihara, T., Aisaka, K., Inoue, T., Ogino, R., Kuroki, M., Miyazaki, T., Satoh, F., Miyano, S. and Sumoto, K. (1996) Chem. Pharm. Bull. 44: 139-144). However, at present the effects of phenylmethyl benzoquinone derivatives on the production of inflammatory mediators and on the activation of NF- κ B have not been known.


Disclosure of the Invention

The present invention provides preventive and therapeutic agents for diseases caused by the activation of NF- κ B, for example, diseases caused by the overproduction of various inflammatory mediators and viral propagation, by suppressing and/or inhibiting the activation of NF- κ B. More specifically it provides therapeutic and preventive agents for diseases that are believed to be caused by the excessive production of NO or TNF- α including, for example, septic shock, osteoarthritis, rheumatoid arthritis, cachexia, multiple organ failure, inflammatory bowel diseases, malaria, acquired immune deficiency syndrome, human T-cell leukemia, meningitis, hepatitis, type II diabetes, multiple sclerosis, Behcet disease, systemic lupus erythematosus, ischemic heart disease, Alzheimer's disease, and the like.

As a result of intensive studies on substances that inhibit the activation of NF- κ B, the present inventors have found that benzoquinone derivatives represented by the general formula (1) or its hydroquinone forms or pharmaceutical acceptable salts thereof potently suppress

and/or inhibit the activation of NF- κ B and that they inhibit the production of NO and TNF- α on the gene level, and thereby have accomplished the present invention.

Thus, the present invention relates to NF- κ B inhibitors comprising as an active ingredient a benzoquinone derivative represented by the following general formula (1):









(1)

wherein

R_1 , R_2 , and R_3 are each independently a hydrogen atom, an alkyl group having 1 to 5 carbons, or an alkoxy group having 1 to 5 carbons;

R_4 is a hydrogen atom, a hydroxymethyl group, an alkyl group, or a carboxyl group which is optionally esterified or amidated;

Z is



and, n is an integer from 0 to 6, or its hydroquinone form, or a pharmaceutically acceptable salts thereof, and to their use in the preventive or therapeutic agents for inflammatory diseases, autoimmune diseases, and viral diseases, in which they are used as suppressing agents for the gene

expression of one or more substances selected from the group consisting of IL-1, TNF- α , IL-2, IL-6, IL-8, iNOS, granulocyte colony-stimulating factor, interferon- β , ICAM-1, VCAM-1, ELAM-1, major histocompatibility system class I, major histocompatibility system class II, β 2-microglobulin, immunoglobulin light chain, serum amyloid A, angiotensinogen, complement B, complement C4, c-myc, HIV, HTLV-1, SV40, CMV, and adenovirus.

The present invention also provides preventive or therapeutic agents for diseases caused by the activation of NF- κ B comprising as an active ingredient a benzoquinone derivative represented by the general formula (1) or its hydroquinone form or a pharmaceutical acceptable salt thereof.

The present invention also relates to inhibitors of TNF- α production comprising as an active ingredient a benzoquinone derivative represented by the general formula (1) or its hydroquinone form or a pharmaceutical acceptable salt thereof, and to their use as the preventive or therapeutic agents for inflammatory diseases, autoimmune diseases, and viral diseases, in which they are used as suppressing agents for the gene expression of one or more substances selected from the group consisting of IL-1, TNF- α , IL-2, IL-6, IL-8, iNOS, granulocyte colony-stimulating factor, interferon- β , ICAM-1, VCAM-1, ELAM-1, plasminogen activator-inhibiting factor I, major histocompatibility system class I, major histocompatibility system class II, β 2-microglobulin, immunoglobulin light chain, serum amyloid A, angiotensinogen, complement B, complement C4, c-myc, HIV, HTLV-1, SV40, CMV, and adenovirus.

The present invention also provides preventive or therapeutic agents for diseases caused by the overproduction of TNF- α comprising as an active

ingredient a benzoquinone derivative represented by the general formula (1) or its hydroquinone form or a pharmaceutical acceptable salt thereof.

5 The present invention also provides a benzoquinone derivative represented by the general formula (1) or its hydroquinone form or a pharmaceutical acceptable salt thereof.

Brief Explanation of Drawings

10 Figure 1 shows a result of the gel shift assay of a nuclear extract when A549 cells were stimulated with a cytokine. Lane 1: no extract, lanes 2 and 3: no cytokine stimulation, lanes 4 and 5: stimulated for 4 hours with IL-1 β , and lanes 6 and 7: stimulated for 4 hours with CM.
15 In lanes 3, 5, and 7, a 20-fold concentrate of DIG-free probe was added.

Figure 2 shows that the compound obtained in Example 4 inhibits the activation of NF- κ B after stimulation with CM as measured by a gel shift assay.

20 L represents a complex of a labeled probe comprising an NF- κ B binding sequence and the nuclear extract, and F shows a result of the experiment in which a non-labeled probe was added at an amount 100 times more than that of the labeled probe under the same condition as that of L.

25 Figure 3 shows the effect of the compound obtained in Example 4 when A549/NF- κ B Luc is stimulated with IL-1 or TNF- α . It shows the result of the experiment in which the compound obtained in Example 4 was added, and one hour later it was stimulated for 4 hours with IL-1 or
30 TNF- α followed by the determination of the activity of the reporter gene.

Figure 4 shows the effect of the compound obtained in Example 4 on the production of NO and TNF- α after stimulation with LPS using the mouse macrophage-derived
35 RAW 264.7.

It shows the result of the experiment in which the compound obtained in Example 4 was added to the culture medium one hour before LPS stimulation and then the NO level (A) in the culture medium 24 hours after the stimulation and the TNF- α level (B) in the culture medium 4 hours after the stimulation were determined.

Figure 5 shows changes in the amount of mRNA of iNOS and TNF- α in the RAW264.7 cells.

A shows the result obtained by the determination of the level of iNOS mRNA and TNF- α mRNA in the cells 6 hours after the LPS stimulation.

B shows the result of the experiment in which the compound (20 μ g/ml) obtained in Example 4 was added to the culture medium one hour before the LPS stimulation and then the levels of iNOS mRNA and TNF- α mRNA in the cells 6 hours after the stimulation were measured.

Figure 6 shows changes with time of the incidence of edema after the administration of a prophlogistic agent when compound 1 (30 mg/kg) was intraperitoneally given 2 hours before the administration of the prophlogistic agent.

Figure 7 shows the incidence of edema suppression 2 hours after the administration of a prophlogistic agent when compound 1 (30 mg/kg) and compound 2 (50 mg/kg) were intraperitoneally given 2 hours before the administration of the prophlogistic agent.

Embodiment for Carrying Out the Invention

The hydroquinone form as used herein refers to the compound that is formed by converting an oxo at position 1 and/or position 4 of the benzoquinone ring of the benzoquinone derivative of the present invention to a hydroxy group chemically with a catalyst etc. or biochemically with an enzyme etc., or by converting with reduction in vivo, and that has an activity equivalent to

that of the benzoquinone derivative.

As the pharmaceutically acceptable salt, there may be mentioned, for example, a salt with an inorganic acid such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, and hydrobromic acid, an organic acid such as maleic acid, fumaric acid, tartaric acid, lactic acid, citric acid, acetic acid, methanesulfonic acid, p-toluenesulfonic acid, adipic acid, palmitic acid, and tannic acid, an inorganic metal including an alkali metal such as lithium, sodium, and potassium, and an alkaline earth metal such as calcium, and magnesium, and a basic amino acid such as lysine, or a salt with an organic amine such as ammonium.

In the formula, R_1 , R_2 , and R_3 are each independently a hydrogen atom, an alkyl group having 1 to 5 carbons, or an alkoxy group having 1 to 5 carbons. Preferred examples of the alkyl group include straight or branched saturated aliphatic hydrocarbon groups having 1 to 5 carbons such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, and tert-pentyl, saturated alicyclic hydrocarbon groups such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl, saturated alicyclic hydrocarbon-aliphatic hydrocarbon groups such as cyclopropylmethyl, cyclopropylethyl, and cyclobutylmethyl, and the alkoxy groups include the oxy groups of the above. Preferred examples of R_1 and R_2 include a hydrogen atom, a methyl group, and a methoxy group, and those of R_3 include a hydrogen atom or a methyl group.

R_4 represents a hydrogen atom, a hydroxymethyl group, an alkyl group, or a carboxyl group which is optionally esterified or amidated, wherein preferred examples of the alkyl group include those mentioned above for R_1 , R_2 and R_3 , and preferred examples of the carboxyl group which is optionally esterified or amidated include: a group $-COOR_5$ wherein R_5 is a hydrogen atom, an

optionally substituted alkyl group having 1 to 8 carbons,
an optionally substituted phenyl group, or an optionally
substituted aralkyl group having 7 to 11 carbons; a group
-CONR₆R₇, wherein R₆ and R₇ are each independently a
5 hydrogen atom, an optionally substituted alkyl group
having 1 to 8 carbons, an optionally substituted bicyclic
unsaturated or partially saturated hydrocarbon ring group
having 9 to 11 carbons, an optionally substituted
heterocyclic group, an optionally substituted phenyl
10 group, an optionally substituted aralkyl group having 7
to 10 carbons, or a heteroaryl-C₁-C₃-alkyl group, or R₆
and R₇, together with the nitrogen atom to which they are
attached, represent a heterocyclic group which may
further contain a nitrogen, oxygen, and/or sulfur atom,
15 and; a group -CONR₆R₇, wherein R₆ and R₇, together with the
nitrogen atom to which they are attached, represent a 5-
to 10-membered optionally substituted, nitrogen-
containing heterocyclic group which may contain, in
addition to the carbon and nitrogen atom, 1 to 3
20 heteroatoms selected from the group consisting of a
nitrogen, oxygen, and sulfur atom, the carbon atom on
said cyclic group being optionally a ketone form or the
sulfur atom on said cyclic group being optionally an
oxide form.

25 As specific examples of the alkyl group R₅ having 1
to 8 carbons, there may be mentioned a straight or
branched saturated aliphatic hydrocarbon group having 1
to 8 carbons such as methyl, ethyl, propyl, isopropyl,
butyl, isobutyl, sec-butyl, tert-butyl, 3-methylbutyl,
30 pentyl, 1-ethylbutyl, isopentyl, neopentyl, tert-pentyl,
1,3-dimethylbutylhexyl, 1-methylhexyl, 3,3-dimethylbutyl,
2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, hexyl,
heptyl, and 1-methylheptyl; a saturated alicyclic
hydrocarbon group such as cyclopropyl, cyclobutyl,
35 cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl; and
a saturated alicyclic hydrocarbon-aliphatic hydrocarbon
group such as cyclopropylmethyl, cyclopropylethyl,

cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, and cyclopentylmethyl, and the like. As specific examples of an aralkyl group having 7 to 11 carbons, there may be mentioned benzyl, phenethyl, 1-phenylethyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl, 1-naphthylmethyl, 2-naphthylmethyl and the like.

The alkyl, phenyl and aralkyl groups described above may be substituted, on the chain or the ring thereof, with one or two substituents or substituents comprising combinations of these substituents, said substituent being selected from, for example, a hydroxyl group; an aldehyde group; a carboxyl group; a carbamoyl group; an amino group; a nitrile group; a cyano group; a halogen atom such as a chlorine and fluorine atom; an alkyl group having preferably 1 to 6 carbons such as a methyl, ethyl, propyl and isopropyl group, or their halogenated or hydroxy-substituted group and alkoxy-alkyl group; an aryl group having preferably 6 to 10 carbons such as a phenyl and naphthyl group, or their halogenated group; an aralkyl group having preferably 7 to 11 carbons such as a benzyl, phenethyl and 3-phenylpropyl group; an alkyloxy group having preferably 1 to 6 carbons such as a methoxy, ethoxy, propyloxy and butyloxy group; a cyclic acetal group such as a methylenedioxy and ethylenedioxy group; an aralkyloxy having preferably 7 to 11 carbons such as a benzyloxy, phenethyloxy and 3-phenylpropyloxy group, and phenoxy group; an alkylcarbonyl group having preferably 2 to 6 carbons such as a methylcarbonyl, ethylcarbonyl and propylcarbonyl group; an arylcarbonyl group having preferably 7 to 11 carbons such as a benzoyl group; an alkyloxycarbonyl group having preferably 2 to 6 carbons such as a methoxycarbonyl, ethoxycarbonyl, propyloxycarbonyl and tert-butyloxycarbonyl group; an aralkyloxycarbonyl having preferably 8 to 12 carbons such as a benzyloxycarbonyl, phenethyloxycarbonyl and 3-phenylpropyloxycarbonyl group, and phenoxycarbonyl group; an amino group substituted with one substituent or a

combination of two substituents that are the same or different, said substituent being selected from an alkyl group having preferably 1 to 4 carbons such as a methyl, ethyl, propyl and isopropyl group, an aralkyl having
5 preferably 7 to 11 carbons such as a benzyl, phenethyl and 3-phenylpropyl group, phenyl group, an alkylcarbonyl group having preferably 2 to 6 carbons such as a methylcarbonyl, ethylcarbonyl and propylcarbonyl group, and an arylcarbonyl group having preferably 7 to 11
10 carbons such as a benzoyl group and the like; a 5- to 10-membered monocyclic or bicyclic unsaturated, partially or fully saturated heterocyclic ring containing 1 to 3 heteroatoms selected from the group consisting of a nitrogen, oxygen and sulfur atom, for example, pyrrole,
15 furan, thiophene, pyran, indole, benzofuran, benzothiophene, benzopyran, pyrazole, isoxazole, isothiazole, indazole, benzoisoxazole, benzoisothiazole, imidazole, oxazole, thiazole, benzimidazole, benzoxazole, benzothiazole, pyridine, quinoline, isoquinoline,
20 pyridazine, pyrimidine, pyrazine, cinnoline, phthalazine, quinazoline, quinoxaline, and a partially or fully saturated ring group thereof; a carbamoyl group having an amino group substituted with one substituent or a combination of two substituents that are the same or
25 different, said substituent being selected from an alkyl group having preferably 1 to 4 carbons such as a methyl, ethyl, propyl and isopropyl group, an aralkyl having preferably 7 to 11 carbons such as a benzyl, phenethyl and 3-phenylpropyl group, phenyl group, an alkylcarbonyl
30 group having preferably 2 to 6 carbons such as a methylcarbonyl, ethylcarbonyl and propylcarbonyl group, and an arylcarbonyl group having preferably 7 to 11 carbons such as a benzoyl group, and the like, or a cyclic amino group such as a 5- to 8-membered
35 heterocyclic ring optionally containing 1 to 3 heteroatoms selected from the group consisting of a nitrogen, oxygen and sulfur atom, for example,

pyrrolidine, piperidine, morpholine, thiomorpholine, and piperazine; and the like.


As the optionally substituted alkyl groups having 1 to 8 carbons, the optionally substituted phenyl group and the optionally substituted aralkyl group having 7 to 11 carbons of R_6 and R_7 , those described for R_5 may be mentioned. As specific examples of the hydrocarbon ring of a bicyclic unsaturated or partially saturated hydrocarbon ring group having 9 to 11 carbons, there may be mentioned indene, indan, naphthalene, 1,2-dihydronaphthalene, 1,2,3,4-tetrahydronaphthalene and the like. As specific examples of the heterocyclic ring of a heterocyclic group, there may be mentioned a 5- to 10-membered monocyclic or bicyclic unsaturated, or partially or fully saturated heterocyclic ring containing 1 to 3 heteroatoms selected from the group consisting of a nitrogen, oxygen and sulfur atom, for example, pyrrole, furan, thiophene, pyran, indole, benzofuran, benzothiophene, benzopyran, pyrazole, isoxazole, isothiazole, indazole, benzoisoxazole, benzoisothiazole, imidazole, oxazole, thiazole, benzimidazole, benzoxazole, benzothiazole, pyridine, quinoline, isoquinoline, pyridazine, pyrimidine, pyrazine, cinnoline, phthalazine, quinazoline, quinoxaline, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroisoquinoline, decahydroquinoline, and the like, as well as the partially or fully saturated ring thereof. Examples of a heteroaryl- C_1 - C_3 -alkyl group include, for example, a 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-pyrimidylmethyl, 2-imidazolylmethyl, 2-pyridylethyl, 3-pyridylethyl, 4-pyridylethyl, 1-(2-pyridyl)ethyl, 1-(3-pyridyl)ethyl, and 1-(4-pyridyl)ethyl group, and they may also be substituted on the chain or ring thereof with the same substituent to those described above for R_5 .

As preferred examples of the heterocyclic group formed by R_6 and R_7 together with the nitrogen atom to which they are attached, which may further contain a


nitrogen, oxygen and/or sulfur atom, or the 5- to 10-membered nitrogen-containing heterocyclic group formed by R_6 and R_7 together with the nitrogen atom to which they are attached, which may contain, in addition to a carbon and nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen, oxygen and sulfur atom, there may be mentioned, for example, morpholino, thiomorpholino, pyrrolidino, piperidino, homopiperidino, piperazino, homopiperazino, and the like.

The carbon atom on the chain or the ring may be a ketone form, or the sulfur atom may be an oxide form, or the carbon atom or the nitrogen atom on the chain or the ring may be substituted with substituents as described for R_5 .


Z is represented by



and n represents an integer from 0 to 6. In a preferred example, Z is




and n is an integer 0, or Z is



and n is a integer 1, 2 or 3.

Most preferably, R_1 and R_2 are a methyl group or methoxy group; R_3 is a methyl group; R_4 is a carboxyl

group which is optionally esterified or amidated; Z is



5

and n is an integer 1, 2 or 3.

Preferred specific compounds include the following compounds:

10 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]morpholine,

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]thiomorpholine,

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]thiomorpholine S-oxide,

15 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]thiomorpholine S-dioxide,

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]piperidine,

20 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]dimethylamine,

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]isopropylamine,

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]ethanolamine,

25 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]benzylamine,

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]phenethylamine,

30 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]morpholine,

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]thiomorpholine,

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]piperidine,

35 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]dimethylamine,

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-

- ylmethyl)phenyl]acryloyl]isopropylamine,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]ethanolamine,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]benzylamine,
5 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]phenethylamine,
3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid,
10 3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid,
2,3-dimethoxy-6-benzyl-5-methyl-1,4-benzoquinone,
3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propanol,
15 3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid ethylester,
3-[3-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid,
3-[3-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid,
20 3-[3-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid ethylester,
N-[3-[3-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]morpholine,
25 1-[3-[3-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-4-methylpiperazine,
4-[3-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]-n-butyric acid,
3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid,
30 3-[4-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid,
3-[4-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid ethylester,
35 3-[4-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid,
4-[4-(3,5,6-trimethyl-1,4-benzoquinon-2-

- ylmethyl)phenyl]-n-butyric acid,
N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]piperidine,
N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]thiomorpholine,
5 N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]morpholine,
N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]isopropylamine,
10 3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid,
N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]piperidine,
N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]morpholine,
15 N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]isopropylamine,
N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]thiomorpholine,
20 N-[3-[4-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]isopropylamine,
N-[3-[4-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]piperidine,
N-[3-[4-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]morpholine,
25 N-[3-[3-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]isopropylamine,
N-[3-[3-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]piperidine,
30 3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid,
N-[3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]thiomorpholine,
3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid,
35 N-[3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]piperidine,

- N-[3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]morpholine,
- N-[3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]thiomorpholine,
- 5 N-[3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]isopropylamine,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-(s)-2-(methoxymethyl)pyrrolidine,
- 10 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]isonipecotamide,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-4-methylpiperidine,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-2-methylpiperidine,
- 15 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-3-methylpiperidine,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-4-methoxyaniline,
- 20 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-2-hydroxyaniline,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-3,4-dimethoxyaniline,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-D,L-alaninol,
- 25 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-D,L-pipecolic acid ethylester,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-L-prolinamide,
- 30 4-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]aminophenylacetonitrile,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-4-pentylaniline,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-(s)-(-)-1-phenylethylamine,
- 35 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-(R)-(+)-1-phenylethylamine,

- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-1,3-dimethylbutylamine,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]cycloheptylamine,
5 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-3,5-dimethylpiperidine,
1-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-4-ethoxycarbonylpiperazine,
1-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-4-phenylpiperazine,
10 1-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-4-hydroxy-4-phenylpiperidine,
1-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-4-(4-chlorophenyl)-4-
15 hydroxypiperidine,
1-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-4-(2-methoxyphenyl)piperazine,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-6,7-dimethoxy-1,2,3,4-
20 tetrahydroisoquinoline,
4-acetyl-4-phenyl-1-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]piperidine,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-1,2,3,4-
25 tetrahydroisoquinoline,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]isoamylamine,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]cyclohexylamine,
30 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-4-hydroxyaniline,
4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoic acid,
N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoyl]morpholine,
35 N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoyl]isopropylamine,

- N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoyl]piperidine,
- N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoyl]thiomorpholine,
- 5 3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoic acid,
- N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoyl]isopropylamine,
- N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)piperidine,
- 10 N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)morpholine,
- N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)thiomorpholine,
- 15 4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]-n-butyric acid,
- N-[4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]morpholine,
- N-[4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]thiomorpholine,
- 20 N-[4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]piperidine,
- N-[4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]isopropylamine,
- 25 4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetic acid,
- N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]morpholine,
- N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]piperidine,
- 30 N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]thiomorpholine,
- N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]isopropylamine,
- 35 3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetic acid,
- N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-

ylmethyl)phenylacetyl]piperidine,

N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]thiomorpholine,

5 N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]morpholine,

N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]morpholine,

4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]-n-butyric acid,

10 N-[4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]piperidine,


N-[4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]thiomorpholine,

15 N-[4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]morpholine, and

N-[4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]isopropylamine.

20 The benzoquinone derivative of the general formula (1) that is used as an active ingredient of the present invention may be prepared according to the method described in Japanese Unexamined Patent Publication (Kokai) No. 62(1987)-286949 or Chem. Pharm. Bull., 44(1): 139-144 (1996) or a method based thereupon.

25 Also, in the general formula (1) a benzoquinone derivative wherein R₁ and R₂ are a hydrogen atom, a methyl group or a methoxy group; R₃ is a hydrogen atom or a methyl group; R₄ is a carboxyl group which is optionally esterified or amidated; Z is




and, n is represented by an integer from 0 or 2,

may also be prepared according to the following synthetic procedure.


Method 1.

An aldehyde represented by the general formula (II):





(II)

wherein R_1 , R_2 , and R_3 are as defined above, and R_8 represents an alkyl group having 1 to 5 carbons is allowed to react with a Grignard reagent of a halide represented by the general formula (III):




(III)

wherein X represents a bromine or a chlorine atom and R_9 represents a group:




to obtain a compound represented by the general formula (IV):



(IV)


wherein R_1 , R_2 , R_3 , R_8 and R_9 are as defined above.

Compound (IV) is allowed to react with acetic anhydride in the presence of, for example, a base such as pyridine and 4-dimethylaminopyridine to prepare an acetylated compound, which is then subjected to a
 5 deacetal reaction in an acetone solution in the presence of an acid such as p-toluenesulfonic acid or camphorsulfonic acid to prepare an aldehyde represented by the general formula (V):



(V)


wherein R_1 , R_2 , R_3 and R_8 are as defined above). The aldehyde is allowed to react with a Wittig reagent of triethyl phosphonoacetate, which is further reduced with a reducing agent such as triethylsilane in the presence
 20 of an acidic catalyst such as trimethylsilyl trifluoromethanesulfonate (hereinafter referred to as TMSOTf) to yield a compound represented by the general formula (VI):



(VI)

wherein R_1 , R_2 , R_3 and R_8 are as defined above.


Compound (VI) is hydrolyzed or is further esterified or amidated in a conventional method to prepare a compound represented by the general formula (VII):



(VII)

wherein R_1 , R_2 , R_3 and R_8 are as defined above, and R_{10} represents a carboxyl group which is optionally esterified or amidated.

The compound (VII) is then oxidized with ceric ammonium nitrate (hereinafter referred to as CAN) to yield the compound of the present invention represented by the general formula (Ia):




(Ia)

wherein R_1 , R_2 , R_3 and R_{10} are as defined above. Using the compound of formula (Ia) wherein R_{10} is a carboxyl group, an ester or an amide derivative may be obtained by a conventionally used esterification or amidation reaction, respectively.

Method 2.

The compound represented by the general formula (VI) obtained in the above method is subjected to a catalytic hydrogenation and then is hydrolyzed or is further esterified or amidated in a conventional method to prepare a compound represented by the general formula (VIII):




5

(VIII)

wherein R_1 , R_2 , R_3 , R_8 and R_{10} are as defined above.

Subsequently, compound (VIII) can be oxidized with CAN to yield the compound of the present invention represented by the general formula (Ib):

10



15

(Ib)


wherein R_1 , R_2 , R_3 and R_{10} are as defined above.

The compound of formula (Ib) wherein R_{10} is a carboxyl group may be converted to an ester or an amide derivative through a conventional procedure of esterification or amidation, respectively.

20

A benzoquinone derivative of the general formula (I) wherein R_1 and R_2 are a hydrogen atom, a methyl group or a methoxy group; R_3 is a hydrogen atom or a methyl group; R_4 is a carboxyl group which is optionally esterified or amidated; Z is

25




30

and n is an integer 0 may also be prepared by the following synthetic procedure.

Method 3.


An aldehyde obtained in the above method represented by the general formula (V):

35



(V)


wherein R_1 , R_2 , R_3 and R_8 are as defined above, is oxidized using an oxidizing agent such as potassium permanganate, silver oxide, activated manganese dioxide and pyridinium dichromate, preferably silver oxide in an aqueous solution of sodium hydroxide to prepare a carboxylic acid represented by the general formula (IX):



(IX)

wherein R_1 , R_2 , R_3 and R_8 are as defined above.


The carboxylic acid is reduced using a reducing agent such as triethylsilane in the presence of an acidic catalyst such as TMSOTf to yield a compound represented by the general formula (X):



(X)

wherein R_1 , R_2 , R_3 and R_8 are as defined above.


Compound (X) may be further esterified or amidated to prepare a compound represented by the general formula (XI):



(XI)

wherein R_1 , R_2 , R_3 and R_8 are as defined above, and R_{10} is a carboxyl group which is optionally esterified or amidated.

Subsequently, compound (XI) can be oxidized with CAN to yield the compound of the present invention represented by the general formula (Ic):




(Ic)

wherein R_1 , R_2 , R_3 and R_{10} are as defined above. The compound of formula (Ic) wherein R_{10} is a carboxyl group may be converted to an ester or an amide derivative through a conventional procedure of esterification or amidation, respectively.


Method 4.

An aldehyde represented by the general formula (II):




(II)

wherein R_1 , R_2 , R_3 and R_8 are as defined above, and an iodobenzoic acid ester represented by the general formula (XII):



(XII)


wherein R_{11} represents an alkyl group such as a methyl group and an ethyl group, may be reacted in the presence of zinc chloride and an alkyllithium reagent such as methyllithium, n-butyllithium, or t-butyllithium to prepare an ester represented by the general formula (XIII):



(XIII)

wherein R_1 , R_2 , R_3 , R_8 and R_{11} are as defined above.


The ester is reduced in a method similar to the one described above and then hydrolyzed or is further esterified or amidated in a conventionally used method, to prepare a compound represented by the general formula (XI):



(XI)

wherein R_1 , R_2 , R_3 and R_8 are as defined above, and R_{10} is a carboxyl group which is optionally esterified or amidated.

Subsequently, compound (XI) can be oxidized with CAN to yield the compound of the present invention represented by the general formula (Ic):



5

(Ic)

wherein R_1 , R_2 , R_3 and R_{10} are as defined above. The compound of formula (Ic) wherein R_{10} is a carboxyl group may be converted to an ester or an amide derivative through a conventional procedure of esterification or amidation, respectively.

A benzoquinone derivative of the general formula (I) wherein R_1 and R_2 are a hydrogen atom, a methyl or a methoxy group; R_3 is a hydrogen atom or a methyl group; R_4 is a carboxyl group which is optionally esterified or amidated; Z is




20

and n is an integer 1 or 3, may also be prepared by the following synthetic procedure.

Method 5.

A carboxylic acid obtained in the above method represented by the general formula (XIV):




30

(XIV)

wherein R_1 , R_2 , R_3 and R_8 are as defined above and m is an integer 0 or 2, is reacted with oxalyl chloride or thionyl chloride to prepare an acid chloride, which is then reacted with an excess of diazomethane to convert to

35


the corresponding diazomethyl ketone. The diazomethyl ketone can be then subjected to Wolff rearrangement reaction in the presence of silver oxide or a silver salt catalyst such as silver acetate to yield a carboxylic acid derivative represented by the general formula (XV):



(XV)

wherein R_1 , R_2 , R_3 and R_8 are as defined above and m is an integer 0 or 2, R_{10} is a carboxyl group which is optionally esterified or amidated, said derivative having a carbon chain increased by one carbon. Through this rearrangement reaction, carboxylic acids, esters, and amides can be synthesized using water, alcohols, and amines as reaction solvent, respectively.

Subsequently, compound (XV) can be oxidized with CAN to yield the compound of the present invention represented by the general formula (Id):




(Id)

wherein R_1 , R_2 , R_3 , R_{10} and m are as defined above. The compound of formula (Id) wherein R_{10} is a carboxyl group may be converted to an ester or an amide derivative through a conventional procedure of esterification or amidation, respectively.

Method 6.

In stead of the compound represented by the above general formula (XIV), a carboxylic acid represented by

the general formula (XVI):



(XVI)

wherein R₁, R₂, R₃ and m are as defined above may be used as a starting material and treated as in Method 5 to produce a carboxylic acid derivative represented by the general formula (Id) having an increased number of carbon.

Using the above method 5 or 6, it is possible to prepare benzoquinone derivatives having a further extended methylene chain wherein m is represented by an integer 4, 5 or 6.

Compound (I) of the present invention thus obtained can be converted to various salts mentioned above, as desired, and can be purified by means of recrystallization, column chromatography, and the like.

Furthermore, some of the compounds (I) of the present invention have an asymmetric center, and these optical isomers are encompassed by the present invention and can be obtained from mixture of racemic compounds as single optically active isomers through separation with various means. Exemplary methods used include:

- (1) separation with an optically active column;
- (2) conversion into salts using an optically active acid, followed by separation via recrystallization;
- (3) separation by enzymatic reactions; and
- (4) separation by combinations of the above (1) to (3).

Since the compounds as claimed in the present invention represented by the general formula (I) can inhibit the activation of NF- κ B, they are useful as preventive and therapeutic agents for diseases caused by

the activation of NF- κ B, for example diseases caused by the excessive production of inflammatory mediators and viral propagation. Specifically, they are useful as therapeutic and preventive agents for diseases caused by the excessive production of NO and/or TNF- α , including for example septic shock, osteoarthritis, rheumatoid arthritis, cachexia, multiple organ failure, inflammatory bowel diseases, malaria, acquired immune deficiency syndrome, human T-cell leukemia, meningitis, hepatitis, type II diabetes, multiple sclerosis, Behcet disease, systemic lupus erythematosus, ischemic heart disease, Alzheimer's disease, and the like.

When the compounds of the present invention are used as the above-mentioned pharmaceutical compositions, they may be used orally in the form of tablets, capsules, elixirs, microcapsules, and the like, or parenterally in the form of injections and the like such as solutions or suspensions with water or other pharmaceutically acceptable liquids. For example, they can be prepared by mixing the invention compound with pharmaceutically acceptable carriers, flavoring agents, excipients, stabilizers, and the like in a commonly recognized form. Additives that can be blended into tablets etc. include, for example, binders such as gelatin, swelling agents such as corn starch, excipients such as crystalline cellulose, lubricants such as magnesium stearate, and the like. When formulated into capsules, the above compositions may further include liquid carriers. Aseptic compositions for injection can also be formulated in the conventional manner.

As aqueous solutions for injection, there may be mentioned isotonic solution that contain glucose etc., and they may be used in combination with suitable solubilizer such as polyethyleneglycol. Buffers, stabilizers, preservatives, antioxidants, soothing agents, and the like may also be blended. The

pharmaceutical preparations thus obtained can be administered to mammals including humans. Though the dosage varies depending on the pathologic state etc. the daily dose per human adult is generally about 0.01 to 100 mg, preferably about 0.1 to 50 mg, and more preferably about 1.0 to 25 mg in oral. When they are given parenterally, the daily dose per human adult is generally intravenously administered at amounts about 0.001 to 50 mg, preferably about 0.01 to 25 mg, more preferably about 0.1 to 10 mg.

The effect of NF- κ B inhibition can be examined by detecting the expression of genes regulated by the activation of NF- κ B, or by determining directly or indirectly the amount expressed of proteins encoded by the genes.

The effect of suppressing the excessive expression of inflammatory proteins may be examined, as shown in the results of Experimental Example 3, by stimulating cells or individual animals with a cytokine such as IL-1 and TNF- α and a lipopolysaccharide, and then determining directly or indirectly the amount of inflammatory proteins that may be increased in the culture medium or the body fluid.

Also, methods of confirming in vivo the general anti-inflammatory effects comprise determining the effect of suppressing edema produced using carrageenin as a prothlogistic agent. It has already been reported that the inhibition of NO and TNF- α production are effective in this model (Filion, M. C. and Phillips, N. C. (1997) Br. J. Pharmacol. 122: 551-557; Tsao, P. W., Suzuki, T., Totsuka, R., Murata, T., Takagi, T., Ohmachi, Y., Fujimura, H. and Takata, I. (1997) Clin. Immunol. Immunopathol. 83: 173-178; Cuzzocrea, S., Zingarelli, B., Hake, P., Salzman, A. L. and Szabo, C. (1998) Free Radic. Biol. Med. 24: 450-459). Furthermore, for specific diseases the efficacy as a therapeutic agent for sepsis

can be evaluated by administering a lipopolysaccharide to animals such as mice and then determining the survival ratio of the animals.

The efficacy as a therapeutic agent for rheumatoid arthritis can also be evaluated in animal models of arthritis using adjuvants. When model animals of myocardial infarction are used, DNA having the decoy sequence of NF- κ B is shown to suppress the lesion of the infarction (Sawa, Y., Morishita, R., Suzuki, K., Kagisaki, K., Kaneda, Y., Maeda, K., Kadoba, K. and Matsuda, H. (1997) Circulation 96: II-280-284; discussion II-285), and thereby such model animals are also suitable for investigating the efficacy of therapeutic agents for ischemic heart diseases.

Thus the efficacy of NF- κ B inhibitors having an activity of inhibiting the production of NO and TNF- α as therapeutic agents can be confirmed using known animal models that can be prepared by a person skilled in the art.

Examples

The present invention is now explained in more detail with reference to the following examples and experimental examples. However, it should be noted that the present invention is not limited by them in any way.

Example 1. 3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid

Step 1. 2-{4-[hydroxy-(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]phenyl}-1,3-dioxolane

To an ice-cold solution of 2,3,4,5-tetramethoxy-6-methylbenzaldehyde (5.03 g, 20.94 mmol) in THF (200 ml) was added dropwise a Grignard reagent prepared from 2-(4-bromophenyl)-1,3-dioxolane (12.0 g, 52.4 mmol) and magnesium (1.40 g, 57.6 mmol), and then stirred at room temperature for 4 hours. The reaction mixture was poured

into water and was extracted with ether. After the extract was washed with water and dried, and then the solvent was distilled off. The residue was purified by a silica gel column chromatography (hexane : ethyl acetate = 3 : 1) to yield the title compound (7.80 g, 20.0 mmol, yield 96%).

Step 2. 4-[acetoxy-(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]benzaldehyde

The compound (7.80 g, 20.0 mmol) obtained in Step 1 was dissolved in methylene chloride (300 ml), and then acetic anhydride (6.12 g, 60.0 mmol), pyridine (4.74 g, 59.9 mmol), and 4-dimethylaminopyridine (1.22 g, 10.0 mmol) were added thereto, which was then stirred at room temperature for 16 hours.

After the reaction mixture was washed with a 5% aqueous solution of hydrochloric acid and saturated saline, it was dried and the solvent was distilled off. The residue and p-toluenesulfonic acid monohydrate (200 mg) were dissolved in acetone (300 ml), which was stirred at room temperature for 6 hours. After the reaction mixture was concentrated under reduced pressure, water and ether were added for extraction. The extract was washed with water, dried, and then the solvent was distilled off. The residue was purified by a silica gel column chromatography (hexane : ethyl acetate = 3 : 1) to yield the title compound (3.97 g, 10.2 mmol, yield 51%).

Step 3. 3-[4-[acetoxy-(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]phenyl]acrylic acid ethylester

Triethyl phosphonoacetate (1.70 g, 7.58 mmol) was dissolved in THF (150 ml) and sodium hydride (303 mg, 60%, 7.58 mmol) was added at room temperature and then the mixture was stirred for 40 minutes. To the reaction mixture was added dropwise under ice-cooling a solution of the compound (2.26 g, 5.82 mmol) obtained in Step 2 in THF (50 ml) and the mixture was stirred at room

temperature for 16 hours. The reaction mixture was poured into water and extracted with ether. The extract was washed with water, dried, and then the solvent was distilled off. The residue was purified by a silica gel column chromatography (hexane : ethyl acetate = 3 : 1) to yield the title compound (2.37 g, 5.17 mmol, yield 89%).

Step 4. 3-[4-(2,3,4,5-tetramethoxy-6-methylbenzyl)phenyl]acrylic acid ethylester

To a solution of triethylsilane (720 mg, 6.21 mmol) and trimethylsilyl trifluoromethanesulfonate (TMSOTf) in methylene chloride (250 ml) was added dropwise a solution of the compound (2.37 g, 5.17 mmol) obtained in Step 3 in methylene chloride (50 ml) and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was washed with water, dried, and then the solvent was distilled off. The residue was purified by a silica gel column chromatography (hexane : ethyl acetate = 4 : 1) to yield the title compound (1.90 g, 4.74 mmol, yield 92%).

Step 5. 3-[4-(2,3,4,5-tetramethoxy-6-methylbenzyl)phenyl]propionic acid ethylester

The compound (1.07 g, 2.67 mmol) obtained in step 4 was dissolved in ethanol (100 ml) and 5% Pd-carbon (200 mg) was added thereto, which was then stirred under a stream of hydrogen at room temperature for 16 hours. The reaction mixture was filtered and the filtrate was concentrated to yield the title compound (914 mg, 2.27 mmol, yield 85%).

Step 6. 3-[4-(2,3,4,5-tetramethoxy-6-methylbenzyl)phenyl]propionic acid

The compound (914 mg, 2.27 mmol) obtained in Step 5 was dissolved in a mixture of an aqueous solution of 2 N sodium hydroxide (30 ml) and 1,4-dioxane (15 ml) and the mixture was stirred at 70°C for 3 hours. The reaction mixture was acidified by adding concentrated hydrochloric acid and then was extracted with ethyl acetate. The extract was washed with water, dried, and then the solvent was distilled off to yield the title compound

(731 mg, 1.95 mmol, yield 86%).

Step 7. 3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid

5 The compound (1.00 g, 2.67 mmol) obtained in Step 6 was dissolved in a mixture of acetonitrile (30 ml) and water (10 ml), to which was added CAN (ceric ammonium nitrate) (2.34 g, 4.27 mmol) and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water and was extracted with ether.

10 After the extract was washed with water and dried, the solvent was distilled off. The residue was purified by a silica gel column chromatography (5% methanol-methylene chloride) and then was crystallized in ethanol/hexane to yield the title compound (662 mg, 1.92 mmol, yield 72%).

15 Example 2. 3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid

Step 1. 3-[4-(2,3,4,5-tetramethoxy-6-methylbenzyl)phenyl]acrylic acid

20 The compound (1.35 g, 3.36 mmol) obtained in Step 4 of Example 1 was dissolved in a mixture of an aqueous solution of 2 N sodium hydroxide (30 ml) and 1,4-dioxane (15 ml), and the mixture was stirred at 70°C for 3 hours. The reaction mixture was acidified by adding concentrated hydrochloric acid and then was extracted with ethyl acetate. The extract was washed with water, dried, and then the solvent was distilled off to yield the title compound (1.20 g, 3.23 mmol, yield 96%).

Step 2. 3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid

30 The compound (589 mg, 1.58 mmol) obtained in Step 1 was dissolved in a mixture of acetonitrile (30 ml) and water (10 ml), to which was added CAN (1.38 g, 2.52 mmol) and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water and was extracted with ether. After the extract was washed with water and dried, the solvent was distilled off. The residue was purified by a silica gel column

35

chromatography (5% methanol-methylene chloride) to yield the title compound (452 mg, 1.32 mmol, yield 84%).

Example 3. N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-

5 ylmethyl)phenyl]propionyl]morpholine

To a solution of 3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (100 mg, 0.29 mmol) obtained in Example 1 and morpholine (30 mg, 0.35 mmol) in methylene chloride (10 ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (84 mg, 0.44 mmol) and the mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure and was purified by a middle-pressure column chromatography using silica gel (hexane : ethyl acetate = 1 : 2).

The yellow powder thus obtained was crystallized from methylene chloride-diethylether to yield the title compound (89 mg, 0.22 mmol, yield 74%) as a yellow crystal.

20 Example 4. N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-

ylmethyl)phenyl]propionyl]thiomorpholine

To a solution of 3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (27 mg, 0.078 mmol) obtained in Example 1 and ethyl chlorocarbonate (15 mg, 0.139 mmol) in THF (10 ml) was added triethylamine (14 mg, 0.139 mmol) at -10°C followed by stirring for 30 minutes, and then thiomorpholine (20 mg, 0.194 mmol) was added thereto followed by stirring at room temperature for 1 hour. The reaction mixture was diluted with water and extracted with ether. The extract was washed with water, dried, and then the solvent was distilled off. The resulting residue was purified by a middle-pressure column chromatography using silica gel (hexane : ethyl acetate = 1 : 1). The yellow powder thus obtained was crystallized from methylene chloride-diethylether to yield the title compound (26 mg, 0.061

mmol, yield 77%) as a yellow crystal.

Examples 5 and 6. N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]thiomorpholine S-oxide
(Example 5) and N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]thiomorpholine S-dioxide (Example 6)

To a solution of the compound (200 mg, 0.47 mmol) obtained in Example 4 in methylene chloride (50 ml) was added m-chloroperbenzoic acid (121 mg, 0.70 mmol) and the mixture was stirred at room temperature for 5 hours. The reaction mixture was washed with water, dried, and then concentrated under reduced pressure. The crude product thus obtained was purified by a silica gel column chromatography (5% methanol-methylene chloride) to yield the compound (60 mg, yield 28%) of Example 5 and the compound (50 mg, yield 24%) of Example 6.

Examples 7 to 20.

According to the method of Example 3, the compounds of Examples 7 to 20 were synthesized.
(Example 7)

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]piperidine

3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (200 mg, 0.58 mmol) obtained in Example 1 and piperidine (64 mg, 0.75 mmol) were used, and a method similar to that described in Example 3 was employed to obtain the title compound (118 mg, 0.79 mmol, yield 50%).

(Example 8)

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]dimethylamine

3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (200 mg, 0.58 mmol) obtained in Example 1 and dimethylamine hydrochloride (62 mg, 0.75 mmol) and triethylamine (76 mg, 0.75 mmol) were

used, and a method similar to that described in Example 3 was employed to obtain the title compound (38 mg, 0.10 mmol, yield 18%).

(Example 9)

5 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]isopropylamine

3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (200 mg, 0.58 mmol) obtained in Example 1 and isopropylamine (44 mg, 0.75 mmol) were used, and a method similar to that described in Example 3 was employed to obtain the title compound (46 mg, 0.12 mmol, yield 21%).

(Example 10)

15 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]ethanolamine

3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (200 mg, 0.58 mmol) obtained in Example 1 and ethanolamine (47 mg, 0.75 mmol) were used, and a method similar to that described in Example 3 was employed to obtain the title compound (65 mg, 0.18 mmol, yield 29%).

(Example 11)

20 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]benzylamine

25 3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (200 mg, 0.58 mmol) obtained in Example 1 and benzylamine (80 mg, 0.75 mmol) were used, and a method similar to that described in Example 3 was employed to obtain the title compound (33 mg, 0.08 mmol, yield 13%).

(Example 12)

30 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]phenethylamine

35 3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (200 mg, 0.58 mmol) obtained in Example 1 and phenethylamine (91 mg, 0.75 mmol) were used, and a method similar to that described

in Example 3 was employed to obtain the title compound (61 mg, 0.14 mmol, yield 24%).

(Example 13)

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]morpholine

3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid (200 mg, 0.58 mmol) obtained in Example 2 and morpholine (65 mg, 0.75 mmol) were used, and a method similar to that described in Example 3 was employed to obtain the title compound (102 mg, 0.25 mmol, yield 43%).

(Example 14)

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]thiomorpholine

3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid (200 mg, 0.58 mmol) obtained in Example 2 and thiomorpholine (77 mg, 0.75 mmol) were used, and a method similar to that described in Example 3 was employed to obtain the title compound (140 mg, 0.33 mmol, yield 56%).

(Example 15)

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]piperidine

3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid (200 mg, 0.58 mmol) obtained in Example 2 and piperidine (65 mg, 0.76 mmol) were used, and a method similar to that described in Example 3 was employed to obtain the title compound (129 mg, 0.32 mmol, yield 54%).

(Example 16)

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]dimethylamine

3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid (200 mg, 0.58 mmol) obtained in Example 2 and dimethylamine hydrochloride (61 mg, 0.75 mmol) and triethylamine (76 mg, 0.75 mmol) were used, and a method similar to that described in Example 3 was

employed to obtain the title compound (23 mg, 0.06 mmol, yield 11%).

(Example 17)

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]isopropylamine

3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid (200 mg, 0.58 mmol) obtained in Example 2 and isopropylamine (44 mg, 0.75 mmol) were used, and a method similar to that described in Example 3 was employed to obtain the title compound (48 mg, 0.13 mmol, yield 22%).

(Example 18)

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]ethanolamine

3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid (200 mg, 0.58 mmol) obtained in Example 2 and ethanolamine (46 mg, 0.75 mmol) were used, and a method similar to that described in Example 3 was employed to obtain the title compound (14 mg, 0.04 mmol, yield 6%).

(Example 19)

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]benzylamine

3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid (200 mg, 0.58 mmol) obtained in Example 2 and benzylamine (80 mg, 0.75 mmol) were used, and a method similar to that described in Example 3 was employed to obtain the title compound (104 mg, 0.24 mmol, yield 42%).

(Example 20)

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]phenethylamine

3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid (200 mg, 0.58 mmol) obtained in Example 2 and phenethylamine (91 mg, 0.75 mmol) were used, and a method similar to that described in Example 3 was employed to obtain the title compound (170 mg, 0.38

mmol, yield 65%).

Example 21. 4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoic acid

Method A

5 Step 1. 4-[hydroxy-(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]benzoic acid

After adding dropwise an aqueous solution (20 ml) of silver nitrate (3.06 g, 18.00 mmol) to an aqueous solution of 1 N sodium hydroxide (36 ml), a solution of
10 4-[acetoxy-(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]benzaldehyde (2.34 g, 6.00 mmol) obtained in Step 2 of Example 1 in THF (30 ml) was added dropwise and the mixture was stirred at room temperature for 5 hours. The reaction mixture was filtered and the
15 solid was washed with hot water. The filtrate and the wash solution were combined, which was then acidified with concentrated hydrochloric acid and then was extracted with ether. The extract was dried and the solvent was distilled off to yield the title compound
20 (2.3 g, 6.37 mmol, yield 100%).

NMR (CDCl₃): 2.27 (3H, s), 3.30 (3H, s), 3.75 (1H, m), 3.82 (3H, s), 3.85 (3H, s), 3.94 (3H, s), 6.04 (1H, broad), 7.42 (2H, m), 8.06 (2H, m)

FABMS (m/z): 362 (M)⁺

25 Step 2. 4-(2,3,4,5-tetramethoxy-6-methylbenzyl)benzoic acid

To a solution of triethylsilane (1.39 ml, 8.74 mmol) and TMSOTf (0.056 ml, 0.31 mmol) in methylene chloride (30 ml) was added dropwise a solution of the compound
30 (2.26 g, 6.24 mmol) obtained in Step 1 in methylene chloride (12 ml) and the mixture was stirred at room temperature for 4 hours. The reaction mixture was washed with water, dried, and then the solvent was distilled off to yield the title compound (1.98 g, 5.75 mmol, yield
35 96%).

NMR (CDCl₃): 2.07 (3H, s), 3.70 (3H, s), 3.79 (3H, s), 3.92 (3H, s), 3.95 (3H, s), 4.07 (2H, s), 7.20 (2H, m),

7.99 (2H, m)

FABMS (m/z): 346 (M+H)⁺

Step 3. 4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoic acid

5 The compound (1.98 g, 5.75 mmol) obtained in Step 2 was dissolved in a mixture of acetonitrile (40 ml) and water (15 ml), to which was added CAN (7.90 g, 14.5 mmol) and the mixture was stirred at room temperature for 40 minutes. The reaction mixture was poured into water and
10 was extracted with ethyl acetate. After the extract was washed with water and dried, the solvent was distilled off. Ether was added to the residue and the resulting precipitate was filtered to yield the title compound (1.82 g, 5.76 mmol, yield 99%).

15 Method B

Step 1. p-iodobenzoic acid methylester

 p-iodobenzoic acid (500 mg, 2.02 mmol) was dissolved in methanol (30 ml), to which was added 2M trimethylsilyl diazomethane/hexane solution (13 ml) and the mixture was
20 stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure to yield a crude product (500 mg) of the title compound. This was used as a raw material in the subsequent reaction without purification.

25 NMR (CDCl₃): 3.91 (3H, s), 7.74 (2H, d, J = 8.4 Hz), 7.80 (2H, d, J = 8.5 Hz)

FABMS (m/z): 263 (M+H)⁺

Step 2. 4-[hydroxy-(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]benzoic acid methylester

30 To a solution of zinc chloride (1.91 mmol) in dry tetrahydrofuran (9.6 ml) was added under ice-cooling a 1.4 M methyllithium/ether solution (4.1 ml, 5.73 mmol), and the mixture was stirred at 0°C for 30 minutes. The reaction mixture was cooled to -78°C, to which was added
35 a solution of the compound (500 mg, 1.91 mmol) obtained in Step 1 in dry tetrahydrofuran (2.0 ml) and the mixture was further stirred at -78°C for 4 hours. Subsequently,

a solution of 2,3,4,5-tetramethoxy-6-methylbenzaldehyde (1.38 g, 5.73 mmol) in dry tetrahydrofuran (2 ml) was added and the mixture was stirred overnight at room temperature. To the reaction mixture an aqueous solution of saturated ammonium chloride (2.5 ml) was added at 0°C. After concentrating under reduced pressure, the concentrate was diluted with water and extracted three times with chloroform. After the organic layer was dried, the solvent was distilled off. After purification by a silica gel column chromatography (ethyl acetate : hexane = 1 : 2), the title compound (237 mg, 0.63 mmol, yield 33%) was obtained.

NMR (CDCl₃): 2.26 (3H, s), 3.28 (3H, s), 3.82 (3H, s), 3.85 (3H, s), 3.90 (3H, s), 3.94 (3H, s), 5.03 (1H, m), 6.01 (1H, d, J = 10.5 Hz), 7.38 (2H, d, J = 8.2 Hz), 7.99 (2H, d, J = 8.4 Hz)

FABMS (m/z): 376 (M+H)⁺

Step 3. 4-(2,3,4,5-tetramethoxy-6-methylbenzyl)benzoic acid methylester

To a solution of triethylsilane (88 mg, 0.76 mmol) and TMSOTf (0.004 ml) in methylene chloride (2 ml) was added dropwise a solution of the compound (237 mg, 0.63 mmol) obtained in Step 2 in methylene chloride (2 ml) and the mixture was stirred at room temperature for 4 hours. The reaction mixture was washed with saturated saline, dried, and then the solvent was distilled off. The residue was purified by a silica gel column chromatography (ethyl acetate : hexane = 1 : 6) to yield the title compound (160 mg, 0.45 mmol, yield 71%).

NMR (CDCl₃): 2.06 (3H, s), 3.68 (3H, s), 3.78 (3H, s), 3.88 (3H, s), 3.92 (3H, s), 3.94 (3H, s), 4.05 (2H, s), 7.16 (2H, d, J = 8.1 Hz), 7.91 (2H, d, J = 8.1 Hz)

FABMS (m/z): 360 (M+H)⁺

Step 4. 4-(2,3,4,5-tetramethoxy-6-methylbenzyl)benzoic acid

The compound (160 mg, 0.45 mmol) obtained in Step 3 was dissolved in a mixture of an aqueous solution of

potassium carbonate (91 mg, 0.66 mmol) in water (1 ml) and methanol (2 ml) and the mixture was stirred at 70°C for 3 hours. The reaction mixture was acidified by adding concentrated hydrochloric acid and then was extracted with diethylether. The extract was washed with water, dried, and then the solvent was distilled off to yield the title compound (116 mg, 0.34 mmol, yield 76%).

Step 5. 4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoic acid

The compound (116 mg, 0.34 mmol) obtained in Step 4 was dissolved in a mixture of acetonitrile (2.2 ml) and water (0.81 ml), to which was added CAN (447 mg, 0.82 mmol). The mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water and was extracted with methylene chloride. After the extract was washed with water and dried, the solvent was distilled off. The residue was purified by a silica gel column chromatography (methylene chloride : methanol = 8 : 1) to yield the title compound (92 mg, 0.29 mmol, yield 85%).

Example 22. N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoyl]morpholine

To 4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoic acid (100 mg, 0.31 mmol) obtained in Example 21 was added oxalyl chloride (0.3 ml) and the mixture was stirred at room temperature for 1 hour. After distilling off the solvent and drying under reduced pressure, an acid chloride was obtained which was dissolved in methylene chloride (2 ml). Morpholine (0.28 ml, 3.3 mmol) was added under ice-cooling and then the mixture was stirred at the same temperature for 30 minutes. The residue obtained after distilling off the solvent was purified by a silica gel column chromatography (hexane : ethyl acetate = 1 : 5) to yield the title compound (56 mg, 0.15 mmol, yield 44%).

Example 23. N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoyl]isopropylamine

5 4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoic acid (100 mg, 0.31 mmol) obtained in Example 21 and isopropylamine (0.28 ml, 3.3 mmol) were used, and a method similar to that described in Example 22 was employed to obtain the title compound (58 mg, 0.16 mmol, yield 49%).

10 Example 24. N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoyl]piperidine

To a solution of 4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoic acid (50 mg, 0.16 mmol) obtained in Example 21 and piperidine (0.021 ml, 0.21 mmol) in methylene chloride (2 ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (46 mg, 0.24 mmol), and then the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure and was purified by a silica gel column chromatography (hexane : ethyl acetate = 1 : 2) to yield the title compound (30 mg, 0.08 mmol, yield 50%).

20 Example 25. N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoyl]thiomorpholine

25 4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoic acid (100 mg, 0.32 mmol) obtained in Example 21 and thiomorpholine (0.035 ml, 0.35 mmol) were used, and a method similar to that described in Example 24 was employed to obtain the title compound (65 mg, 0.16 mmol, yield 51%).

30 Example 26. 4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]-n-butyric acid

35 Method A

Step 1. 3-[4-(2,3,4,5-tetramethoxy-6-methylbenzyl)phenyl]propionic acid diazomethyl ketone

3-[4-(2,3,4,5-tetramethoxy-6-methylbenzyl)phenyl]propionic acid (750 mg, 2.00 mmol) obtained in Step 6 of Example 1 was dissolved in methylene chloride (2 ml), to which was added oxalyl chloride (2 ml) and the mixture was stirred at room temperature for 1 hour. The acid chloride obtained after distilling off the solvent was dried under reduced pressure. To a diazomethane solution [prepared using p-toluenesulfonyl-N-methyl-N-nitrosoamide (8.6 g), potassium hydroxide (2.4 g), carbitol (14 ml), water (5 ml), and ether (100 ml)] was added under ice-cooling triethylamine (0.7 ml) and then an ether solution of the above acid chloride (10 ml) was added. The reaction mixture was stirred at the same temperature for 2 hours. After the solvent was distilled off, the residue was purified by a silica gel column chromatography (hexane : ethyl acetate = 2 : 1 to 1 : 1) to yield the title compound (380 mg, 0.98 mmol, yield 49%).
NMR (CDCl₃): 2.07 (3H, s), 2.60 (2H, m), 2.90 (2H, m), 3.69 (3H, s), 3.78 (3H, s), 3.91 (3H, s), 3.93 (3H, s), 3.97 (2H, s), 5.16 (1H, broad), 7.04 (4H, m)
FABMS (m/z): 398 (M)⁺

Step 2. 4-[4-(2,3,4,5-tetramethoxy-6-methylbenzyl)phenyl]-n-butyric acid

Sodium thiosulfate pentahydrate (230 mg, 0.93 mmol) and silver oxide (130 mg, 0.56 mmol) were dissolved in water (5 ml) and the mixture was heated to 50°C to 70°C. A solution of the compound (380 mg, 0.98 mmol) obtained in Step 1 in dioxane (3.5 ml) was added dropwise, and the mixture was stirred at the same temperature for 10 minutes. The reaction mixture was cooled and was acidified with an aqueous solution of diluted nitric acid and then was extracted with ether. The extract was washed with water, dried, and then the solvent was

distilled off to yield the title compound (210 mg, 0.54 mmol, yield 93%).

NMR (CDCl₃): 1.92 (2H, m), 2.08 (3H, s), 2.34 (2H, m), 2.61 (2H, m), 3.70 (6H, s), 3.78 (2H, s), 3.91 (3H, s), 3.93 (3H, s), 7.03 (4H, m)

FABMS (m/z): 388 (M)⁺

Step 3. 4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]-n-butyric acid

The compound (260 mg, 0.67 mmol) obtained in Step 2, acetonitrile (5 ml), water (1.6 ml), and CAN (920 mg, 1.70 mmol) were used, and a method similar to that described in Step 3 of Example 21 was employed and then the reaction mixture was purified by a silica gel column chromatography (methylene chloride : methanol = 9 : 1) to yield the title compound (154 mg, 0.43 mmol, yield 74%).

Method B

Step 1. 3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid diazomethyl ketone

The 3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (340 mg, 1.00 mmol) obtained in Step 7 of Example 1, oxalyl chloride (0.5 ml), and triethylamine (0.14 ml) were used, and a method similar to that described in Step 1 of Method A of Example 26 was employed to obtain the title compound (140 mg, 0.38 mmol, yield 38%).

NMR (CDCl₃): 2.07 (3H, s), 2.59 (2H, m), 2.90 (2H, m), 3.80 (2H, s), 3.98 (3H, s), 3.99 (3H, s), 5.17 (1H, broad), 7.08 (4H, s)

FABMS (m/z): 369 (M+H)⁺

Step 2. 4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]-n-butyric acid

The compound (70 mg, 0.20 mmol) obtained in Step 1, sodium thiosulfate pentahydrate (81 mg, 0.33 mmol), and silver oxide (44 mg, 0.19 mmol) were used, and a method similar to that described in Step 2 of Method A of Example 26 was employed to obtain the title compound (13

mg, 0.04 mmol, yield 20%).

Example 27. N-[4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]morpholine

5 3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid diazomethyl ketone (70 mg, 0.20 mmol) obtained in Step 1 of Method B of Example 26 was dissolved in dry ethanol (5 ml), to which were added silver nitrate (34 mg, 0.20 mmol) and morpholine (0.090
10 ml, 1.0 mmol), and the mixture was heated to reflux for 20 minutes. The reaction mixture was filtered and the solid was washed with ethanol. The filtrate and the wash solution were combined and the solvent was distilled off, the resulting residue was purified by a silica gel column
15 chromatography (hexane : ethyl acetate = 1 : 3) to yield the title compound (42 mg, 0.098 mmol, yield 49%).

Example 28. N-[4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]thiomorpholine

20 4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]-n-butyric acid (50 mg, 0.14 mmol) obtained in Example 26 and thiomorpholine (0.016 ml, 0.15 mmol) were used, a method similar to that described in Example 24 was employed to obtain the title compound (15
25 mg, 0.034 mmol, yield 24%).

Example 29. N-[4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]piperidine

30 4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]-n-butyric acid (50 mg, 0.14 mmol) obtained in Example 26 and piperidine (0.015 ml, 0.15 mmol) were used, and a method similar to that described in Example 24 was employed to obtain the title compound (19 mg, 0.045 mmol, yield 32%).

Example 30. N-[4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]isopropylamine

4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]-n-butyric acid (50 mg, 0.14 mmol) obtained in Example 26 and isopropylamine (0.013 ml, 0.15 mmol) were used, and a method similar to that described in Example 24 was employed to obtain the title compound (30 mg, 0.075 mmol, yield 54%).

Example 31. 3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acide

2,3,4,5-tetramethoxy-6-methylbenzaldehyde (960 mg, 4.00 mmol) and 2-(3-bromophenyl)-1,3-dioxolane (2.3 g, 10 mmol) were used, and a method similar to that described in Example 1 was employed to obtain the title compound (300 mg, 0.87 mmol).

Example 32. N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propioyl]piperidine

3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (65 mg, 0.19 mmol) obtained in Example 31 and piperidine (0.022 ml, 0.21 mmol) were used, and a method similar to that described in Example 24 was employed to obtain the title compound (27 mg, 0.066 mmol, yield 35%).

Example 33. N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propioyl]thiomorpholine

3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (65 mg, 0.19 mmol) obtained in Example 31 and thiomorpholine (0.022 ml, 0.21 mmol) were used, and a method similar to that described in Example 24 was employed to obtain the title compound (26 mg, 0.061 mmol, yield 32%).

Example 34. N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propioyl]morpholine

3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (65 mg, 0.19 mmol) obtained in Example 31 and morpholine (0.019 ml, 0.21 mmol) were used, and a method similar to that described in Example 24 was employed to obtain the title compound (29 mg, 0.069 mmol, yield 36%).

Example 35. N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propioyl]isopropylamine

3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (65 mg, 0.19 mmol) obtained in Example 31 and isopropylamine (0.019 ml, 0.21 mmol) were used, and a method similar to that described in Example 24 was employed to obtain the title compound (12 mg, 0.031 mmol, yield 16%).

Example 36. 3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid

3-[3-(2,3,4,5-tetramethoxy-6-methylbenzyl)phenyl]acrylic acid ethylester (300 mg, 0.75 mmol) was used, and a method similar to that described in Example 2 was employed to obtain the title compound (220 mg, 0.64 mmol).

Example 37. N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]piperidine

3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid (55 mg, 0.16 mmol) obtained in Example 36 and piperidine (0.018 ml, 0.18 mmol) were used, and a method similar to that described in Example 24 was employed to obtain the title compound (30 mg, 0.073 mmol, yield 46%).

Example 38. N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]morpholine

3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid (55 mg, 0.16 mmol) obtained in Example 36 and morpholine (0.016 ml, 0.18 mmol) were used, and a method similar to that described in Example 24 was employed to obtain the title compound (36 mg, 0.088 mmol, yield 55%).

Example 39. N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]isopropylamine

3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid (55 mg, 0.16 mmol) obtained in Example 36 and isopropylamine (0.016 ml, 0.18 mmol) were used, and a method similar to that described in Example 24 was employed to obtain the title compound (21 mg, 0.055 mmol, yield 34%).

Example 40. N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]thiomorpholine

3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid (55 mg, 0.16 mmol) obtained in Example 36 and thiomorpholine (0.018 ml, 0.18 mmol) were used, and a method similar to that described in Example 24 was employed to obtain the title compound (32 mg, 0.075 mmol, yield 47%).

Example 41. 3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoic acid

Step 1. m-iodobenzoic acid methylester

m-iodobenzoic acid (1 g, 4.03 mmol) was used, and a method similar to that described in Step 1 of Method B of Example 21 was employed to obtain the title compound as a crude product (1.08 g). This was used as a raw material for the subsequent reaction without purification.

NMR (CDCl₃): 3.92 (3H, s), 7.18 (1H, m), 7.88 (1H, d, J = 8.0 Hz), 8.00 (1H, d, J = 7.8 Hz), 8.38 (1H, s)

FABMS (m/z): 263 (M+H)⁺

Step 2. 3-[hydroxy-(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]benzoic acid methylester

Method 1

5 The compound (1.08 g, 4.1 mmol) obtained in Step 1 was used, and a method similar to that described in Step 2 of Method B of Example 21 was employed to obtain the title compound (490 mg, 1.30 mmol, yield 32%).

NMR (CDCl₃): 2.26 (3H, s), 3.32 (3H, s), 3.82 (3H, s),
10 3.86 (3H, s), 3.90 (3H, s), 3.94 (3H, s), 6.02 (1H, d, J = 10.6 Hz), 7.39 (1H, m), 7.47 (1H, d, J = 7.6 Hz), 7.91 (1H, J = 7.4 Hz), 8.04 (1H, s)

FABMS (m/z): 376 (M+H)⁺

Method 2

15 A 1.54 M solution of t-butyllithium/pentane and the compound (1.05 g, 4.00 mmol) obtained in Step 1 were used, and a method similar to that described in Step 2 of Method B of Example 21 was employed to obtain the title compound (684 mg, 1.28 mmol, yield 32%).

20 Step 3. 3-(2,3,4,5-tetramethoxy-6-methylbenzyl)benzoic acid methylester

 The compound (245 mg, 0.65 mmol) obtained in Step 2 was used, and a method similar to that described in Step 3 of Method B of Example 21 was employed to obtain the
25 title compound (170mg, 0.47 mmol, yield 72%).

NMR (CDCl₃): 2.08 (3H, s), 3.70 (3H, s), 3.78 (3H, s),
3.89 (3H, s), 3.92 (3H, s), 3.94 (3H, s), 4.05 (2H, s),
7.26 - 7.32 (2H, m), 7.83 (2H, m)

FABMS (m/z): 360 (M+H)⁺

30 Step 4. 3-(2,3,4,5-tetramethoxy-6-methylbenzyl)benzoic acid

 The compound (170 mg, 0.47 mmol) obtained in Step 3 was used, and a method similar to that described in Step 4 of Method B of Example 21 was employed to obtain the
35 title compound (150 mg, 0.43 mmol, yield 91%).

NMR (CDCl₃): 2.09 (3H, s), 3.71 (3H, s), 3.79 (3H, s),
3.92 (3H, s), 3.94 (3H, s), 4.06 (2H, s), 7.33 (2H, m),

7.90 (2H, m)

FABMS (m/z): 346 (M+H)⁺

Step 5. 3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoic acid

5 The compound (150 mg, 0.43 mmol) obtained in Step 4 was used, and a method similar to that described in Step 5 of Method B of Example 21 was employed to obtain the title compound (117 mg, 0.37 mmol, yield 86%).

10 Example 42. N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoyl]isopropylamine

 3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoic acid (85 mg, 0.27 mmol) obtained in Example 41, isopropylamine (0.035 ml, 0.41 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (78 mg, 0.41 mmol) in dry methylene chloride (3.4 ml) were stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure and then was purified by a silica gel column chromatography (methylene chloride : methanol = 20 : 1) to obtain the title compound (37 mg, 0.10 mmol, yield 37%).

Example 43. N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)piperidine

25 3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoic acid (85 mg, 0.27 mmol) obtained in Example 41 and piperidine (0.036 ml, 0.41 mmol) were used, and a method similar to that described in Example 42 was employed to obtain the title compound (40 mg, 0.10 mmol, yield 37%).

30 Example 44. N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)morpholine

 3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoic acid (85 mg, 0.27 mmol) obtained in Example 41 and morpholine (0.036 ml, 0.41 mmol) were used, and a method similar to that described in Example 42 was employed to obtain the title compound (57 mg, 0.15

mmol, yield 54%).

Example 45. N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)thiomorpholine

3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoic acid (85 mg, 0.27 mmol) obtained in Example 41 and thiomorpholine (0.041 ml, 0.41 mmol) were used, and a method similar to that described in Example 42 was employed to obtain the title compound (61 mg, 0.15 mmol, yield 54%).

Example 46. N-[3-[4-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]isopropylamine

3-[4-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (25 mg, 0.08 mmol), isopropylamine (0.010 ml, 0.12 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (28 mg, 0.12 mmol) in dry methylene chloride (1 ml) were stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure and was purified by a silica gel column chromatography (methylene chloride : ethyl acetate = 4 : 1) to obtain the title compound (18 mg, 0.051 mmol, yield 64%).

Example 47. N-[3-[4-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]piperidine

3-[4-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (25 mg, 0.08 mmol) and piperidine (0.012 ml, 0.12 mmol) were used, and a method similar to that described in Example 46 was employed to obtain the title compound (53 mg, 0.14 mmol, yield 59%).

Example 48. N-[3-[4-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]morpholine

3-[4-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (25 mg, 0.08 mmol) and morpholine (0.010 ml, 0.12 mmol) were used, and a method similar to that described in Example 46 was employed to obtain the title compound (21 mg, 0.055 mmol, yield 69%).

Example 49. N-[3-[3-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]isopropylamine

3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (30 mg, 0.096 mmol) and isopropylamine (0.010 ml, 0.12 mmol) were used, and a method similar to that described in Example 46 was employed to obtain the title compound (14 mg, 0.040 mmol, yield 42%).

Example 50. N-[3-[3-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]piperidine

3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (30 mg, 0.096 mmol) and piperidine (0.010 ml, 0.12 mmol) were used, and a method similar to that described in Example 46 was employed to obtain the title compound (19 mg, 0.050 mmol, yield 52%).

Example 51. N-[3-[3-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]morpholine

3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (30 mg, 0.096 mmol) and morpholine (0.010 ml, 0.12 mmol) were used, and a method similar to that described in Example 46 was employed to obtain the title compound (25 mg, 0.066 mmol, yield 69%).

Example 52. 4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetic acid

Step 1. 4-(2,3,4,5-tetramethoxy-6-methylbenzyl)benzoic acid diazomethyl ketone

4-(2,3,4,5-tetramethoxy-6-methylbenzyl)benzoic acid (700 mg, 2.02 mmol) obtained in Step 2 of Method A of Example 21 was used, and a method similar to that described in Step 1 of Method A of Example 26 was employed to obtain the title compound (96 mg, 0.26 mmol, yield).

NMR (CDCl₃): 2.07 (3H, s), 3.70 (3H, s), 3.79 (3H, s), 3.92 (3H, s), 3.95 (3H, s), 4.05 (2H, s), 5.85 (1H, s), 7.18 (2H, d, J = 8.0 Hz), 7.65 (2H, d, J = 8.0 Hz)

FABMS (m/z): 370 (M)⁺

Step 2. 4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetic acid

The compound (96 mg, 0.26 mmol) obtained in Step 1 was used, and a method similar to that described in Step 2 of Method A of Example 26 was employed to obtain 4-(2,3,4,5-tetramethoxy-6-methylbenzyl)phenylacetic acid as a crude product. This was used without further purification, and a method similar to that described in Step 3 of Method A of Example 26 was employed to obtain the title compound (63 mg, 0.19 mmol).

Example 53. N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]morpholine

4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoic acid (100 mg, 0.32 mmol) obtained in Example 21 was used, and a method similar to that described in Step 1 of Method A of Example 26 was employed to obtain 4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoic acid diazomethyl ketone as a crude product. Without further purification, this was dissolved in dry ethanol (5 ml). Silver nitrate (56 mg, 0.33 mmol) and morpholine (0.14 ml, 1.65 mmol) were added thereto and the mixture was heated to reflux for one hour. The resulting residue obtained after the distilling off the solvent was purified by a silica gel column chromatography (hexane : ethyl acetate = 1 : 3 to 1 : 4) to yield a crude fraction containing the title compound. The fraction was purified again by silica gel column chromatography (methylene chloride : methanol = 20 : 1) to obtain the title compound (9 mg, 0.02 mmol, yield 7%).

Example 54. N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]piperidine

4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetic acid (21 mg, 0.063 mmol) obtained in Example 52 and piperidine (0.0094 ml, 0.095 mmol) were

used, and a method similar to that described in Example 46 was employed to obtain the title compound (7.8 mg, 0.020 mmol, yield 32%).

Example 55. N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]thiomorpholine

4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetic acid (21 mg, 0.063 mmol) obtained in Example 52 and thiomorpholine (0.0096 ml, 0.095 mmol) were used, and a method similar to that described in Example 46 was employed to obtain the title compound (5.1 mg, 0.012 mmol, yield 19%).

Example 56. N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]isopropylamine

4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetic acid (21 mg, 0.063 mmol) obtained in Example 52 and isopropylamine (0.008 ml, 0.095 mmol) were used, and a method similar to that described in Example 46 was employed to obtain the title compound (5.1 mg, 0.014 mmol, yield 22%).

Example 57. 3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetic acid

Step 1. 3-(2,3,4,5-tetramethoxy-6-methylbenzyl)benzoic acid diazomethyl ketone

3-(2,3,4,5-tetramethoxy-6-methylbenzyl)benzoic acid (560 mg, 1.6 mmol) obtained in Step 4 of Example 41 was used, and a method similar to that described in Step 1 of Method A of Example 26 was employed to obtain the title compound (410 mg, 1.1 mmol, yield 69%).

NMR (CDCl₃): 2.08 (3H, s), 3.71 (3H, s), 3.78 (3H, s), 3.93 (3H, s), 3.94 (3H, s), 4.05 (2H, s), 5.84 (1H, s), 7.26 (1H, m), 7.32 (1H, m), 7.53 (1H, m), 7.58 (1H, m)
FABMS (m/z): 370 (M)⁺

Step 2. 3-(2,3,4,5-tetramethoxy-6-methylbenzyl)phenylacetic acid

The compound (410 mg, 1.11 mmol) obtained in Step 1

was used, and a method similar to that described in Step 2 of Method A of Example 26 was employed to obtain the title compound (370 mg, 1.03 mmol, yield 93%).

NMR (CDCl₃): 2.08 (3H, s), 3.60 (2H, s), 3.68 (3H, s),
5 3.78 (3H, s), 3.92 (3H, s), 3.94 (3H, s), 4.00 (2H, s),
6.99 - 7.09 (3H, m), 7.21 (1H, m)

FABMS (m/z): 360 (M)⁺

Step 3. 3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetic acid

10 The compound (370 mg, 1.03 mmol) obtained in Step 2 was used, and a method similar to that described in Step 3 of Method A of Example 26 was employed to obtain the title compound (330 mg, 1.00 mmol, yield 97%).

Example 58. N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]piperidine

3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetic acid (90 mg, 0.27 mmol) obtained in Example 57 and piperidine (0.040 ml, 0.41 mmol) were
20 used, and a method similar to that described in Example 46 was employed to obtain the title compound (35 mg, 0.088 mmol, yield 33%).

Example 59. N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]thiomorpholine

3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetic acid (90 mg, 0.27 mmol) obtained in Example 57 and thiomorpholine (0.040 ml, 0.41 mmol) were
25 used, and a method similar to that described in Example 46 was employed to obtain the title compound (47 mg, 0.11 mmol, yield 41%).

Example 60. N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]morpholine

35 3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetic acid (90 mg, 0.27 mmol) obtained in Example 57 and morpholine (0.035 ml, 0.41 mmol) were

used, and a method similar to that described in Example 46 was employed to obtain the title compound (41 mg, 0.10 mmol, yield 37%).

Example 61. N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]isopropylamine

3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetic acid (90 mg, 0.27 mmol) obtained in Example 57 and isopropylamine (0.035 ml, 0.41 mmol) were used, and a method similar to that described in Example 46 was employed to obtain the title compound (43 mg, 0.12 mmol, yield 44%).

Example 62. 4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]-n-butyric acid

Step 1. 3-[3-(2,3,4,5-tetramethoxy-6-methylbenzyl)phenyl]propionic acid diazomethyl ketone

3-[3-(2,3,4,5-tetramethoxy-6-methylbenzyl)phenyl]propionic acid (500 mg, 1.34 mmol) obtained as an intermediate in the synthesis of the compound of Example 31 was used, and a method similar to that described in Step 1 of Method A of Example 26 was employed to obtain the title compound (330 mg, 0.83 mmol, yield 62%).

NMR (CDCl₃): 2.07 (3H, s), 2.58 (2H, broad), 2.89 (2H, m), 3.65 (3H, s), 3.78 (3H, s), 3.93 (3H, s), 3.94 (3H, s), 3.98 (2H, s), 5.17 (1H, broad), 6.91 - 6.99 (3H, m), 7.16 (1H, m)

FABMS (m/z): 398 (M)⁺

Step 2. 4-[3-(2,3,4,5-tetramethoxy-6-methylbenzyl)phenyl]-n-butyric acid

The compound (330 mg, 0.83 mmol) obtained in Step 1 was used, and a method similar to that described in Step 2 of Method A of Example 26 was employed to obtain the title compound (320 mg, 0.83 mmol, yield 100%).

NMR (CDCl₃): 1.93 (2H, m), 2.08 (3H, s), 2.35 (2H, m),

2.62 (2H, m), 3.69 (3H, s), 3.78 (3H, s), 3.92 (3H, s),
3.94 (3H, s), 3.99 (2H, s), 6.91 - 6.98 (3H, m), 7.16
(1H, m)

FABMS (m/z): 388 (M)⁺

5 Step 3. 4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]-n-butyric acid

The compound (330 mg, 0.85 mmol) obtained in Step 2 was used, and a method similar to that described in Step 3 of Method A of Example 26 was employed to obtain the
10 title compound (290 mg, 0.81 mmol, yield 98%).

Example 63. N-[4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]piperidine

4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]-n-butyric acid (73 mg, 0.20 mmol)
15 obtained in Example 62 and piperidine (0.030 ml, 0.30 mmol) were used, and a method similar to that described in Example 46 was employed to obtain the title compound (16 mg, 0.038 mmol, yield 19%).

20 Example 64. N-[4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]thiomorpholine

4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]-n-butyric acid (73 mg, 0.20 mmol)
25 obtained in Example 62 and thiomorpholine (0.030 ml, 0.30 mmol) were used, and a method similar to that described in Example 46 was employed to obtain the title compound (26 mg, 0.059 mmol, yield 29%).

30 Example 65. N-[4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]morpholine

4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]-n-butyric acid (73 mg, 0.20 mmol)
35 obtained in Example 62 and morpholine (0.026 ml, 0.30 mmol) were used, and a method similar to that described in Example 46 was employed to obtain the title compound (28 mg, 0.066 mmol, yield 33%).

Example 66. N-[4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]isopropylamine

4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]-n-butyric acid (73 mg, 0.20 mmol) obtained in Example 62 and isopropylamine (0.019 ml, 0.30 mmol) were used, and a method similar to that described in Example 46 was employed to obtain the title compound (17 mg, 0.043 mmol, yield 21%).

Example 67. 3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid

Step 1. 2-[2-[hydroxy-(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]phenyl]-1,3-dioxolane

2-(2-bromophenyl)-1,3-dioxolane (2.03 g, 8.90 mmol) was used, and a method similar to that described in Step 1 of Example 1 was employed to obtain the title compound (1.64 g, 4.20 mmol, yield 47%).

NMR (CDCl₃): 2.14 (3H, s), 3.64 (3H, s), 3.79 (3H, s), 3.90 (3H, s), 3.96 (3H, s), 4.08 - 4.19 (2H, m), 4.43 (1H, d, J = 8.8 Hz), 6.37 (1H, s), 6.46 (1H, d, J = 8.8 Hz), 6.97 (1H, d, J = 7.6 Hz), 7.24 - 7.30 (2H, m), 7.70 (1H, d, J = 7.6 Hz)

FABMS (m/z): 390 (M+H)⁺

Step 2. 2-[2-[acetoxy-(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]benzaldehyde

The compound (640 mg, 1.64 mmol) obtained in Step 1 was used, and a method similar to that described in Step 2 of Example 1 was employed to obtain the title compound (590 mg, 1.51 mmol, yield 92%).

NMR (CDCl₃): 2.15 (3H, s), 2.17 (3H, s), 3.64 (3H, s), 3.79 (3H, s), 3.87 (3H, s), 3.95 (3H, s), 7.33 (1H, d, J = 7.7 Hz), 7.45 (1H, m), 7.53 (1H, m), 7.88 (1H, m), 7.94 (1H, s), 10.20 (1H, s)

FABMS (m/z): 388 (M+H)⁺

Step 3. 3-[2-[acetoxo-(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]phenyl]acrylic acid ethylester

5 The compound (590 mg, 1.51 mmol) obtained in Step 2 was used, and a method similar to that described in Step 3 of Example 1 was employed to obtain the title compound (490 mg, 1.07 mmol, yield 71%).

NMR (CDCl₃): 1.32 (3H, s), 2.15 (3H, s), 2.21 (3H, s),
3.58 (3H, s), 3.78 (3H, s), 3.86 (3H, s), 3.94 (3H, s),
10 4.22 (2H, m), 6.19 (1H, d, J = 15.7 Hz), 7.24 - 7.33 (2H, m), 7.49 (1H, m), 7.60 (1H, s), 7.80 (1H, d, J = 15.7 Hz)
FABMS (m/z): 458 (M+H)⁺

Step 4. 3-[2-(2,3,4,5-tetramethoxy-6-methylbenzyl)phenyl]acrylic acid ethylester

15 The compound (490 mg, 1.07 mmol) obtained in Step 3 was used, and a method similar to that described in Step 4 of Example 1 was employed to obtain the title compound (230 mg, 0.58 mmol, yield 54%).

NMR (CDCl₃): 1.36 (3H, m), 2.00 (3H, s), 3.64 (3H, s),
20 3.80 (3H, s), 3.92 (3H, s), 3.96 (3H, s), 4.11 (2H, s), 4.29 (2H, m), 6.40 (1H, d, J = 15.8 Hz), 6.71 (1H, broad), 7.19 (2H, m), 7.59 (1H, m), 8.22 (1H, d, J = 15.8 Hz)

FABMS (m/z): 400 (M+H)⁺

25 Step 5. 3-[2-(2,3,4,5-tetramethoxy-6-methylbenzyl)phenyl]acrylic acid

The compound (137 mg, 0.34 mmol) obtained in Step 4 was used, and a method similar to that described in Step 1 of Example 2 was employed to obtain the title compound
30 (71 mg, 0.19 mmol, yield 56%).

NMR (CDCl₃): 2.02 (3H, s), 3.64 (3H, s), 3.80 (3H, s),
3.92 (3H, s), 3.96 (3H, s), 4.12 (2H, s), 6.42 (1H, d, J = 15.8 Hz), 6.75 (1H, m), 7.21 - 7.25 (2H, m), 7.60 (1H, m), 8.32 (1H, d, J = 15.8 Hz)

35 FABMS (m/z): 372 (M+H)⁺

Step 6. 3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid

The compound (71 mg, 0.34 mmol) obtained in Step 5 was used, and a method similar to that described in Step 2 of Example 2 was employed to obtain the title compound (23 mg, 0.067 mmol, yield 35%).

Example 68. N-[3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]thiomorpholine

3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid (20 mg, 0.058 mmol) obtained in Example 67 and thiomorpholine (0.009 ml, 0.087 mmol) were used, and a method similar to that described in Example 46 was employed to obtain the title compound (10 mg, 0.023 mmol, yield 40%).

Example 69. 3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid

Step 1. 3-[2-(2,3,4,5-tetramethoxy-6-methylbenzyl)phenyl]propionic acid ethylester

3-[2-(2,3,4,5-tetramethoxy-6-methylbenzyl)phenyl]acrylic acid ethylester (85 mg, 0.21 mmol) obtained in Step 4 of Example 67 was used, and a method similar to that described in Step 5 of Example 1 was employed to obtain the title compound (80 mg, 0.20 mmol, yield 95%).

NMR (CDCl₃): 1.27 (3H, m), 2.03 (3H, s), 2.68 (2H, m), 3.11 (2H, m), 3.61 (3H, m), 3.81 (3H, s), 3.92 (3H, s), 3.96 (3H, s), 3.98 (2H, s), 4.17 (2H, m), 6.63 (1H, d, J = 7.6 Hz), 7.04 (1H, m), 7.11 (1H, m), 7.18 (1H, m)

FABMS (m/z): 402 (M+H)⁺

Step 2. 3-[2-(2,3,4,5-tetramethoxy-6-methylbenzyl)phenyl]propionic acid

The compound (80 mg, 0.20 mmol) obtained in Step 1 was used, and a method similar to that described in Step 6 of Example 1 was employed to obtain the title compound (63 mg, 0.17 mmol, yield 85%).

NMR (CDCl₃): 2.03 (3H, s), 2.75 (2H, m), 3.12 (2H, m),

3.61 (3H, s), 3.81 (3H, s), 3.91 (3H, s), 3.96 (3H, s),
3.98 (2H, s), 6.65 (1H, d, J = 7.6 Hz), 7.06 (1H, m),
7.13 (1H, m), 7.20 (1H, d, J = 7.2 Hz)

FABMS (m/z): 374 (M+H)⁺

5 Step 3. 3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid

 The compound (63 mg, 0.17 mmol) obtained in Step 2
was used, and a method similar to that described in Step
7 of Example 1 was employed to obtain the title compound
10 (50 mg, 0.15 mmol, yield 88%).

Example 70. N-[3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]piperidine

 3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (20 mg, 0.058 mmol)
15 obtained in Example 69 and piperidine (0.009 ml, 0.087 mmol) were used, and a method similar to that described
in Example 46 was employed to obtain the title compound
(8.4 mg, 0.020 mmol, yield 34%).

20 Example 71. N-[3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]morpholine

 3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (25 mg, 0.070 mmol)
25 obtained in Example 69 and morpholine (0.009 ml, 0.11 mmol) were used, and a method similar to that described
in Example 46 was employed to obtain the title compound
(10 mg, 0.024 mmol, yield 34%).

Example 72. N-[3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]thiomorpholine

 3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid (25 mg, 0.070 mmol)
35 obtained in Example 69 and thiomorpholine (0.011 ml, 0.11 mmol) were used, and a method similar to that described
in Example 46 was employed to obtain the title compound
(10 mg, 0.024 mmol, yield 34%).







Example 73. N-[3-[2-(5,6-dimethoxy-3-methyl-1,4-
benzoquinon-2-
ylmethyl)phenyl]propionyl]isopropylamine







5 3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-
ylmethyl)phenyl]propionic acid (15 mg, 0.044 mmol)
obtained in Example 69 and isopropylamine (0.005 ml,
0.066 mmol) were used, and a method similar to that
described in Example 46 was employed to obtain the title
compound (4.7 mg, 0.012 mmol, yield 27%).







10 Example 74 to 189.







The compounds of Example 74 to 189 were prepared
using a synthesizer (MORITEX Corp.) in the following
method:







15 To a solution of 3-[4-(5,6-dimethoxy-3-methyl-1,4-
benzoquinon-2-ylmethyl)phenyl]propionic acid (100 mg,
0.30 mmol) obtained in Example 1 in dry methylene
chloride (0.3 ml) were sequentially added triethylamine
(0.2 ml, 1.40 mmol), a solution of an amine (0.4 mmol) in
20 methylene chloride (0.6 ml) and propane phosphonic acid
anhydride (a 25% solution in ethyl acetate, 0.6 ml), and
the mixture was stirred at 25°C for 1 to 2 hours. Water
was added to the reaction mixture, extracted with ethyl
acetate, and after drying the solvent was distilled off.
The resulting residue was purified by a silica gel column
25 chromatography (methylene chloride - methanol) to yield
the desired compound.







Ex. No.	Structure	Property (mp °C)	FABMS(m/z)	NMR(CDCl ₃ , δ)
1		crystal (139-141)	344(M) ⁺ (EIMS)	2.09(3H, s), 2.62(2H, m), 2.89(2H, m), 3.80(2H, s), 3.99(6H, s), 6.95-7.30(4H, m)
2		crystal (203-205)	343(M+H) ⁺	2.09(3H, s), 3.87(2H, s), 4.00(6H, s), 6.39(1H, d), 7.22(2H, d), 7.47(2H, d), 7.73(1H, d)
3		crystal (65-67)	414(M+H) ⁺	2.08(3H, s), 2.57(2H, m), 2.93(2H, m), 3.30-3.40(2H, m), 3.45-3.55(2H, m), 3.55-3.65(4H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 7.10(4H, s)
4		crystal (65-67)	429(M) ⁺ (EIMS)	2.09(3H, s), 2.25-2.65(4H, m), 2.57(2H, m), 2.91(2H, m), 3.55-4.95(2H, m), 3.81(2H, s), 3.99(6H, s), 7.12(4H, s)
5		crystal (114-116)	446(M+H) ⁺	2.09(3H, s), 2.10-2.20(1H, m), 2.50-2.70(4H, m), 2.70-2.85(1H, m), 2.85-3.00(2H, m), 3.60-3.80(2H, m), 3.80(2H, s), 3.98(3H, s), 3.99(3H, s), 3.95-4.10(1H, m), 4.40-4.55(1H, m), 7.12(4H, s)
6		crystal (104-105)	462(M+H) ⁺	2.10(3H, s), 2.50-2.70(4H, m), 2.85-3.00(4H, m), 3.70-3.90(4H, m), 3.98(3H, s), 3.99(3H, s), 4.00-4.15(2H, m), 7.00-7.20(4H, m)







Ex. No.	Structure	Property (mp °C)	FABMS(m/z)	NMR(CDCl ₃ , δ)
7		crystal (63-64)	412(M+H) ⁺	1.52(6H, m), 2.07(3H, s), 2.56(2H, m), 2.91(2H, m), 3.32(2H, m), 3.54(2H, m), 3.80(2H, s), 3.98(3H, s), 3.99(3H, s), 7.10(4H, m)
8		oil	372(M+H) ⁺	2.07(3H, s), 2.57(2H, m), 2.91(2H, m), 2.92(3H, s), 2.94(3H, s), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 7.10(4H, m)
9		crystal (114-116)	386(M+H) ⁺	1.06(6H, d), 2.07(3H, s), 2.37(2H, m), 2.90(2H, m), 3.80(2H, s), 3.98(3H, s), 3.99(3H, s), 4.00(1H, m), 5.05(1H, broad), 7.09(4H, s)
10		crystal (97-98)	388(M+H) ⁺	2.08(3H, s), 2.45(2H, m), 2.92(2H, m), 3.33(2H, m), 3.59(2H, m), 3.80(2H, s), 3.98(6H, s), 5.67(1H, broad), 7.10(4H, m)
11		crystal (119-121)	434(M+H) ⁺	2.06(3H, s), 2.47(2H, m), 2.94(2H, m), 3.80(2H, s), 3.98(6H, s), 4.40(2H, d, J=5.7Hz), 5.55(1H, broad), 7.08(4H, s), 7.17(2H, m), 7.28(3H, m)
12		crystal (118-119)	448(M+H) ⁺	2.06(3H, s), 2.37(2H, m), 2.72(2H, m), 2.88(2H, m), 3.47(2H, m), 3.80(2H, s), 3.96(3H, s), 3.97(3H, s), 5.27(1H, broad), 7.08(6H, m), 7.20-7.29(3H, m)







Ex. No.	Structure	Property (mp °C)	FABMS(m/z)	NMR(CDCl ₃ , δ)
13		crystal (124-125)	412(M+H) ⁺	2.08(3H, s), 3.17(8H, m), 3.95(2H, s), 3.99(6H, s), 6.77(1H, d, J=15.4Hz), 7.18(2H, m), 7.41(2H, m), 7.64(1H, d, J=15.4Hz)
14		crystal (120-121)	428(M+H) ⁺	2.08(3H, s), 2.66(4H, m), 3.85(2H, s), 3.99(6H, s), 6.77(1H, d, J=15.4Hz), 7.18(2H, m), 7.41(2H, m), 7.61(1H, d, J=15.4Hz)
15		crystal (162-163)	410(M+H) ⁺	1.50-1.75(6H, m), 2.08(3H, s), 3.45-3.75(4H, m), 3.85(2H, s), 3.99(6H, s), 6.84(1H, d, J=15.4Hz), 7.17(2H, m), 7.41(2H, m), 7.59(1H, d, J=15.4Hz)
16		crystal (93-94)	370(M+H) ⁺	2.08(3H, s), 3.06(3H, s), 3.15(3H, s), 3.85(2H, s), 3.99(6H, s), 6.38(1H, d, J=15.4Hz), 7.18(2H, m), 7.42(2H, m), 7.61(1H, d, J=15.4Hz)
17		crystal (118-119)	384(M+H) ⁺	1.22(6H, d, J=6.5Hz), 2.08(3H, s), 3.99(6H, s), 4.21(1H, m), 5.35(1H, broad d), 6.28(1H, d, J=15.6Hz), 7.17(2H, m), 7.39(2H, m), 7.55(1H, d, J=15.6Hz)
18		crystal (114-115)	386(M+H) ⁺	2.08(3H, s), 2.51(1H, broad), 3.55(2H, m), 3.80(2H, m), 3.85(2H, s), 3.99(6H, s), 6.02(1H, broad), 6.36(1H, d, J=15.6Hz), 7.18(2H, m), 7.40(2H, m), 7.59(1H, d, J=15.6Hz)







Ex. No.	Structure	Property (mp °C)	FABMS(m/z)	NMR(CDCl ₃ , δ)
19		crystal (124-125)	432(M+H) ⁺	2.08(3H, s), 3.85(2H, s), 3.99(6H, s), 4.57(2H, d, J=5.7Hz), 5.82(1H, m), 6.34(1H, d, J=15.6Hz), 7.17(2H, m), 7.28-7.36(5H, m), 7.39(2H, m), 7.62(1H, d, J=15.6Hz)
20		crystal (141-142)	446(M+H) ⁺	2.08(3H, s), 2.88(2H, m), 3.65(2H, m), 3.84(2H, s), 3.99(6H, s), 5.54(1H, broad), 6.25(1H, d, J=15.6Hz), 7.16(2H, m), 7.22(3H, m), 7.32(2H, m), 7.38(2H, m), 7.55(1H, d, J=15.6Hz)
21		powder	317(M+H) ⁺	2.08(3H, s), 3.91(3H, s), 4.00(3H, s), 4.00(3H, s), 7.27(2H, m), 7.99(2H, m)
22		oil	386(M+H) ⁺	2.08(3H, s), 3.68(8H, broad), 3.86(2H, s), 4.00(6H, s), 7.22(2H, m), 7.31(2H, m)
23		oil	358(M+H) ⁺	1.25(6H, d, J=6.6Hz), 2.07(3H, s), 3.88(2H, s), 3.98(3H, s), 3.99(3H, s), 4.27(1H, m), 5.82(1H, broad d), 7.22(2H, m), 7.65(2H, m)
24		oil	384(M+H) ⁺	1.54-1.66(6H, m), 2.08(3H, s), 3.49-3.68(4H, broad), 3.86(2H, s), 4.00(6H, s), 7.19(2H, m), 7.29(2H, m)







Ex. No.	Structure	Property. (mp °C)	FABMS(m/z)	NMR(CDCl ₃ , δ)
25		oil	402(M+H) ⁺	2.08(3H, s), 2.64(4H, broad), 3.60-4.10(4H, broad), 3.86(2H, s), 4.00(6H, s), 7.21(2H, m), 7.28(2H, m)
26		oil	359(M+H) ⁺	1.92(2H, m), 2.08(3H, s), 2.34(2H, m), 2.61(2H, m), 3.80(2H, s), 3.95(3H, s), 3.98(3H, s), 7.08(4H, m)
27		oil	428(M+H) ⁺	1.94(2H, m), 2.08(3H, s), 2.28(2H, m), 2.62(2H, m), 3.37(2H, m), 3.62(6H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 7.08(4H, s)
28		oil	444(M+H) ⁺	1.93(2H, m), 2.08(3H, s), 2.28(2H, m), 2.54-2.64(6H, m), 3.64(2H, m), 3.81(2H, s), 3.86(2H, m), 3.98(3H, s), 3.99(3H, s), 7.08(4H, m)
29		oil	426(M+H) ⁺	1.51-1.62(6H, m), 1.92(2H, m), 2.08(3H, s), 2.22(2H, m), 2.72(2H, m), 3.31(2H, m), 3.53(2H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 7.08(4H, m)
30		powder	400(M+H) ⁺	1.13(6H, d, J=6.6Hz), 1.92(2H, m), 2.08(3H, s), 2.10(2H, m), 2.59(2H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 4.08(1H, m), 5.15(1H, broad), 7.08(4H, m)







Ex. No.	Structure	Property (mp °C)	FABMS(m/z)	NMR(CDCl ₃ , δ)
31		crystal (119-121)	345(M+H) ⁺	2.08(3H, s), 2.64(2H, m), 2.90(2H, m), 3.84(2H, s), 3.98(6H, s), 6.90-7.30(4H, m)
32		oil	412(M+H) ⁺	1.46-1.61(6H, m), 2.08(3H, s), 2.58(2H, m), 2.91(2H, m), 3.32(2H, m), 3.55(2H, m), 3.82(2H, s), 3.99(3H, s), 4.00(3H, s), 6.98-7.06(3H, m), 7.20(1H, m)
33		oil	430(M+H) ⁺	2.08(3H, s), 2.48(2H, m), 2.55-2.60(4H, m), 2.92(2H, m), 3.66(2H, m), 3.82(2H, s), 3.88(2H, m), 3.99(3H, s), 4.00(3H, s), 7.00-7.05(3H, m), 7.19(1H, m)
34		oil	414(M+H) ⁺	2.08(3H, s), 2.58(2H, m), 2.93(2H, m), 3.36(2H, m), 3.52-3.63(6H, m), 3.82(2H, s), 3.99(3H, s), 4.00(3H, s), 6.99-7.05(3H, m), 7.19(1H, m)
35		oil	386(M+H) ⁺	1.07(6H, d, J=6.5Hz), 2.07(3H, s), 2.38(2H, m), 2.90(2H, m), 3.81(2H, s), 3.99(3H, s), 4.00(3H, s), 4.03(1H, m), 5.13(1H, broad d), 6.98-7.04(3H, m), 7.17(1H, m)
36		powder	343(M+H) ⁺	2.11(3H, s), 3.89(2H, s), 4.00(6H, s), 6.42(1H, d, J=15.4Hz), 7.15-7.50(4H, m), 7.73(1H, d, J=15.4Hz)

Ex. No.	Structure	Property (mp °C)	FABMS(m/z)	NMR(CDCl ₃ , δ)
37		oil	410(M+H) ⁺	1.61-1.71(6H, m), 2.09(3H, s), 3.57-3.66(4H, broad), 3.86(2H, s), 4.00(6H, s), 6.86(1H, d, J=15.4Hz), 7.13-7.39(4H, m), 7.57(1H, d, J=15.4Hz)
38		oil	412(M+H) ⁺	2.09(3H, s), 3.73(8H, broad), 3.86(2H, s), 4.00(6H, s), 6.80(1H, d, J=15.4Hz), 7.15-7.37(4H, m), 7.63(1H, d, J=15.4Hz)
39		oil	384(M+H) ⁺	1.22(6H, d, J=6.6Hz), 2.09(3H, s), 3.84(2H, s), 3.99(3H, s), 4.00(3H, s), 4.21(1H, m), 5.42(1H, broad d), 6.31(1H, d, J=15.4Hz), 7.15-7.33(4H, m), 7.54(1H, d, J=15.4Hz)
40		oil	428(M+H) ⁺	2.09(3H, s), 2.68(4H, m), 3.86(2H, s), 3.94(4H, broad), 4.00(6H, s), 6.80(1H, d, J=15.4Hz), 7.14-7.37(4H, m), 7.60(1H, d, J=15.4Hz)
41		powder	317(M+H) ⁺	2.08(3H, s), 3.88(2H, s), 3.99(6H, s), 7.35-7.40(2H, m), 7.89-7.93(2H, m)
42		oil	358(M+H) ⁺	1.25(3H, s), 1.27(3H, s), 2.09(3H, s), 3.88(2H, s), 3.99(3H, s), 4.00(3H, s), 4.27(1H, m), 5.85(1H, broad), 7.26-7.33(2H, m), 7.51(1H, d, J=7.1Hz)


Ex. No.	Structure	Property (mp °C)	FABMS(m/z)	NMR(CDCl ₃ , δ)
43		powder	384(M+H) ⁺	1.50(2H, broad), 1.67(4H, broad), 2.08(3H, s), 3.30(2H, broad), 3.70(2H, broad), 3.86(2H, s), 3.99(3H, s), 4.00(3H, s), 7.20(3H, m), 7.29(1H, m)
44		oil	386(M+H) ⁺	2.08(3H, s), 3.47-3.82(8H, broad), 3.86(2H, s), 3.99(6H, s), 7.21-7.33(4H, m)
45		oil	402(M+H) ⁺	2.08(3H, s), 2.61-2.65(4H, broad), 3.57-3.86(6H, broad), 3.99(6H, s), 7.18-7.33(4H, m)
46		powder	354(M+H) ⁺	1.05(6H, d, J=6.6Hz), 2.01(6H, s), 2.08(3H, s), 2.37(2H, m), 2.89(2H, m), 3.82(2H, s), 4.03(1H, m), 5.05(1H, broad), 7.08(4H, s)
47		oil	380(M+H) ⁺	1.43-1.60(6H, broad), 2.01(6H, s), 2.09(3H, s), 2.57(2H, m), 2.90(2H, m), 3.31(2H, m), 3.54(2H, m), 3.82(2H, s), 7.10(4H, s)
48		oil	382(M+H) ⁺	2.01(6H, s), 2.09(3H, s), 2.57(2H, m), 2.92(2H, m), 3.35(2H, m), 3.49(2H, m), 3.61(4H, broad), 3.83(2H, s), 7.10(4H, s)







Ex. No.	Structure	Property (mp °C)	FABMS(m/z)	NMR(CDCl ₃ , δ)
49		powder	354(M+H) ⁺	1.07(6H, d, J=6.5Hz), 2.02(6H, s), 2.08(3H, s), 2.38(2H, m), 2.90(2H, m), 3.82(2H, s), 4.03(1H, m), 5.09(1H, broad), 7.00(3H, m), 7.16(1H, m)
50		oil	380(M+H) ⁺	1.46-1.62(6H, broad), 2.02(6H, s), 2.08(3H, s), 2.57(2H, m), 2.91(2H, m), 3.32(2H, m), 3.55(2H, m), 3.84(2H, s), 6.98-7.04(3H, m), 7.17(1H, m)
51		oil	382(M+H) ⁺	2.02(3H, s), 2.04(3H, s), 2.09(3H, s), 2.58(2H, m), 2.93(2H, m), 3.36(2H, broad), 3.52(2H, broad), 3.62(4H, broad), 3.84(2H, s), 7.01(3H, m), 7.18(1H, m)
52		oil	331(M+H) ⁺	2.08(3H, s), 3.63(2H, s), 3.83(2H, s), 3.98(6H, s), 7.16(2H, d, J=7.8Hz), 7.21(2H, d, J=7.8Hz)
53		oil	400(M+H) ⁺	2.07(3H, s), 3.43(2H, m), 3.51(2H, m), 3.64(4H, broad), 3.66(2H, s), 3.82(2H, s), 3.98(6H, s), 7.13(4H, m)
54		oil	398(M+H) ⁺	1.38(2H, broad), 1.52(2H, broad), 1.55(2H, broad), 2.08(3H, s), 3.36(2H, m), 3.55(2H, m), 3.66(2H, s), 3.82(2H, s), 3.98(3H, s), 3.99(3H, s), 7.13(4H, m)







Ex. No.	Structure	Property (mp °C)	FABMS(m/z)	NMR(CDCl ₃ , δ)
55		oil	416(M+H) ⁺	2.08(3H, s) 2.34(2H, m) 2.58(2H, m) 3.67(2H, s) 3.69(2H, m) 3.82(2H, s) 3.88(2H, m) 3.99(6H, s) 7.14(4H, s)
56		powder	372(M+H) ⁺	1.07(6H, d, J=6.6Hz) 2.09(3H, s) 3.47(2H, s) 3.84(2H, s) 3.99(3H, s) 4.00(3H, s) 4.04(1H, m) 5.14(1H, broad) 7.15(4H, s)
57		oil	331(M+H) ⁺	2.09(3H, s) 3.62(2H, s) 3.84(2H, s) 3.99(6H, s) 7.11(3H, m) 7.24(1H, m)
58		oil	398(M+H) ⁺	1.34(2H, broad) 1.53(2H, broad) 1.55(2H, broad) 2.07(3H, s) 3.35(2H, m) 3.56(2H, m) 3.68(2H, s) 3.82(2H, s) 3.99(6H, s) 7.02(1H, d, J=7.6Hz) 7.08(2H, m) 7.21(1H, m)
59		oil	416(M+H) ⁺	2.08(3H, s) 2.29(2H, m) 2.57(2H, m) 3.68(4H, m) 3.83(2H, s) 3.88(2H, m) 3.99(6H, s) 7.06(3H, m) 7.23(1H, m)
60		oil	400(M+H) ⁺	2.08(3H, s) 3.42(2H, m) 3.49(2H, m) 3.64(4H, s) 3.68(2H, s) 3.82(2H, s) 3.99(6H, s) 7.06(3H, m) 7.23(1H, m)







Ex. No.	Structure	Property (mp °C)	FABMS(m/z)	NMR(CDCl ₃ , δ)
61		powder	372(M+H) ⁺	1.07(6H, d, J=6.6Hz) 2.08(3H, s) 3.49(2H, s) 3.84(2H, s) 4.00(6H, s) 4.04(1H, m) 5.14(1H, broad) 7.08(3H, m) 7.25(1H, m)
62		oil	359(M+H) ⁺	1.93(2H, m), 2.08(3H, s), 2.36(2H, m), 2.63(2H, m), 3.82(3H, s), 3.99(6H, s), 6.99-7.03(3H, m), 7.18(1H, m)
63		oil	426(M+H) ⁺	1.51-1.63(6H, m), 1.92(2H, m), 2.08(3H, s), 2.31(2H, m), 2.62(2H, m), 3.33(2H, m), 3.54(2H, m), 3.82(2H, s), 3.99(3H, s), 4.00(3H, s), 6.97-7.04(3H, m), 7.18(1H, m)
64		oil	444(M+H) ⁺	1.94(2H, m), 2.08(3H, s), 2.29(2H, m), 2.56-2.65(6H, m), 3.66(2H, m), 3.82(2H, s), 3.87(2H, m), 3.99(3H, s), 4.00(3H, s), 6.98-7.03(3H, m), 7.18(1H, m)
65		oil	428(M+H) ⁺	1.94(2H, m), 2.08(3H, s), 2.30(2H, m), 2.63(2H, m), 3.39(2H, m), 3.61-3.65(6H, m), 3.82(2H, s), 3.99(3H, s), 4.00(3H, s), 6.98-7.03(3H, m), 7.18(1H, m)
66		oil	400(M+H) ⁺	1.15(6H, d, J=6.5Hz), 1.93(2H, m), 2.10(3H, s), 2.10(2H, m), 2.60(2H, m), 3.81(2H, s), 3.99(6H, s), 4.09(1H, m), 5.32(1H, broad), 6.97-7.02(3H, m), 7.18(1H, m)







Ex. No.	Structure	Property (mp °C)	FABMS(m/z)	NMR(CDCl ₃ , δ)
67		powder	343(M+H) ⁺	2.00(3H, s), 3.99(5H, s), 4.02(3H, s), 6.39(1H, d, J=15.7Hz), 6.96(1H, d, J=7.0Hz), 7.25-7.31(2H, m), 7.59(1H, d, J=7.2Hz), 8.22(1H, d, J=15.7Hz)
68		powder	428(M+H) ⁺	1.97(3H, s), 2.70(4H, broad), 3.97(2H, s), 3.98(2H, s), 3.99(3H, s), 4.02(3H, s), 6.75(1H, d, J=15.1Hz), 6.89(1H, m), 7.23(2H, m), 7.51(1H, m), 8.07(1H, d, J=15.1Hz)
69		oil	345(M+H) ⁺	2.02(3H, s), 2.77(2H, m), 3.10(2H, m), 3.85(2H, s), 3.98(3H, s), 4.03(3H, s), 6.81(1H, d, J=7.5Hz), 7.10-7.21(3H, m)
70		oil	412(M+H) ⁺	1.47-1.62(6H, broad), 2.00(3H, s), 2.70(2H, m), 3.10(2H, m), 3.38(2H, m), 3.58(2H, m), 3.86(2H, s), 3.98(3H, s), 4.03(3H, s), 6.78(1H, d, J=7.4Hz), 7.09(1H, m), 7.14(1H, m), 7.20(1H, m)
71		oil	414(M+H) ⁺	2.02(3H, s), 2.73(2H, m), 3.11(2H, m), 3.42(2H, m), 3.49(2H, m), 3.64(4H, s), 3.85(2H, s), 3.98(3H, s), 4.03(3H, s), 6.79(1H, d, J=7.5Hz), 7.10-7.19(3H, m)
72		powder	430(M+H) ⁺	2.02(3H, s), 2.44(2H, m), 2.60(2H, m), 2.72(2H, m), 3.10(2H, m), 3.68(2H, m), 3.85(2H, s), 3.90(2H, m), 3.98(3H, s), 4.03(3H, s), 6.79(1H, d, J=7.5Hz), 7.08-7.21(3H, m)







Ex. No.	Structure	Property (mp °C)	FABMS(m/z)	NMR(ODCl ₃ , δ)
73		powder	386(M+H) ⁺	1.02(6H, d, J=6.6Hz) 2.06(3H, s) 2.56(2H, m) 3.08(2H, m) 3.85(2H, s) 3.97(3H, s) 4.00(1H, m) 4.04(3H, s) 5.52(1H, broad) 6.79(1H, d, J=7.4Hz) 7.10(2H, m) 7.18(1H, d, J=7.3Hz)

Ex. No.	Structure	Weight (yield)	Property	FABMS(m/z)	NMR(CDCl ₃ , δ)
74		38mg(29%)	oil	442(M+H) ⁺	1.82-1.98(4H, m), 2.08(3H, s), 2.52(2H, m), 2.93(3H, m), 3.15-3.23(1H, m), 3.33(3H, s), 3.36-3.40(1H, m), 3.50-5.53(1H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 4.24(1H, m), 7.10(4H, m)
75		34mg(25%)	powder	460(M+H) ⁺	1.66(1H, m), 2.07(3H, s), 2.37(2H, m), 2.53(1H, m), 2.86(2H, m), 2.96(2H, m), 3.81(2H, s), 3.98(3H, s), 5.46(1H, m), 5.50(1H, d, J=8.4Hz), 7.10-7.22(5H, m)
76		36mg(27%)	oil	442(M+H) ⁺	1.82-1.98(4H, m), 2.08(3H, s), 2.52(2H, m), 2.92(3H, m), 3.15-3.23(1H, m), 3.33(3H, s), 3.36-3.40(1H, m), 3.50-5.54(1H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 4.24(1H, m), 7.10(4H, m)
77		79mg(58%)	oil	456(M+H) ⁺	1.90-2.16(4H, m), 2.08(3H, s), 2.38-2.63(2H, m), 2.93(2H, m), 3.37(1H, m), 3.56(1H, m), 3.73(3H, s), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 4.48(1H, m), 7.12(4H, m)
78		61mg(23%)	powder	531(M+H) ⁺	2.17(3H, s), 2.53(3H, s), 2.63(2H, m), 2.95(2H, m), 3.24(2H, m), 3.32(2H, m), 3.54(2H, m), 3.78(2H, m), 3.80(2H, m), 3.98(6H, s), 6.84(2H, m), 7.11(4H, m), 7.89(2H, m)
79		41mg(30%)	powder	455(M+H) ⁺	1.43-1.60(2H, m), 1.80-1.92(2H, m), 2.08(3H, s), 2.34(1H, m), 2.58(2H, m), 2.67(1H, m), 2.89-2.97(3H, m), 3.78(1H, m), 3.81(2H, s), 3.99(6H, s), 4.59(1H, m), 5.38(1H, broad s), 5.51(1H, broad s), 7.10(4H, m)







Ex. No.	Structure	Weight (yield)	Property	FABMS(m/z)	NMR(ODCl ₃ , δ)
80		59mg(38%)	powder	517(M+H) ⁺	1.29-1.35(2H, m), 1.82(2H, m), 2.07(3H, s), 2.09(2H, m), 2.38-2.42(2H, m), 2.76(2H, m), 2.87-2.91(2H, m), 3.47(2H, s), 3.76(1H, m), 3.80(2H, s), 3.98(6H, s), 5.14(1H, d, J=8.1Hz), 7.08(4H, s), 7.24-7.33(4H, m)
81		68mg(53%)	oil	426(M+H) ⁺	0.92(3H, t, J=6.5Hz), 0.96-1.10(2H, m), 1.55-1.66(3H, m), 2.08(3H, s), 2.52-2.59(3H, m), 2.89-2.94(3H, m), 3.74(1H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 4.58(1H, m), 7.07-7.13(4H, m)
82		120mg(78%)	oil	511(M+H) ⁺	1.10 and 1.21(total 6H, both d, J=7.1Hz), 1.71-1.92(3H, m), 2.08(3H, s), 2.43-2.69(4H, m), 2.89-3.00(3H, m), 3.20-3.49(5H, m), 3.78(1H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 4.65(1H, m), 7.08-7.11(4H, m)
83		59mg(46%)	oil	426(M+H) ⁺	1.10-1.17(3H, m), 1.24-1.37(1H, broad), 1.50-1.58(5H, m), 2.08(3H, s), 2.53-2.67(2.5H, m), 2.90-3.13(2.5H, m), 3.56(0.5H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 4.06(0.5H, m), 4.52(0.5H, m), 4.93(0.5H, broad), 7.08-7.13(4H, m)
84		63mg(46%)	powder	460(M+H) ⁺	2.07(3H, s), 2.37(2H, m), 2.65-2.70(2H, m), 2.89(2H, m), 3.23-3.29(2H, m), 3.80(2H, s), 3.98(6H, s), 4.71(1H, m), 5.51(1H, d, J=7.4Hz), 7.07(4H, s), 7.16-7.22(4H, m)
85		69mg(54%)	oil	426(M+H) ⁺	0.85 and 0.88(total 3H, both d, J=6.6Hz), 1.03-1.14(1H, m), 1.24-1.67(3H, m), 1.78(1H, m), 2.08(3H, s), 2.17-2.23(0.5H, m), 2.55-2.60(3H, m), 2.83-2.93(2.5H, m), 3.60(0.5H, m), 3.68(0.5H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 4.44(1H, m), 7.09-7.13(4H, m)

Ex. No.	Structure	Weight (yield)	Property	FABMS(m/z)	NMR(CDCl ₃ , δ)
86		20mg(15%)	oil	440(M+H) ⁺	1.19(6H, d, J=7.0Hz), 1.42-1.63(5H, m), 1.73-1.79(1H, m), 2.08(3H, s), 2.53-2.64(2H, m), 2.91-2.95(2H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 4.00(1H, broad), 4.77(1H, broad), 7.08-7.14(4H, m)
87		64mg(50%)	oil	428(M+H) ⁺	1.52-1.57(1H, m), 1.74-1.88(2H, m), 1.95-2.02(1H, m), 2.08(3H, s), 2.53-2.59(2H, m), 2.90-2.96(2H, m), 3.27-3.41(2H, m), 3.51-3.57(1H, m), 3.62-3.68(1H, m), 3.81(2H, s), 3.99(6H, s), 4.18-4.21(1H, m), 5.05-5.30(1H, m), 7.09-7.14(4H, m)
88		48mg(36%)	oil	442(M+H) ⁺	1.01-1.93(6H, m), 2.08(3H, s), 2.43-2.71(3H, m), 2.89-3.11(3H, m), 3.58-3.66(2H, m), 3.78-3.91(1H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 4.59-4.79(1H, m), 7.08-7.13(4H, m)
89		120mg(86%)	oil	464(M+H) ⁺	2.07(3H, s), 2.58(2H, m), 2.99(2H, m), 3.81(2H, s), 3.98(6H, s), 5.94(2H, s), 6.65(1H, m), 6.71(1H, m), 6.87(1H, broad), 7.12(5H, m)
90		110mg(77%)	oil	478(M+H) ⁺	2.07(3H, s), 2.58(2H, m), 2.99(2H, m), 3.81(2H, s), 3.98(6H, s), 4.23(4H, broad s), 6.77(2H, m), 6.81(1H, broad), 7.12(4H, m)
91		46mg(30%)	powder	505(M+H) ⁺	2.07(3H, s), 2.59(2H, m), 3.00(2H, m), 3.11(4H, m), 3.84(6H, m), 3.98(6H, s), 6.85(4H, m), 7.12(4H, m), 7.28(1H, m)







Ex. No.	Structure	Weight (yield)	Property	FABMS(m/z)	NMR(CDCl ₃ , δ)
92		136mg(52%)	oil	524(M+H) ⁺	2.08(3H, s), 2.68(2H, m), 3.02(2H, m), 3.81(3H, s), 3.97(6H, s), 7.12(4H, m), 7.41(1H, broad s), 7.46-7.60(4H, m), 7.78(4H, m)
93		59mg(43%)	powder	462(M+H) ⁺	2.08(3H, s), 2.57(3H, s), 2.67(2H, m), 3.01(2H, m), 3.81(2H, s), 3.98(6H, s), 7.13(4H, m), 7.21(1H, broad), 7.53(2H, m), 7.91(2H, m)
94		79mg(59%)	powder	450(M+H) ⁺	2.08(3H, s), 2.60(2H, m), 3.00(2H, m), 3.78(3H, s), 3.81(2H, s), 3.98(6H, s), 6.83(2H, m), 6.86(1H, broad), 7.12(4H, m), 7.30(2H, m)
95		63mg(45%)	powder	463(M+H) ⁺	2.08(3H, s), 2.58(2H, m), 2.91(6H, s), 3.00(2H, m), 3.81(2H, s), 3.98(6H, s), 6.67(2H, d, J=9.0Hz), 6.81(1H, broad), 7.12(4H, m), 7.24(2H, d, J=8.9Hz)
96		45mg(34%)	powder	436(M+H) ⁺	2.08(3H, s), 2.72(2H, m), 3.02(2H, m), 3.82(2H, s), 3.98(3H, s), 3.99(3H, s), 6.82(2H, d, J=4.2Hz), 6.99(1H, d, J=7.9Hz), 7.08-7.19(6H, m), 8.58(1H, broad)
97		60mg(46%)	oil	436(M+H) ⁺	2.12(3H, s), 2.62(2H, m), 3.00(2H, m), 3.83(2H, s), 3.98(3H, s), 3.99(3H, s), 6.61(1H, d, J=8.1Hz), 6.66(1H, broad), 6.78(1H, broad), 6.83(1H, d, J=8.1Hz), 7.11-7.17(5H, m), 8.02(1H, broad)

Ex. No.	Structure	Weight (yield)	Property	FABMS(m/z)	NMR(CDCl ₃ , δ)
98		94mg(64%)	oil	488(M+H) ⁺	2.08(3H, s), 2.62(2H, m), 2.99(2H, m), 3.81(2H, s), 3.98(6H, s), 7.00(1H, broad), 7.08(1H, broad), 7.12(4H, s), 7.40(2H, s)
99		120mg(84%)	oil	480(M+H) ⁺	2.07(3H, s), 2.61(2H, m), 3.00(2H, m), 3.75(3H, s), 3.77(3H, s), 3.81(2H, s), 3.98(6H, s), 6.22(1H, broad), 6.69(2H, broad), 6.95(1H, broad), 7.12(4H, m)
100		71mg(48%)	powder	492(M+H) ⁺	1.38(3H, m), 2.08(3H, s), 2.66(2H, m), 3.01(2H, m), 3.81(2H, s), 3.98(6H, s), 4.35(2H, m), 7.11(4H, m), 7.15(1H, broad), 7.51(2H, d, J=8.5Hz), 7.98(2H, d, J=8.7Hz)
101		63mg(41%)	powder	510(M+H) ⁺	2.08(3H, s), 2.61(2H, m), 3.00(2H, m), 3.81(5H, s), 3.84(6H, s), 3.98(6H, s), 6.76(2H, s), 6.98(1H, broad), 7.12(4H, m)
102		94mg(56%)	oil	556(M+H) ⁺	2.07(3H, s), 2.67(2H, m), 3.01(2H, m), 3.81(2H, s), 3.98(6H, s), 7.12(4H, s), 7.43(1H, broad), 7.59(1H, broad), 7.95(2H, s)
103		31mg(20%)	powder	480(M+H) ⁺	2.08(3H, s), 2.60(2H, m), 3.00(2H, m), 3.81(2H, s), 3.85(3H, s), 3.88(3H, s), 3.98(6H, s), 6.71(1H, m), 6.78(1H, m), 6.91(1H, broad), 7.13(4H, m), 7.31(1H, broad)







Ex. No.	Structure	Weight (yield)	Property	FABMS(m/z)	NMR(CDCl ₃ , δ)
104		46mg(40%)	oil	402(M+H) ⁺	1.06(3H, d, J=7.0Hz), 2.08(3H, s), 2.41-2.46(2H, m), 2.91(2H, m), 3.40-3.44(1H, m), 3.52-3.56(1H, m), 3.81(2H, s), 3.99(6H, s), 5.40(1H, m), 7.10(4H, s)
105		91mg(63%)	oil	484(M+H) ⁺	1.27(3H, t, J=7.1Hz), 1.28-1.70(4H, m), 2.08(3H, s), 2.25(1H, m), 2.64(2H, m), 2.92(2H, m), 3.19-3.36(1H, m), 3.71(1H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 4.15-4.21(3H, m), 5.37(1H, m), 7.08-7.14(4H, m)
106		93mg(70%)	oil	441(M+H) ⁺	1.78(1H, m), 1.93(1H, m), 2.04(1H, m), 2.08(3H, s), 2.40(1H, m), 2.60(2H, m), 2.94(2H, m), 3.29(1H, m), 3.45(1H, m), 3.81(2H, m), 3.98(3H, s), 3.99(3H, s), 4.58(1H, m), 5.30(1H, broad s), 6.92(1H, broad s), 7.11(4H, m)
107		110mg(76%)	oil	484(M+H) ⁺	1.25(3H, t, J=7.1Hz), 1.29-1.48(1H, m), 1.58-1.78(2H, m), 2.02(1H, m), 2.08(3H, s), 2.25-2.43(1H, m), 2.56-2.67(2H, m), 2.78-3.01(3.5H, m), 3.28-3.34(0.5H, m), 3.66-3.75(1H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 4.11-4.16(3H, m), 4.65(0.5H, m), 7.10(4H, m)
108		140mg(90%)	powder	512(M+H) ⁺	2.07(3H, s), 2.61(2H, m), 3.00(2H, m), 3.81(2H, s), 3.98(6H, s), 6.92-6.98(4H, m), 7.04-7.15(6H, m), 7.30-7.38(4H, m)
109		59mg(43%)	oil	466(M+H) ⁺	0.98-1.76(13H, broad), 2.07(1H, broad), 2.08(3H, s), 2.56(2H, m), 2.92(2H, m), 3.14(2H, broad), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 7.11(4H, m)







Ex. No.	Structure	Weight (yield)	Property	FABMS(m/z)	NMR(CDCl ₃ , δ)
110		130mg(88%)	oil	492(M+H) ⁺	1.38(3H, t, J=7.1Hz), 2.07(3H, s), 2.64(2H, m), 3.00(2H, m), 3.81(2H, s), 3.98(6H, s), 4.32-4.39(3H, m), 7.12(4H, m), 7.20(1H, m), 7.36(1H, m), 7.76-7.93(3H, m)
111		72mg(52%)	powder	459(M+H) ⁺	2.07(3H, s), 2.63(2H, m), 3.00(2H, m), 3.71(2H, s), 3.81(2H, s), 3.99(6H, s), 7.02(1H, broad s), 7.11(4H, m), 7.25(2H, m), 7.44(2H, m)
112		130mg(94%)	powder	462(M+H) ⁺	1.22(6H, d, J=6.9Hz), 2.07(3H, s), 2.60(2H, m), 2.86(1H, m), 3.00(2H, m), 3.81(2H, s), 3.98(6H, s), 6.96(1H, broad s), 7.09-7.16(6H, m), 7.32(2H, m)
113		60mg(41%)	powder	490(M+H) ⁺	0.88(3H, t, J=6.7Hz), 1.27-1.35(4H, m), 1.56-1.61(2H, m), 2.07(3H, s), 2.53-2.62(4H, m), 3.00(2H, m), 3.81(2H, s), 3.98(6H, s), 6.96(1H, broad s), 7.11-7.15(6H, m), 7.31(2H, m)
114		84mg(28%)	powder	594(M+H) ⁺	2.08(3H, s), 2.59(2H, m), 2.98(2H, m), 3.82(2H, s), 3.98(6H, s), 5.75(1H, broad s), 6.95(1H, broad s), 7.11(4H, s), 7.58(2H, s)
115		42mg(30%)	powder	446(M+H) ⁺	2.08(3H, s), 2.58(2H, m), 2.99(2H, m), 3.81(2H, s), 3.86(3H, s), 3.98(6H, s), 6.76(1H, d, J=8.6Hz), 6.90-7.09(3H, m), 7.11(4H, m)

Ex. No.	Structure	Weight (yield)	Property	FABMS(m/z)	NMR(CDCl ₃ , δ)
116		92mg(62%)	powder	492(M+H) ⁺	0.97(3H, t, J=7.4Hz), 1.45-1.52(2H, m), 1.71-1.78(2H, m), 2.08(3H, s), 2.59(2H, m), 3.00(2H, m), 3.81(2H, s), 3.92(2H, m), 3.98(6H, s), 6.82(2H, m), 7.12(4H, m), 7.29(2H, m)
117		85mg(58%)	powder	488(M+H) ⁺	2.08(3H, s), 2.65(2H, m), 3.00(2H, m), 3.81(2H, s), 3.98(6H, s), 7.12(5H, m), 7.54(4H, m)
118		71mg(60%)	powder	445(M+H) ⁺	2.08(3H, s), 2.66(2H, m), 3.00(2H, m), 3.81(2H, s), 3.99(6H, s), 7.10-7.15(5H, m), 7.53-7.60(4H, m)
119		88mg(33%)	oil	536(M+H) ⁺	1.60(9H, s), 2.08(3H, s), 2.63(2H, m), 2.99(2H, m), 3.81(2H, s), 3.98(6H, s), 6.99-7.13(7H, m), 7.68(1H, m), 11.12(1H, s)
120		75mg(61%)	oil	448(M+H) ⁺	1.40(3H, d, J=7.0Hz), 2.07(3H, s), 2.43(2H, m), 2.91(2H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 5.09(1H, m), 5.49(1H, broad), 7.07(4H, s), 7.21(2H, m), 7.24-7.33(3H, m)
121		80mg(58%)	oil	448(M+H) ⁺	1.40(3H, d, J=7.0Hz), 2.08(3H, s), 2.43(2H, m), 2.91(2H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 5.09(1H, m), 5.48(1H, broad), 7.07(4H, s), 7.21(2H, m), 7.25-7.33(3H, m)

Ex. No.	Structure	Weight (yield)	Property	FABMS(m/z)	NMR(CDCl ₃ , δ)
122		39mg(28%)	powder	457(M+H) ⁺	2.07(3H, s), 2.38-2.48(8H, m), 2.90(2H, m), 3.32(2H, m), 3.67(4H, m), 3.80(2H, s), 3.98(3H, s), 3.99(3H, s), 5.86(1H, broad), 7.10(4H, m)
123		68mg(53%)	oil	428(M+H) ⁺	0.90(9H, s), 1.32(2H, m), 2.07(3H, s), 2.40(2H, m), 2.90(2H, m), 3.21(2H, m), 3.80(2H, s), 3.98(3H, s), 3.99(3H, s), 5.19(1H, broad), 7.09(4H, s)
124		59mg(48%)	powder	414(M+H) ⁺	0.78(6H, m), 1.27(2H, m), 1.46(2H, m), 2.07(3H, s), 2.43(2H, m), 2.92(2H, m), 3.74(1H, m), 3.80(2H, s), 3.98(3H, s), 3.99(3H, s), 4.96(1H, broad), 7.10(4H, m)
125		22mg(18%)	powder	418(M+H) ⁺	2.10(3H, s), 2.47(2H, m), 2.93(2H, m), 3.59(2H, m), 3.73(2H, m), 3.81(2H, s), 3.85(1H, m), 3.98(3H, s), 3.99(3H, s), 5.96(1H, broad), 7.10(4H, m)
126		49mg(40%)	powder	416(M+H) ⁺	0.84(2H, m), 1.38(1H, m), 1.49(1H, m), 2.08(3H, s), 2.33(1H, broad), 2.46(2H, m), 2.92(2H, m), 3.52(2H, m), 3.78(1H, broad), 3.81(2H, s), 3.99(6H, s), 5.37(1H, broad), 7.10(4H, s)
127		53mg(44%)	powder	400(M+H) ⁺	0.80(3H, m), 1.02(3H, d, J=6.6Hz), 1.36(2H, m), 2.07(3H, s), 2.40(2H, m), 2.91(2H, m), 3.80(2H, s), 3.87(1H, m), 3.98(3H, s), 3.99(3H, s), 5.03(1H, broad), 7.09(4H, s)







Ex. No.	Structure	Weight (yield)	Property	FABMS(m/z)	NMR(CDCl ₃ , δ)
128		61mg(48%)	oil	428(M+H) ⁺	0.86(6H, m) 1.02(3H, d, J=6.5Hz) 1.12-1.27(2H, m) 1.46(1H, m) 2.07(3H, s) 2.39(2H, m) 2.90(2H, m) 3.80(2H, s) 3.98(3H, s) 3.99(3H, s) 4.01(1H, m) 4.99(1H, broad) 7.09(4H, s)
129		62mg(45%)	powder	456(M+H) ⁺	0.87(3H, m) 1.03(3H, d, J=6.5Hz) 1.24-1.32(10H, broad) 2.07(3H, s) 2.39(2H, m) 2.90(2H, m) 3.80(2H, s) 3.93(1H, m) 3.98(3H, s) 3.99(3H, s) 5.03(1H, broad) 7.09(4H, s)
130		59mg(43%)	oil	458(M+H) ⁺	1.14(3H, d, J=6.7Hz) 1.26(3H, m) 2.07(3H, s) 2.38-2.45(4H, m) 2.89(2H, m) 3.80(2H, s) 3.98(3H, s) 3.99(3H, s) 4.13(2H, m) 4.32(1H, m) 5.98(1H, broad) 7.09(4H, s)
131		49mg(39%)	powder	444(M+H) ⁺	0.87(3H, m) 1.22-1.37(6H, m) 2.08(3H, s) 2.33(1H, m) 2.46(2H, m) 2.92(2H, m) 3.48(1H, m) 3.54(1H, m) 3.81(2H, s) 3.86(1H, m) 3.99(6H, s) 5.37(1H, broad) 7.10(4H, s)
132		49mg(41%)	oil	398(M+H) ⁺	1.80-1.90(4H, m) 2.08(3H, s) 2.52(2H, m) 2.93(2H, m) 3.28(2H, m) 3.45(2H, m) 3.80(2H, s) 3.98(3H, s) 3.99(3H, s) 7.11(4H, m)
133		43mg(32%)	powder	455(M+H) ⁺	1.39(2H, broad) 1.82(2H, broad) 2.02(2H, broad) 2.07(3H, s) 2.50(2H, m) 2.91(2H, m) 3.25(2H, m) 3.80(2H, s) 3.98(3H, s) 3.99(3H, s) 4.48(1H, m) 5.87(1H, broad) 6.80(1H, broad) 7.09(4H, s)







Ex. No.	Structure	Weight (yield)	Property	FABMS(m/z)	NMR(CDCl ₃ , δ)
134		70mg(56%)	oil	414(M+H) ⁺	1.76-2.00(3H, broad) 2.08, 2.09(total 3H, both s) 2.53(2H, m) 2.93(2H, m) 3.15(0.4H, m) 3.34-3.62(3.6H, m) 3.81(2H, s) 3.98(3H, s) 3.99(3H, s) 4.46(1H, broad) 7.10(4H, m)
135		25mg(19%)	oil	426(M+H) ⁺	1.08, 1.13, 1.29(total 6H, all d, J=6.4, 6.5, 6.3Hz) 1.48-1.66(2.5H, m) 1.80-1.88(0.7H, m) 1.99-2.06(1.3H, m) 2.08(3H, s) 2.53(2H, m) 2.94(2H, m) 3.81(2H, s) 3.82(1H, m) 3.98(3H, s) 3.99(3H, s) 4.05-4.23(0.5H, m) 7.11(4H, m)
136		79mg(60%)	powder	440(M+H) ⁺	1.30(2H, m) 1.45-1.58(5H, broad) 1.82(2H, broad) 2.07(3H, s) 2.18(3H, s) 2.38(2H, m) 2.90(2H, m) 3.80(2H, s) 3.91(1H, m) 3.98(3H, s) 3.99(3H, s) 5.19(1H, broad) 7.09(4H, s)
137		72mg(55%)	oil	440(M+H) ⁺	0.71(1H, m) 0.83, 0.88(total 6H, both d, J=6.6, 6.5Hz) 1.37-1.54(1.8H, broad) 1.75-1.98(2.2H, m) 2.09(3H, s) 2.40(0.7H, m) 2.58(2H, m) 2.90(2H, m) 3.05(0.3H, m) 3.30(0.2H, broad) 1.95(1H, broad) 2.09(2H, s) 3.98(3H, s) 3.99(3H, s) 4.59(0.8H, broad) 7.11(4H, m)
138		35mg(27%)	oil	428(M+H) ⁺	1.33-1.92(4.7H, m) 2.09, 2.08(total 3H, both s) 2.61(2H, m) 2.92(2H, m) 3.02-3.89(5.3H, m) 3.81(2H, s) 3.98(3H, s) 3.99(3H, s) 7.11(4H, m)
139		27mg(21%)	oil	427(M+H) ⁺	2.08(3H, s) 2.28(5H, s) 2.34(2H, m) 2.58(2H, m) 2.91(2H, m) 3.40(2H, m) 3.63(2H, broad) 3.81(2H, s) 3.98(3H, s) 3.99(3H, s) 7.11(4H, s)







Ex. No.	Structure	Weight (yield)	Property	FABMS(m/z)	NMR(CDCl ₃ , δ)
140		140mg(95%)	oil	491(M+H) ⁺	1.86(3H, s), 2.07(3H, s), 2.65(2H, m), 3.01(2H, m), 3.23(3H, s), 3.81(2H, s), 3.98(6H, s), 7.12(6H, m), 7.36(1H, broad s), 7.49(2H, m)
141		114mg(76%)	oil	501(M+H) ⁺	2.08(3H, s), 2.40(2H, m), 2.46(2H, m), 2.57(4H, m), 2.91(2H, m), 3.42(2H, m), 3.60-3.71(8H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 7.11(4H, m)
142		44mg(33%)	oil	441(M+H) ⁺	2.08(3H, s), 2.62(2H, m), 2.93(2H, m), 3.15-3.65(8H, m), 3.80(2H, s), 3.98(3H, s), 3.99(3H, s), 7.11(4H, m), 8.06(1H, s)
143		80mg(59%)	oil	455(M+H) ⁺	2.08(3H, s), 2.11(3H, s), 2.61(2H, m), 2.93(2H, m), 3.29-3.65(8H, m), 3.81(2H, s), 3.99(6H, s), 7.11(4H, m)
144		57mg(42%)	oil	455(M+H) ⁺	1.25-1.92(4H, m), 2.09(3.8H, m), 2.38(0.7H, m), 2.53-2.72(2.5H, m), 2.90(2H, m), 3.30-3.42(1.4H, m), 3.66-3.71(0.7H, m), 3.81(3H, m), 3.97, 3.98, 3.99, 4.00(total 6H, all s), 4.51(0.2H, broad s), 5.30(1H, broad s), 5.80(0.2H, broad s), 6.47(0.6H, broad s), 7.10(4H, m)
145		102mg(74%)	oil	460(M+H) ⁺	1.85(2H, m), 2.07(3H, s), 2.57(2H, broad), 2.77(2H, m), 2.93(2H, m), 3.73(2H, m), 3.79(2H, s), 3.98(3H, s), 3.99(3H, s), 6.98-7.16(4H, m)







Ex. No.	Structure	Weight (yield)	Property	FABMS(m/z)	NMR(CDCl ₃ , δ)
146		110mg(76%)	oil	484(M+H) ⁺	1.25(3H, t, J=7.1Hz), 1.55-1.64(2H, m), 1.83-1.94(2H, m), 2.08(3H, s), 2.49(1H, m), 2.58(2H, m), 2.80(1H, m), 2.91(2H, m), 3.03(1H, m), 3.75(1H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 4.14(2H, q, J=7.1Hz), 4.42(1H, m), 7.11(4H, m)
147		91mg(63%)	oil	485(M+H) ⁺	1.27(3H, t, J=7.1Hz), 2.08(3H, s), 2.59(2H, m), 2.92(2H, m), 3.36(2H, m), 3.44(2H, m), 3.60(2H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 4.15(2H, q, J=7.1Hz), 7.11(4H, m)
148		90mg(62%)	oil	489(M+H) ⁺	2.07(3H, s), 2.63(2H, m), 2.94(2H, m), 3.06(2H, m), 3.12(2H, m), 3.54(2H, m), 3.80(4H, m), 3.98(3H, s), 3.99(3H, s), 6.91(3H, m), 7.11(4H, m), 7.28(2H, m)
149		107mg(71%)	oil	502(M+H) ⁺	0.98-1.17(2H, m), 1.64-1.73(3H, m), 2.08(3H, s), 2.47-2.58(5H, m), 2.86-2.92(3H, m), 3.76(1H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 4.61(1H, m), 7.08-7.30(9H, m)
150		76mg(52%)	oil	490(M+H) ⁺	2.07(3H, s), 2.63(2H, m), 2.95(2H, m), 3.50(6H, m), 3.75(2H, m), 3.80(2H, s), 3.98(3H, s), 3.99(3H, s), 6.65(2H, m), 7.11(4H, m), 7.50(1H, m), 8.18(1H, m)
151		74mg(48%)	powder	486(M+H-H ₂ O) ⁺	1.70-1.79(4H, m), 2.00(1H, m), 2.07(3H, s), 2.63(2H, m), 2.94(2H, m), 3.09(1H, m), 3.41-3.48(1H, m), 3.66(1H, m), 3.79(2H, s), 3.98(6H, s), 4.59(1H, m), 7.12(4H, m), 7.28-7.45(5H, m)







Ex. No.	Structure	Weight (yield)	Property	FABMS(m/z)	NMR(CDCl ₃ , δ)
152		107mg(70%)	oil	503(M+H) ⁺	2.08(3H, s), 2.32-2.41(4H, m), 2.57(2H, m), 2.91(2H, m), 3.38(2H, m), 3.49(2H, s), 3.62(2H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 7.10(4H, s), 7.26-7.34(5H, m)
153		118mg(80%)	oil	491(M+H) ⁺	2.07(3H, s), 2.64(2H, m), 2.95(2H, m), 3.44(2H, m), 3.71(4H, m), 3.79(4H, m), 3.98(6H, s), 6.54(1H, m), 7.12(4H, m), 8.32(2H, d), J=4.6Hz
154		140mg(86%)	oil	520(M+H-H ₂ O) ⁺	1.68-1.79(4H, m), 1.94(1H, m), 2.07(3H, s), 2.62(2H, m), 2.94(2H, m), 3.07(1H, m), 3.36-3.45(1H, m), 3.65(1H, m), 3.79(2H, s), 3.98(6H, s), 4.59(1H, m), 7.11(4H, m), 7.35(4H, m)
155		81mg(63%)	oil	428(M+H) ⁺	1.27(1H, m), 1.41(1H, m), 1.75(1H, broad), 1.85(1H, broad), 2.09(3H, s), 2.59(2H, m), 2.92(2H, m), 3.12(2H, m), 3.63(1H, broad), 3.81(2H, s), 3.86(1H, m), 3.99(6H, s), 4.12(1H, broad), 7.11(4H, m)
156		77mg(58%)	oil	442(M+H) ⁺	1.12(3H, d, J=6.3Hz), 1.18(3H, d, J=6.2Hz), 2.09(3H, s), 2.28(1H, m), 2.57(2H, m), 2.68(1H, m), 2.92(2H, m), 3.31(1H, broad), 3.43-3.52(2H, broad), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 4.45(1H, d, J=13.2Hz), 7.11(4H, s)
157		62mg(47%)	oil	442(M+H) ⁺	1.18-1.79(5H, broad), 2.08, 2.09(total 3H, both s), 2.33(0.5H, broad), 2.61(2H, m), 2.80(0.8H, m), 2.92(2H, m), 3.26-3.53(3.9H, broad), 3.76(1H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 4.32(0.4, broad), 7.11(4H, m)



Ex. No.	Structure	Weight (yield)	Property	FABMS(m/z)	NMR(CDCl ₃ , δ)
158		59mg(50%)	oil	396(M+H) ⁺	2.08(3H, s) 2.53(2H, m) 2.96(2H, m) 3.81(2H, s) 3.98(3H, s) 3.99(3H, s) 4.13(2H, broad) 4.23(2H, broad) 5.75(1H, m) 5.86(1H, m) 7.12(4H, m)
159		60mg(49%)	oil	410(M+H) ⁺	2.08(3H, s) 2.11(2H, broad) 2.59(2H, m) 2.93(2H, m) 3.44(1H, m) 3.63(1H, m) 3.80(2H, s) 3.84(1H, m) 3.98(3H, s) 3.99(3H, s) 4.05(1H, m) 5.63(1H, broad) 5.83(1H, broad) 7.11(4H, m)
160		24mg(18%)	oil	456(M+H) ⁺	1.33(1H, m) 1.54-1.70(6H, m) 1.89(1H, m) 2.08(3H, s) 2.63(2H, m) 2.83-2.94(3H, m) 3.20(1H, m) 3.55-3.65(2H, m) 3.81(2H, s) 3.98(3H, s) 3.99(3H, s) 4.85(1H, broad) 7.11(4H, m)
161		74mg(54%)	oil	456(M+H) ⁺	0.91-1.35(3H, broad) 1.51(2H, m) 1.60-1.73(3H, m) 2.08(3H, s) 2.54(3H, m) 2.91(3H, m) 3.69(2H, m) 3.74(1H, m) 3.81(2H, s) 3.98(3H, s) 3.99(3H, s) 4.61(1H, broad) 7.10(4H, m)
162		40mg(29%)	oil	457(M+H) ⁺	2.08(3H, s) 2.38(2H, m) 2.45(2H, m) 2.52-2.60(4H, m) 2.92(2H, m) 3.40(2H, m) 3.63(4H, m) 3.81(2H, s) 3.98(3H, s) 3.99(3H, s) 7.10(4H, m)
163		80mg(51%)	oil	519(M+H) ⁺	2.10(3H, s) 2.63(2H, m) 2.93-3.01(6H, m) 3.58(2H, m) 3.80(4H, s) 3.87(3H, s) 3.98(3H, s) 3.99(3H, s) 6.87-6.93(3H, m) 7.03(1H, m) 7.12(4H, m)

Ex. No.	Structure	Weight (yield)	Property	FABMS(m/z)	NMR(CDCI ₃ , δ)
164		88mg(53%)	oil	507(M+H) ⁺	2.07(3H, s), 2.63(2H, m), 2.95(4H, m), 3.03(2H, m), 3.53(2H, m), 3.77(2H, m), 3.80(2H, s), 3.98(3H, s), 3.99(3H, s), 6.86(2H, m), 6.98(2H, m), 7.11(4H, m)
165		112mg(76%)	oil	495(M+H) ⁺	1.38-1.88(10H, m), 2.08(3H, s), 2.47-2.60(8H, m), 2.90(3H, m), 3.80(2H, s), 3.84(1H, m), 3.98(3H, s), 3.99(3H, s), 4.70(1H, m), 7.11(4H, m)
166		64mg(50%)	oil	428(M+H) ⁺	1.55(1H, m), 1.78(1H, m), 1.86(1H, m), 2.00(1H, m), 2.08(3H, s), 2.57(2H, m), 2.94(2H, m), 3.35(2H, m), 3.54(1H, m), 3.65(1H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 4.21(1H, m), 5.06(1H, m), 7.11(4H, m)
167		98mg(63%)	oil	520(M+H) ⁺	2.08(3H, s), 2.66(2H, m), 2.73(2H, m), 2.93(2H, m), 3.58(1.2H, m), 3.78-3.86(9.2H, m), 3.98(3H, s), 3.99(3H, s), 4.46(0.8H, s), 4.66(1.2H, s), 6.49, 6.60, 6.63(totaal 2H, all s), 7.10(4H, m)
168		83mg(52%)	oil	530(M+H) ⁺	1.67(1H, m), 1.91(3H, s), 2.06(3H, s), 2.08(1H, m), 2.36(2H, m), 2.57(2H, m), 2.89(2H, m), 3.08(1H, m), 3.33(1H, m), 3.54(1H, m), 3.75(2H, s), 3.98(3H, s), 3.99(3H, s), 4.23(1H, m), 7.09(4H, m), 7.24-7.31(3H, m), 7.38(2H, m)
169		95mg(69%)	oil	460(M+H) ⁺	2.08(3H, s), 2.67(2H, m), 2.82(2H, m), 2.95(2H, m), 3.59(1.2H, m), 3.81(2.8H, m), 3.98(3H, s), 3.99(3H, s), 4.53(0.8H, s), 4.73(1.2H, s), 7.01-7.20(8H, m)

Ex. No.	Structure	Weight (yield)	Property	FABMS(m/z)	NMR(CDCl ₃ , δ)
170		98mg(77%)	oil	426(M+H) ⁺	2.08(3H, s) 2.26(2H, m) 2.42(2H, m) 2.68(2H, m) 2.94(2H, m) 3.64(2H, m) 3.80(2H, s) 3.87(2H, m) 3.99(6H, s) 7.12(4H, m)
171		80mg(67%)	powder	400(M+H) ⁺	0.82(6H, d, J=6.6Hz) 1.67(1H, m) 2.07(3H, s) 2.44(2H, m) 2.91(2H, m) 3.03(2H, m) 3.80(2H, s) 3.98(3H, s) 3.99(3H, s) 5.31(1H, broad) 7.09(4H, s)
172		107mg(89%)	powder	400(M+H) ⁺	1.27(9H, s) 2.07(3H, s) 2.33(2H, m) 2.88(2H, m) 3.81(2H, s) 3.98(3H, s) 3.99(3H, s) 5.07(1H, broad) 7.09(4H, s)
173		86mg(69%)	powder	414(M+H) ⁺	0.88(6H, d, J=6.6Hz) 1.31(2H, m) 1.52(1H, m) 2.07(3H, s) 2.41(2H, m) 2.91(2H, m) 3.22(2H, m) 3.80(2H, s) 3.98(3H, s) 3.99(3H, s) 5.24(1H, broad) 7.09(4H, s)
174		79mg(60%)	powder	428(M+H) ⁺	0.88(3H, m) 1.27(6H, broad) 1.42(2H, broad) 2.07(3H, s) 2.41(2H, m) 2.91(2H, m) 3.20(2H, m) 3.80(2H, s) 3.98(3H, s) 3.99(3H, s) 5.29(1H, broad) 7.09(4H, s)
175		65mg(50%)	powder	426(M+H) ⁺	0.99(2H, broad) 1.12(1H, broad) 1.32(2H, broad) 1.61(3H, broad) 1.81(2H, broad) 2.07(3H, s) 2.39(2H, m) 2.90(2H, m) 3.72(1H, m) 3.81(2H, s) 3.98(3H, s) 3.99(3H, s) 5.11(1H, broad) 7.09(4H, s)

Ex. No.	Structure	Weight (Yield)	Property	FABMS(m/z)	NMR(CDCl ₃ , δ)
176		67mg(54%)	powder	412(M+H) ⁺	1.23(2H, m), 1.56(4H, m), 1.91(2H, m), 2.07(3H, s), 2.38(2H, m), 2.90(2H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 4.15(1H, m), 5.18(1H, broad), 7.09(4H, s)
177		61mg(53%)	powder	384(M+H) ⁺	0.37(2H, m), 0.72(2H, m), 2.08(3H, s), 2.37(2H, m), 2.64(1H, m), 2.89(2H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 5.39(1H, broad), 7.08(4H, s)
178		66mg(55%)	powder	398(M+H) ⁺	0.13(2H, m), 0.45(2H, m), 0.86(1H, m), 2.08(3H, s), 2.44(2H, m), 2.92(2H, m), 3.06(2H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 5.39(1H, broad), 7.10(4H, s)
179		65mg(52%)	powder	420(M+H) ⁺	2.08(3H, s), 2.62(2H, m), 3.01(2H, m), 3.81(2H, s), 3.98(6H, s), 6.96(1H, broad), 7.12(5H, m), 7.30(2H, m), 7.42(2H, d, J=8.0Hz)
180		73mg(56%)	oil	435(M+H) ⁺	2.07(3H, s), 2.55(2H, m), 2.96(2H, m), 3.80(2H, s), 3.98(3H, s), 3.99(3H, s), 4.54(2H, d, J=4.9Hz), 6.65(1H, broad), 7.10(4H, m), 7.20(2H, m), 7.65(1H, m), 8.51(1H, m)
181		45mg(35%)	oil	435(M+H) ⁺	2.08(3H, s), 2.49(2H, m), 2.94(2H, m), 3.81(2H, s), 3.99(6H, s), 4.41(2H, d, J=5.9Hz), 5.67(1H, broad), 7.08(4H, s), 7.24(1H, m), 7.50(1H, d, J=7.6Hz), 8.44(1H, s), 8.51(1H, d, J=4.7Hz)

Ex. No.	Structure	Weight (yield)	Property	FABMS(m/z)	NMR(CDCl ₃ , δ)
182		67mg(51%)	powder	435(M+H) ⁺	2.08(3H, s), 2.54(2H, m), 2.96(2H, m), 3.82(2H, s), 3.99(6H, s), 4.41(2H, d, J=6.1Hz), 5.75(1H, broad), 7.04(2H, d, J=5.5Hz), 7.10(4H, s), 8.51(2H, d, J=5.9Hz)
183		83mg(65%)	oil	426(M+H) ⁺	1.51(4H, broad), 1.66(4H, broad), 2.08(3H, s), 2.57(2H, m), 2.93(2H, m), 3.36(2H, m), 3.52(2H, m), 3.81(2H, s), 3.98(3H, s), 3.99(3H, s), 7.11(4H, m)
184		16mg(56%)	powder		(DMSO-d ₆) 1.96(3H, s), 2.58(2H, m), 2.83(2H, m), 3.74(2H, s), 3.87(3H, s), 3.88(3H, s), 6.78(1H, m), 6.99(1H, s), 7.07(2H, m), 7.14(2H, m), 7.55(1H, m), 9.77(1H, s)
185		116mg(87%)	oil	450(M+H) ⁺	2.07(3H, s), 2.67(2H, m), 3.01(2H, m), 3.81(2H, s), 3.84(3H, s), 3.98(3H, s), 3.99(3H, s), 6.85(1H, d, J=8.0Hz), 6.96(1H, m), 7.02(1H, m), 7.10(2H, d, J=8.1Hz), 7.15(2H, d, J=8.0Hz), 7.69(1H, broad), 8.37(1H, d, J=7.8Hz)
186		112mg(93%)	oil	450(M+H) ⁺	2.07(3H, s), 2.61(2H, m), 3.00(2H, m), 3.79(3H, s), 3.81(2H, s), 3.98(6H, s), 6.65(1H, broad), 6.85(1H, broad), 6.96(1H, broad), 7.10-7.20(5H, m), 7.25(1H, broad)
187		108mg(76%)	oil	480(M+H) ⁺	2.07(3H, s), 2.64(2H, m), 3.00(2H, m), 3.79(3H, s), 3.81(3H, s), 3.83(2H, s), 3.98(3H, s), 3.99(3H, s), 6.45(2H, m), 7.13(4H, m), 7.47(1H, broad s), 8.23(1H, m)

Ex. No.	Structure	Weight (yield)	Property	FABMS(m/z)	NMR(CDCl ₃ , δ)
188		103mg(77%)	powder	451(M+H) ⁺	2.08(3H, s) 2.62(2H, m) 3.00(2H, m) 3.81(2H, s) 3.90(3H, s) 3.98(6H, s) 6.71(1H, d, J=8.9Hz) 6.87(1H, broad) 7.13(4H, m) 7.81(1H, m) 8.02(1H, m)
189		84mg(64%)	powder	436(M+H) ⁺	(DMSO-d ₆) 1.96(3H, s) 2.83(2H, m) 3.74(2H, s) 3.87(3H, s) 3.88(3H, s) 6.66(2H, m) 7.07(1H, s) 7.07(2H, m) 7.13(2H, m) 9.13(1H, s) 9.61(1H, s)

Experiment 1. Gel shift method

According to the gel shift method, a protein that binds to the NF- κ B binding sequence [115th base to 106th base upstream of the transcription initiation point (No. -115 to No. -106), 17th (G) to 26th (C) in SEQ ID NO: 1] on the 5'-flanking sequence [131st base to 97th base upstream of the transcription initiation point (No. -131 to No. -97); SEQ ID NO: 1] of the hINOS gene can be observed by cytokine stimulation.

The gel shift method was carried out as follows: the present sequence (SEQ ID NO: 1) was labelled by digoxigenin (DIG), which was incubated with a nuclear fraction extracted from A549 cells available from ATCC (CCL185) and then was electrophoresed at 4°C using a 7.5% polyacrylamide gel. The nuclear fractions of the cell were extracted from the non-stimulated cells, the cells stimulated for 4 hours with IL-1 β (1 ng/ml) or CM (human IL-1 β (1 ng/ml) + human IFN- γ (1000 U/ml) + human TNF- α (500 ng/ml)) by the method of Schreiber et al. (Auphan, N., DiDonato, J. A., Rosette, C., Helmborg, A. and Karin, M. (1995) Science 270: 286-290). The DNA in the electrophoresed gel was transferred to a nylon membrane by electrotransferring and the DIG-labelled DNA was detected as a chemiluminescence DIG-recognition antibody.

Figure 1 shows the result of the above experiment, which revealed that there is a protein (A) that binds to the present sequence in the A549 nuclear fraction in a non-specific manner in the case of non-stimulation. However, it was found that stimulation with IL-1 β or CM results in the binding of another stronger binding protein (B). These findings have indicated that cytokine stimulation of the cells activates NF- κ B.

It was demonstrated that the prior addition of the compound (20 μ g/ml) of the present invention obtained in Example 4 under this experimental condition inhibits the

activation of NF- κ B of A549 cells caused by CM stimulation (Figure 2).

Experiment 2. Effect on human lung carcinoma cell line A549 (A549/NF- κ BLuc) that has stably introduced a luciferase plasmid (pNF κ B-Luc, Stratagene, U.S.A.) regulated by the NF- κ B binding sequence.

Using lipofectamine (Lifetech Oriental K.K., Tokyo) according to the conventional method, A549 cells were co-transfected with pNF κ B-Luc and pSV2neo (Clontech, U.S.A.), and then A549/NF- κ BLuc, the cell that has stably introduced pNF κ B-Luc, was selected by adding G418 sulfate (1 mg/ml, Lifetech Oriental K.K.) to the culture medium.

It was confirmed and revealed that when A549/NF- κ BLuc is stimulated with IL-1 β (1 ng/ml) or TNF- α (500 ng/ml) for 4 hours, the compound obtained in Example 4 suppresses luciferase activity that has been regulated by the activation of NF- κ B (Figure 3). The luciferase activity was measured using the Luciferase Assay System (Promega, U.S.A.). IC₅₀ values are also shown in Table 1 together with the compounds of Examples 7 and 9.

Table 1

Test compound	IC50 (μM)		Test compound	IC50 (μM)
	IL-1 stimulation	TNF stimulation		
Example 3	29		Example 65	12
Example 4	10	10	Example 66	3
Example 7	4	10	Example 70	44
Example 9	3	4	Example 71	56
Example 23	42		Example 72	42
Example 27	15		Example 73	34
Example 28	14		Example 76	14
Example 29	13		Example 79	13
Example 30	14		Example 81	5
Example 32	24		Example 83	1
Example 33	28		Example 85	5
Example 34	29		Example 94	1
Example 35	8		Example 96	17
Example 37	49		Example 103	10
Example 39	39		Example 104	12
Example 42	22		Example 105	16
Example 43	21		Example 106	7
Example 44	39		Example 111	14
Example 45	17		Example 113	16
Example 46	17		Example 120	2
Example 47	21		Example 121	7
Example 48	18		Example 128	19
Example 49	28		Example 136	18
Example 50	16		Example 137	7
Example 51	18		Example 147	47
Example 53	8		Example 148	25
Example 54	5		Example 151	20
Example 55	7		Example 154	28
Example 56	5		Example 163	19
Example 58	13		Example 167	15
Example 59	12		Example 168	9
Example 60	18		Example 169	43
Example 61	24		Example 173	36
Example 63	2		Example 175	19
Example 64	5		Example 189	28

Experiment 3. Effect of lipopolysaccharide (LPS)
stimulation on NO and TNF-α production

5 When various cells are stimulated with LPS, NF-κB is activated which results in the expression and induction of proteins represented by NDS and TNF-α, and thereby the cells start to produce NO and TNF-α.

The Griess' method utilizing a diazo reaction has

been known as a method for indirectly knowing that a cell actually produces NO. In the Griess' method, the Griess' reagent in which naphthylethylenediamine and sulfanilic acid have been mixed is reacted with NO₂ ion in the culture medium, and the color development thereof is measured by absorbance at 540 nm. The amount of NO accumulated in the cell culture medium after 24 hours was measured in this method with a result that the production of NO released from LPS (10 µg/ml)-stimulated RAW264.7 cells (ATCC, TIB-71) derived from macrophage is suppressed by the compound obtained in Example 4 (Figure 4A).

The result of measurement using the Biotrack mouse TNF-α ELISA kit (Amersham Life Science, England) revealed that the compound obtained in Example 4 can also inhibit the production of TNF-α released from the RAW264.7 cells that were stimulated with LPS (10 µg/ml) for 4 hours (Figure 4B).

The inhibitory activity of the compounds shown in the Examples is expressed as an IC₅₀ value.

Table 2

Test compound	IC50 (μ M)	
	NO production	TNF- α Production
Example 4	21	21
Example 7	15	22
Example 9	10	16
Example 35	19	19
Example 53	19	19
Example 81	13	13
Example 83	6	9
Example 85	21	26
Example 94	9	11
Example 103	31	31
Example 106	17	25
Example 120	7	11
Example 121	13	17
Example 137	20	20
Example 168	17	17

Furthermore, when mRNA extracted from the RAW264.7 cells was determined by a reverse transcriptase-polymerase chain reaction (RT-PCR) method, it was confirmed that the mechanism of these suppressions are based on the level of gene expression of iNOS and TNF- α (Figure 5).

Experiment 4. Suppressive effect on carrageenin foot pad edema

Experimental method

Male Wistar rats (5 weeks old) weighing 90 - 120 g were used in the experiment. The rats were acclimated for one week and then were divided in following groups of eight animals:

Test compound group 1: Compound 1 (Example 4) 30 mg/kg
 Test compound group 2: Compound 2 (Example 7) 50 mg/kg
 Control group: 5% Dimethyl sulfoxide

The test compound was given once intraperitoneally, and two hours later 0.1 ml of a proinflammatory agent was given once intradermally on the foot pad of the right hind leg of the animals to induce foot pad edema. The amount of the test compound administered was set at 10 ml/kg, and was calculated based on the body weight on the day of the experiment. The control group received the

same amount of 5% dimethyl sulfoxide. As the prophlogistic agent, carrageenin (CARRAGEENAN Lambda, Sigma Chemical Company) was suspended in Japanese Pharmacopeia saline and was used as a 1% carrageenin suspension. Foot volume was measured by determining the volume of the right hind leg using a volume meter (TK-101, manufactured by Yunikomu) before the administration of the test compound, 1, 2, 3, and 4 hours after the administration of the prophlogistic agent. The edema ratio and the edema suppression ratio was calculated by the following method. The suppressive effect of the compound of the present invention on edema was confirmed (Figures 6 and 7):

Edema ratio (%) = (foot volume after the administration of the prophlogistic agent - foot volume before the administration of the test compound) / foot volume before the administration of the test compound x 100

Edema suppression ratio (%) = (mean edema ratio of the control group - mean edema ratio of the test compound group) / mean edema ratio of the control group x 100


Industrial Applicability

Since the compounds of the present invention can inhibit the activation of NF- κ B, they are useful as preventive and/or therapeutic agents for diseases caused by the activation of NF- κ B, for example diseases caused by the excessive production of inflammatory mediators and viral propagation. More specifically the NF- κ B inhibitors of the present invention are useful as therapeutic and/or preventive agents for diseases caused by, for example, the excessive production of NO or TNF- α including septic shock, osteoarthritis, rheumatoid arthritis, cachexia, multiple organ failure, inflammatory bowel diseases, malaria, acquired immune deficiency syndrome, human T-cell leukemia, meningitis, hepatitis, type II diabetes, multiple sclerosis, Behcet's disease,

systemic lupus erythematosus, ischemic heart disease, Alzheimer's disease, and the like.

CLAIMS

1. An NF-κB inhibitor comprising as an active ingredient a benzoquinone derivative represented by the following general formula (1):









(I)

wherein

R₁, R₂, and R₃ are each independently a hydrogen atom, an alkyl group having 1 to 5 carbons, or an alkoxy group having 1 to 5 carbons;

R₄ is a hydrogen atom, a hydroxymethyl group, an alkyl group, or a carboxyl group which is optionally esterified or amidated;

Z is






and, n is an integer from 0 to 6, or its hydroquinone form, or a pharmaceutically acceptable salt thereof.

2. The NF-κB inhibitor according to claim 1 in which R₁ and R₂ are a hydrogen atom, a methyl group, or a methoxy group.

3. The NF-κB inhibitor according to claim 1 or 2 in which R₃ is a hydrogen atom or a methyl group.




4. The NF-κB inhibitor according to claim 1, 2, or 3 in which Z is



5

and n is an integer 0.

5. The NF- κ B inhibitor according to claim 1, 2, or 3 in which Z is



10

and n is an integer 1, 2, or 3.

6. The NF- κ B inhibitor according to any one of claims 1 to 5 in which R_4 is a group $-\text{COOR}_5$, wherein R_5 is a hydrogen atom, an optionally substituted alkyl group having 1 to 8 carbons, an optionally substituted phenyl group, or an optionally substituted aralkyl group having 7 to 11 carbons.

20

7. The NF- κ B inhibitor according to any one of claims 1 to 5 in which R_4 is a group $-\text{CONR}_6\text{R}_7$, wherein R_6 and R_7 are each independently a hydrogen atom, an optionally substituted alkyl group having 1 to 8 carbons, an optionally substituted bicyclic unsaturated or partially saturated hydrocarbon ring group having 9 to 11 carbons, an optionally substituted heterocyclic group, an optionally substituted phenyl group, an optionally substituted aralkyl group having 7 to 11 carbons, or a heteroaryl- $\text{C}_1\text{-C}_3$ -alkyl group, or R_6 and R_7 , together with the nitrogen atom to which they are attached, represent a heterocyclic group which may further contain a nitrogen, oxygen, and/or sulfur atom.


30

8. The NF- κ B inhibitor according to any one of claims 1 to 5 in which R_4 is a group $-\text{CONR}_6\text{R}_7$, wherein R_6 and R_7 , together with the nitrogen atom to which they are attached, represent a 5- to 10-membered optionally

35

substituted, nitrogen-containing heterocyclic group which may contain, in addition to the carbon and nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen, oxygen and sulfur atom, the carbon atom on said cyclic group being optionally a ketone form or the sulfur atom on said cyclic group being optionally an oxide form.

9. The NF-kB inhibitor according to claim 1, 6, 7, or 8 in which R_1 and R_2 are a methyl group or a methoxy group; R_3 is a methyl group; R_4 is a carboxyl group which is optionally esterified or amidated; Z is



and n is an integer 1, 2, or 3.


10. The NF-kB inhibitor according to any one of claims 1 to 9 which is a suppressing agent for the gene expression of one or more substances selected from the group consisting of IL-1, TNF- α , IL-2, IL-6, IL-8, iNOS, granulocyte colony-stimulating factor, interferon- β , ICAM-1, VCAM-1, ELAM-1, major histocompatibility system class I, major histocompatibility system class II, β 2-microglobulin, immunoglobulin light chain, serum amyloid A, angiotensinogen, complement B, complement C4, c-myc, HIV, HTLV-1, SV40, CMV, and adenovirus.

11. The NF-kB inhibitor according to any one of claims 1 to 9 which is a preventive or therapeutic agent for inflammatory diseases.

12. The NF-kB inhibitor according to any one of claims 1 to 9 which is a preventive or therapeutic agent for autoimmune diseases.

13. The NF-kB inhibitor according to any one of claims 1 to 9 which is a preventive or therapeutic agent for viral diseases.

14. A preventive or therapeutic agent for diseases caused by the activation of NF- κ B comprising as an active ingredient a benzoquinone derivative represented by the following general formula (1):









(1)

wherein

R_1 , R_2 , and R_3 are each independently a hydrogen atom, an alkyl group having 1 to 5 carbons, or an alkoxy group having 1 to 5 carbons;

R_4 is a hydrogen atom, a hydroxymethyl group, an alkyl group, or a carboxyl group which is optionally esterified or amidated;

Z is



and, n is an integer from 0 to 6, or its hydroquinone form, or a pharmaceutically acceptable salt thereof.

15. A novel compound selected from:

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]morpholine,

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]thiomorpholine S-oxide,

N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-

- benzoquinon-2-ylmethyl)phenyl]propionyl]thiomorpholine S-dioxide,
- 5 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]piperidine,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]dimethylamine,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]isopropylamine,
- 10 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]ethanolamine,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]benzylamine,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]phenethylamine,
- 15 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]morpholine,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]thiomorpholine,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]piperidine,
- 20 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]dimethylamine,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]isopropylamine,
- 25 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]ethanolamine,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]benzylamine,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]phenethylamine,
- 30 N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]piperidine,
- N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]thiomorpholine,
- 35 N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]morpholine,
- N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-

- benzoquinon-2-ylmethyl)phenyl]propionyl]isopropylamine,
3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid,
N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]piperidine,
5 N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]morpholine,
N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]isopropylamine,
10 N-[3-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]thiomorpholine,
N-[3-[4-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]isopropylamine,
N-[3-[4-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]piperidine,
15 N-[3-[4-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]morpholine,
N-[3-[3-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]isopropylamine,
20 N-[3-[3-(3,5,6-trimethyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]piperidine,
3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acrylic acid,
N-[3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]acryloyl]thiomorpholine,
25 3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionic acid,
N-[3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]piperidine,
30 N-[3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]morpholine,
N-[3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]thiomorpholine,
N-[3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]isopropylamine,
35 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-(s)-2-


- (methoxymethyl)pyrrolidine,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-
benzoquinon-2-ylmethyl)phenyl]propionyl]isonipecotamide,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-
5 benzoquinon-2-ylmethyl)phenyl]propionyl]-4-
methylpiperidine,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-
benzoquinon-2-ylmethyl)phenyl]propionyl]-2-
methylpiperidine,
10 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-
benzoquinon-2-ylmethyl)phenyl]propionyl]-3-
methylpiperidine,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-
benzoquinon-2-ylmethyl)phenyl]propionyl]-4-
15 methoxyaniline,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-
benzoquinon-2-ylmethyl)phenyl]propionyl]-2-
hydroxyaniline,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-
20 benzoquinon-2-ylmethyl)phenyl]propionyl]-3,4-
dimethoxyaniline,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-
benzoquinon-2-ylmethyl)phenyl]propionyl]-D,L-alaninol,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-
25 benzoquinon-2-ylmethyl)phenyl]propionyl]-D,L-pipecolic
acid ethylester,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-
benzoquinon-2-ylmethyl)phenyl]propionyl]-L-prolinamide,
4-[3-[4-(5,6-dimethoxy-3-methyl-1,4-
30 benzoquinon-2-ylmethyl)phenyl]propionyl]
aminophenylacetonitrile,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-
benzoquinon-2-ylmethyl)phenyl]propionyl]-4-pentylaniline,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-
35 benzoquinon-2-ylmethyl)phenyl]propionyl]-(s)-(-)-1-
phenylethylamine,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-

- benzoquinon-2-ylmethyl)phenyl]propionyl]-(R)-(+)-1-phenylethylamine,
- 5 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-1,3-dimethylbutylamine,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]cycloheptylamine,
- 10 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-3,5-dimethylpiperidine,
- 1-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-4-ethoxycarbonylpiperazine,
- 15 1-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-4-phenylpiperazine,
- 1-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-4-hydroxy-4-phenylpiperidine,
- 20 1-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-4-(4-chlorophenyl)-4-hydroxypiperidine,
- 1-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-4-(2-methoxyphenyl)piperazine,
- 25 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline,
- 4-acetyl-4-phenyl-1-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]piperidine,
- 30 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-1,2,3,4-tetrahydroisoquinoline,
- 35 N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]isoamylamine,
- N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-

- benzoquinon-2-ylmethyl)phenyl]propionyl]cyclohexylamine,
N-[3-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]propionyl]-4-hydroxyaniline,
- 5 4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoic acid,
N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoyl]morpholine,
N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoyl]isopropylamine,
- 10 N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoyl]piperidine,
N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoyl]thiomorpholine,
- 15 3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoic acid,
N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoyl]isopropylamine,
N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoyl]piperidine,
- 20 N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)benzoyl]morpholine,
N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)thiomorpholine,
- 25 4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]-n-butyric acid,
N-[4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]morpholine,
N-[4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]thiomorpholine,
- 30 N-[4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]piperidine,
N-[4-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]isopropylamine,
- 35 4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetic acid,
N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-

ylmethyl)phenylacetyl]morpholine,
N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]piperidine,
N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]thiomorpholine,
N-[4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]isopropylamine,
3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetic acid,
N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]piperidine,
N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]thiomorpholine,
N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]morpholine,
N-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenylacetyl]morpholine,
4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]-n-butyric acid,
N-[4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]piperidine,
N-[4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]thiomorpholine,
N-[4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]morpholine, and
N-[4-[3-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-ylmethyl)phenyl]butanoyl]isopropylamine.

16. An inhibitor of TNF- α production comprising as an active ingredient a benzoquinone derivative represented by the following general formula (1):




(I)

wherein

R_1 , R_2 , and R_3 are each independently a hydrogen atom, an alkyl group having 1 to 5 carbons, or an alkoxy group having 1 to 5 carbons;

5 R_4 is a hydrogen atom, a hydroxymethyl group, an alkyl group, or a carboxyl group which is optionally esterified or amidated;

Z is




and, n is an integer from 0 to 6, or its hydroquinone form, or a pharmaceutically acceptable salt thereof.

17. The inhibitor of TNF- α production according to claim 16 in which R_1 and R_2 are a hydrogen atom, a methyl group, or a methoxy group.




18. The inhibitor of TNF- α production according to claim 16 or 17 in which R_3 is a hydrogen atom or a methyl group.

19. The inhibitor of TNF- α production according to claim 16, 17, or 18 in which Z is



and n is an integer 0.

20. The inhibitor of TNF- α production according to claim 16, 17, or 18 in which Z is



5 and n is an integer 1, 2, or 3.

21. The inhibitor of TNF- α production according to
any one of claims 16 to 20 in which R_4 is a group $-COOR_5$
wherein R_5 is a hydrogen atom, an optionally substituted
alkyl group having 1 to 8 carbons, an optionally
10 substituted phenyl group, or an optionally substituted
aralkyl group having 7 to 11 carbons.


22. The inhibitor of TNF- α production according to
any one of claims 16 to 20 in which R_4 is a group $-CONR_6R_7$
wherein R_6 and R_7 are each independently a hydrogen atom,
15 an optionally substituted alkyl group having 1 to 8
carbons, an optionally substituted bicyclic unsaturated
or partially saturated hydrocarbon ring group having 9 to
11 carbons, an optionally substituted heterocyclic group,
an optionally substituted phenyl group, an optionally
20 substituted aralkyl group having 7 to 11 carbons, or a
heteroaryl- C_1 - C_3 -alkyl group, or R_6 and R_7 , together with
the nitrogen atom to which they are attached, represent a
heterocyclic group which may further contain a nitrogen,
oxygen, and/or sulfur atom.

23. The inhibitor of TNF- α production according to
any one of claims 16 to 20 in which R_4 is a group $-CONR_6R_7$
wherein R_6 and R_7 , together with the nitrogen atom to
which they are attached, represent a 5- to 10-membered
optionally substituted, nitrogen-containing heterocyclic
30 group which may contain, in addition to the carbon and
nitrogen atom, 1 to 3 heteroatoms selected from the group
consisting of a nitrogen, oxygen and sulfur atom, the
carbon atom on said cyclic group being optionally a
ketone form or the sulfur atom on said cyclic group being
35 optionally an oxide form.

24. The inhibitor of TNF- α production according to

claim 16, 21, 22, or 23 in which R_1 and R_2 are a methyl group or a methoxy group; R_3 is a methyl group; R_4 is a carboxyl group which is optionally esterified or amidated; Z is

5



and n is an integer 1, 2, or 3.


10 25. The inhibitor of TNF- α production according to any one of claims 16 to 24 which is a suppressing agent for the gene expression of one or more substances selected from the group consisting of IL-1, TNF- α , IL-2, IL-6, IL-8, iNOS, granulocyte colony-stimulating factor,
15 interferon- β , ICAM-1, VCAM-1, ELAM-1, plasminogen activator-inhibiting factor I, major histocompatibility system class I, major histocompatibility system class II, β 2-microglobulin, immunoglobulin light chain, serum amyloid A, angiotensinogen, complement B, complement C4,
20 c-myc, HIV, HTLV-1, SV40, CMV, and adenovirus.

26. The inhibitor of TNF- α production according to any one of claims 16 to 24 which is a preventive or therapeutic agent for inflammatory diseases.

25 27. The inhibitor of TNF- α production according to any one of claims 16 to 24 which is a preventive or therapeutic agent for autoimmune diseases.

28. The inhibitor of TNF- α production according to any one of claims 16 to 24 which is a preventive or therapeutic agent for viral diseases.

30 29. A preventive or therapeutic agent for diseases caused by the excessive production of TNF- α comprising as an active ingredient a benzoquinone derivative represented by the following general formula (1):



5

(I)

wherein




R_1 , R_2 , and R_3 are each independently a hydrogen atom, an alkyl group having 1 to 5 carbons, or an alkoxy group having 1 to 5 carbons;

10




R_4 is a hydrogen atom, a hydroxymethyl group, an alkyl group, or a carboxyl group which is optionally esterified or amidated;

Z is

15




20



and, n is an integer from 0 to 6, or its hydroquinone form, or a pharmaceutically acceptable salt thereof.

25

30. A benzoquinone derivative represented by the following general formula (1):



30

(1)

wherein

R_1 , R_2 , and R_3 are each independently a hydrogen atom, an alkyl group having 1 to 5 carbons, or an alkoxy group having 1 to 5 carbons;




35

R_4 is a hydrogen atom, a hydroxymethyl group, an alkyl group, or a carboxyl group which is optionally




esterified or amidated;

Z is

5






10






and, n is an integer from 0 to 6,
provided that when Z is

15



n is not 0, and when Z is

20



n is neither 0 nor 2,
or its hydroquinone form, or a pharmaceutically
acceptable salt thereof.




25

31. The benzoquinone derivative according to claim 30 in which R_1 and R_2 are a hydrogen atom, a methyl group, or a methoxy group, or its hydroquinone form or a pharmaceutically acceptable salt thereof.

30

32. The benzoquinone derivative according to claim 30 or 31 in which R_3 is a hydrogen atom or a methyl group, or its hydroquinone form or a pharmaceutically acceptable salt thereof.

33. The benzoquinone derivative according to claim 30, 31, or 32 in which Z is



5 and n is an integer 1 or 3, or its hydroquinone form or a pharmaceutically acceptable salt thereof.

34. The benzoquinone derivative according to any one of claims 30 to 33 in which R_4 is a group $-COOR_5$ wherein R_5 is a hydrogen atom, an optionally substituted
10 alkyl group having 1 to 8 carbons, an optionally substituted phenyl group, or an optionally substituted aralkyl group having 7 to 11 carbons, or its hydroquinone form or a pharmaceutically acceptable salt thereof.




35. The benzoquinone derivative according to any one of claims 30 to 33 in which R_4 is a group $-CONR_6R_7$ wherein R_6 and R_7 are each independently a hydrogen atom, an optionally substituted alkyl group having 1 to 8
15 carbons, an optionally substituted bicyclic unsaturated or partially saturated hydrocarbon ring group having 9 to 11 carbons, an optionally substituted heterocyclic group, an optionally substituted phenyl group, an optionally substituted aralkyl group having 7 to 11 carbons, or a heteroaryl- C_1 - C_3 -alkyl group, or R_6 and R_7 , together with the nitrogen atom to which they are attached, represent a
20 heterocyclic group which may further contain a nitrogen, oxygen and/or sulfur atom, or its hydroquinone form or a pharmaceutically acceptable salt thereof.

36. The benzoquinone derivative according to any one of claims 30 to 33 in which R_4 is a group $-CONR_6R_7$ wherein R_6 and R_7 , together with the nitrogen atom to which they are attached, represent a 5- to 10-membered
30 optionally substituted, nitrogen-containing heterocyclic group which may contain, in addition to the carbon and nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen, oxygen and sulfur atom, the carbon atom on said cyclic group being optionally a
35 ketone form or the sulfur atom on said cyclic group being

optionally an oxide form, or its hydroquinone form or a pharmaceutically acceptable salt thereof.

37. The benzoquinone derivative according to claim 30, 34, 35, or 36 in which R_1 and R_2 are a methyl group or a methoxy group; R_3 is a methyl group; R_4 is a carboxyl group which is optionally esterified or amidated; Z is


10




and n is an integer 1 or 3, or its hydroquinone form or a pharmaceutically acceptable salt thereof.

ABSTRACT

An NF- κ B inhibitor having as an active ingredient a benzoquinone derivative represented by the general formula (1) wherein R_1 , R_2 , and R_3 are each independently H, alkyl having 1 to 5 carbons, or alkoxy having 1 to 5 carbons; R_4 is H, hydroxymethyl, alkyl, or carboxyl which is optionally esterified or amidated; Z is represented by the formula (A); and, n is an integer from 0 to 6, or its hydroquinone form or a pharmaceutically acceptable salt thereof.



(I)



(A)

Fig. 1




Fig. 2





Fig.3

A



B





Fig. 4

A



B




Fig.5




Fig. 6





Fig. 7



Declaration and Power of Attorney For Patent Application

特許出願宣言書及び委任状

Japanese Language Declaration

日本語宣言書

下記の氏名の発明者として、私は以下の通り宣言します。

As a below named inventor, I hereby declare that:

私の住所、私書箱、国籍は下記の私の氏名の後に記載された通りです。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明に関して請求範囲に記載され、特許出願している発明内容について、私が最初かつ唯一の発明者（下記の氏名が一つの場合）もしくは最初かつ共同発明者であると（下記の名称が複数の場合）信じています。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

NF- κ B INHIBITOR COMPRISING PHENYL-
METHYL BENZOQUINONE AS AN ACTIVE
INGREDIENT

上記発明の明細書（下記の欄でx印がついていない場合は、本書に添付）は、

the specification of which is attached hereto unless the following box is checked:

☐ 月 日 に提出され、米国出願番号または特許協定条約国際出願番号を _____ とし、
（該当する場合） _____ に訂正されました。

☐ was filed on _____
as United States Application Number or
PCT International Application Number
_____ and was amended on
_____ (if applicable).

私は、特許請求範囲を含む上記訂正後の明細書を検討し、内容を理解していることをここに表明します。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第37編第1条56項に定義されるとおり、特許資格の有無について重要な情報を開示する義務があることを認めます。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Japanese Language Declaration (日本語宣言書)

私は、米国法典第35編119条(a)-(d)項又は365条(b)項に基づき下記の、米国以外の国の少なくとも一カ国を指定している特許協力条約365(a)項に基づき国際出願、又は外国での特許出願もしくは発明者証の出願についての外国優先権をここに主張するとともに、優先権を主張している、本出願の前に出願された特許または発明者証の外国出願を以下に、枠内をマークすることで、示しています。

Prior Foreign Application(s)

外国での先行出願

10-092431 (Pat. Appln.) Japan
(Number) (Country)
(番号) (国名)

(Number) (Country)
(番号) (国名)

私は、第35編米国法典119条(e)項に基づいて下記の米国外特許出願規定に記載された権利をここに主張いたします。

(Application No.) (Filing Date)
(出願番号) (出願日)

私は、下記の米国法典第35編120条に基づいて下記の米国外特許出願に記載された権利、又は米国を指定している特許協力条約365条(c)に基づき権利をここに主張します。また、本出願の各請求範囲の内容が米国法典第35編112条第1項又は特許協力条約で規定された方法で先行する米国外特許出願に開示されていない限り、その先行米国外出願書提出日以降で本出願書の日本国内または特許協力条約国際提出日までの期間中に入手された、連邦規則法典第37編1条56項で定義された特許資格の有無に関する重要な情報について開示義務があることを認識しています。

International Application
No. PCT/JP99/01422 19/March/1999
(Application No.) (Filing Date)
(出願番号) (出願日)

(Application No.) (Filing Date)
(出願番号) (出願日)

私は、私自身の知識に基づいて本宣言書で私が行なう表明が真実であり、かつ私の入手した情報と私の信じることに基づき表明が全て真実であると信じていること、さらに故意になされた虚偽の表明及びそれと同等の行為は米国法典第18編第1001条に基づき、罰金または拘禁、もしくはその両方により処罰されること、そしてそのような故意による虚偽の表明を行えば、出願した、又は既に許可された特許の有効性が失われることを認識し、よってここに上記のごとく宣誓を致します。

I hereby claim foreign priority under Title 35, United States Code, Section 119 (a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Priority Not Claimed

優先権主張なし

20/March/1998
(Day/Month/Year Filed)
(出願年月日)

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

(Application No.) (Filing Date)
(出願番号) (出願日)

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or 366(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

pending
(Status: Patented, Pending, Abandoned)
(現況: 特許許可済、係属中、放棄済)

(Status: Patented, Pending, Abandoned)
(現況: 特許許可済、係属中、放棄済)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Japanese Language Declaration
(日本語宣言書)

委任状: 私は下記の発明者として、本出願に関する一切の
手続きを米特許商標局に対して遂行する弁理士または代理人
として、下記の者を指名いたします。(弁理士、または代理
人の氏名及び登録番号を明記のこと)

POWER OF ATTORNEY: As a named inventor, I hereby appoint
the following attorney(s) and/or agent(s) to prosecute this
application and transact all business in the Patent and Trademark
Office connected therewith (list name and registration number)

William L. Mathis 17,337
Peter H. Smolka 15,913
Robert S. Swecker 19,885
Platon N. Mandros 22,124
Benton S. Duffett, Jr. 22,030
Joseph R. Magnone 24,239
Norman H. Stepno 22,716
Ronald L. Grudziecki 24,970
Frederick G. Michaud, Jr. 26,003
Alan E. Kopecki 25,813
Regis E. Slutter 26,999
Samuel C. Miller, III 27,360
Ralph L. Freeland, Jr. 16,110

Robert G. Mukai 28,531
George A. Hovanec, Jr. 28,223
James A. LaBarre 28,632
E. Joseph Gess 28,510
R. Danny Huntington 27,903
Eric H. Weisblatt 30,505
James W. Peterson 26,057
Teresa Stanek Rea 30,427
Robert E. Krebs 25,885
William C. Rowland 30,888
T. Gene Dillahunty 25,423
Patrick C. Keane 32,858
Bruce J. Boggs, Jr. 32,344

William H. Benz 25,952
Peter K. Skiff 31,917
Richard J. McGrath 29,195
Matthew L. Schneider 32,814
Michael G. Savage 32,596
Gerald F. Swiss 30,113
Michael J. Ure 33,089
Charles F. Wieland III 33,096
Bruce T. Wieder 33,815
Todd R. Walters 34,040

書類送付先

Send Correspondence to:

Ronald L. Grudziecki
BURNS, DOANE, SWECKER & MATHIS, L.L.P.
P.O. Box 1404
Alexandria, Virginia 22313-1404

直接電話連絡先: (名前及び電話番号)

Direct Telephone Calls to: (name and telephone number)

Ronald L. Grudziecki
at (703) 836-6620

唯一または第一発明者名

Full name of sole or first inventor
Yoichi Nunokawa

発明者の署名

日付

Inventor's signature

Date

Yoichi Nunokawa November 11, 1999

住所

Residence

Toyonaka-shi, Osaka, Japan

国籍

Citizenship

Japanese

私書箱

Post Office Address

3-6-1-403, Toneyama, Toyonaka-shi,
Osaka 560-0045, Japan

第二共同発明者

Full name of second joint inventor, if any

Kenji Suzuki

第二共同発明者

日付

Second inventor's signature

Date

Kenji Suzuki November 11, 1999

住所

Residence

Osaka-shi, Osaka, Japan

国籍

Citizenship

Japanese

私書箱

Post Office Address

2-5-2-305, Imazunaka, Tsurumi-ku,
Osaka-shi, Osaka 538-0042, Japan

(第三以降の共同発明者についても同様に記載し、署名をす
ること)

(Supply similar information and signature for third and subsequent
joint inventors.)

第三共同発明者名		Full name of third joint inventor, if any 3-0 Masayuki Saitoh	
第三共同発明者の署名	日付	Third inventor's signature Masayuki Saitoh	Date November 11, 1999
住所	Residence Ibaraki-shi, Osaka, Japan		
国籍	Citizenship Japanese		
私書箱	Post Office Address 18-7-301, Inaba-cho, Ibaraki-shi, Osaka		
567-0827, Japan			
第四共同発明者名		Full name of fourth joint inventor, if any	
第四共同発明者の署名	日付	Fourth inventor's signature	Date
住所	Residence		
国籍	Citizenship		
私書箱	Post Office Address		
第五共同発明者名		Full name of fifth joint inventor, if any	
第五共同発明者の署名	日付	Fifth inventor's signature	Date
住所	Residence		
国籍	Citizenship		
私書箱	Post Office Address		
第六共同発明者名		Full name of sixth joint inventor, if any	
第六共同発明者の署名	日付	Sixth inventor's signature	Date
住所	Residence		
国籍	Citizenship		
私書箱	Post Office Address		

SEQUENCE LISTING

<100> SUNTORY LIMITED

<120> NF-κB inhibitor comprising phenylmethyl benzo-
quinone as an active ingredient

<130> G830

<150> JP-10-092431
<151> 1998-03-20

<160> 1

<210> 1
<211> 35
<212> DNA
<213> Artificial sequent

<220>
<221>
<222>
<223>

<400> 1
aactgtacac aagctgggga cactcccttt ggaaa 35